{"id":"F2014L01343","name":"Poisons Standard 2014","slug":"poisons-standard-2014","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":438153,"registerId":"F2014L01343-fast-fetch-1775954695646","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"Sch 1","sectionType":"schedule","heading":"Standard for the Uniform Scheduling of Medicines and Poisons No. 5","content":"Schedule 1-Standard for the Uniform Scheduling of Medicines and Poisons No. 5\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nSTANDARD FOR THE UNIFORM SCHEDULING OF\n\nMEDICINES AND POISONS\n\n \n\nOctober 2014\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe amendments listed in this document are a result of decisions made by the Secretary of the Department of Health or the Secretary’s Delegate in July 2014.  The basis of these amendments can be found in the ‘Reasons for scheduling delegate’s final decisions’, which can be accessed from the TGA website at <http://www.tga.gov.au/industry/scheduling-decisions-final.htm>.\n\n \n\n \n\nFurther inquiries should be directed to:\n\n \n\n| The Secretary<br>Chemicals Scheduling Secretariat (MDP88)<br>Office of Chemical Safety<br>Department of Health<br>GPO Box 9848<br>CANBERRA  ACT  2601<br> <br>or by email to <Chemicals.Scheduling@health.gov.au><br> | The Secretary<br>Medicines Scheduling Secretariat (MD122)  Communications and Secretariat  Therapeutic Goods Administration  PO Box 100  WODEN ACT 2606<br> <br>or by email to <Medicines.Scheduling@tga.gov.au><br> |\n| --- | --- |\n\n \n\nMedia Liaison Unit\n\nAustralian Government Department of Health\n\n \n\n \n\n \n\n \n\nContents\n\n[INTRODUCTION](#_Toc359452330)\n\n[CLASSIFICATION](#_Toc359452331)\n\n[PRINCIPLES OF SCHEDULING](#_Toc359452332)\n\n[READING THE SCHEDULES](#_Toc359452333)\n\n[Availability of poisons](#_Toc359452334)\n\n[Preparations containing poisons listed in two or more Schedules](#_Toc359452335)\n\n[PART 1](#_Toc359452336) - [INTERPRETATION](#_Toc359452337)\n\n[PART 2](#_Toc359452338) - [LABELS AND CONTAINERS](#_Toc359452339)\n\n[LABELS](#_Toc359452340)\n\n[General requirements](#_Toc359452341)\n\n[Immediate wrapper](#_Toc359452342)\n\n[Primary packs and immediate containers](#_Toc359452343)\n\n[Statements of quantity, proportion or strength](#_Toc359452344)\n\n[Exemptions](#_Toc359452345)\n\n[Selected containers and measure packs](#_Toc359452346)\n\n[Ampoules, pre-filled syringes and injection vials](#_Toc359452347)\n\n[Transport containers and wrappings](#_Toc359452348)\n\n[Dispensary, industrial, laboratory and manufacturing poisons](#_Toc359452349)\n\n[Exemptions from label requirements in certain circumstances](#_Toc359452350)\n\n[Dispensed medicines](#_Toc359452351)\n\n[Gas cylinders](#_Toc359452352)\n\n[Paints](#_Toc359452353)\n\n[Camphor and naphthalene](#_Toc359452354)\n\n[Prohibitions](#_Toc359452355)\n\n[CONTAINERS](#_Toc359452356)\n\n[Containers for poisons other than Schedule 5 poisons](#_Toc359452357)\n\n[Containers for Schedule 5 poisons](#_Toc359452358)\n\n[Approved containers](#_Toc359452359)\n\n[Child-resistant closures](#_Toc359452360)\n\n[Schedule 8 poisons](#_Toc359452361)\n\n[Exemptions](#_Toc359452362)\n\n[Camphor and naphthalene](#_Toc359452363)\n\n[Prohibitions](#_Toc359452364)\n\n[PART 3](#_Toc359452365) - [MISCELLANEOUS REGULATIONS](#_Toc359452366)\n\n[ADVERTISING](#_Toc359452367)\n\n[SALE OR SUPPLY](#_Toc359452368)\n\n[Schedule 2 poisons](#_Toc359452369)\n\n[Schedule 3 poisons](#_Toc359452370)\n\n[Schedule 4 poisons](#_Toc359452371)\n\n[Schedule 7 poisons](#_Toc359452372)\n\n[PROHIBITIONS ON SALE, PRESCRIBING AND POSSESSION](#_Toc359452373)\n\n[STORAGE](#_Toc359452374)\n\n[PART 4 -](#_Toc359452375)[THE SCHEDULES](#_Toc359452376)\n\n[SCHEDULE 1](#_Toc359452377)\n\n[SCHEDULE 2](#_Toc359452378)\n\n[SCHEDULE 3](#_Toc359452379)\n\n[SCHEDULE 4](#_Toc359452380)\n\n[SCHEDULE 5](#_Toc359452381)\n\n[SCHEDULE 6](#_Toc359452382)\n\n[SCHEDULE 7](#_Toc359452383)\n\n[SCHEDULE 8](#_Toc359452384)\n\n[SCHEDULE 9](#_Toc359452385)\n\n[PART 5 -](#_Toc359452386)[THE APPENDICES](#_Toc359452387)\n\n[APPENDIX A](#_Toc359452388) - [General exemptions](#_Toc359452389)\n\n[APPENDIX B](#_Toc359452390) - [Substances considered not to require control by scheduling](#_Toc359452391) [](#_Toc359452392)\n\n[APPENDIX C](#_Toc359452393) - [Substances, other than those included in Schedule 9,](#_Toc359452394) [of such danger to health as to warrant](#_Toc359452395) [prohibition of sale, supply and use](#_Toc359452396)\n\n[APPENDIX D](#_Toc359452397) - [Additional controls on possession or supply of poisons included in Schedule 4 or 8](#_Toc359452398)\n\n[APPENDIX E](#_Toc359452399) - [First aid instructions for poisons](#_Toc359452400)\n\n[APPENDIX F](#_Toc359452401) - [Warning statements and general safety directions for poisons](#_Toc359452402)\n\n[APPENDIX G](#_Toc359452403) - [Dilute preparations](#_Toc359452404)\n\n[APPENDIX H](#_Toc359452405) - [Schedule 3 poisons permitted to be advertised](#_Toc359452406)\n\n[APPENDIX I](#_Toc359452407) - [Uniform Paint Standard](#_Toc359452408)\n\n[APPENDIX J](#_Toc359452409) - [Conditions for availability and use of Schedule 7 poisons](#_Toc359452410)\n\n[APPENDIX K](#_Toc359452411) - [Drugs required to be labelled](#_Toc359452412) [with a sedation warning](#_Toc359452413)\n\n[APPENDIX L](#_Toc359452414) - [Requirements for dispensing labels for](#_Toc359452415) [human and veterinary medicines](#_Toc359452416)\n\n \n\n \n\n# INTRODUCTION\n\n \n\nThe Poisons Standard 2014, which, under section 2 above consists of the Standard for the Uniform Scheduling of Medicines and Poisons (the Standard, or the SUSMP), is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989, and is a compilation of the decisions made under section 52D of the same Act.  The SUSMP should be read in conjunction with the Scheduling Policy Framework (SPF) of the National Coordinating Committee on Therapeutic Goods.  Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au.  Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).\n\n \n\nThe SUSMP serves two key purposes.\n\n \n\nFirstly, the SUSMP contains the decisions of the Secretary of the Department of Health or the Secretary's delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories.  The scheduling classification sets the level of control on the availability of poisons.  The scheduling of poisons is implemented through relevant State and Territory legislation.  Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.\n\n \n\nSecondly, the SUSMP includes model provisions for labelling, containers, storage and possession of poisons in general, which are intended to be adopted for use in each jurisdiction of Australia, according to local requirements and local law.  Appropriate labelling and container requirements for products, other than therapeutic goods and agricultural and veterinary chemicals, are imposed through adoption of Parts 1, 2 and 3 of the SUSMP into State or Territory legislation.  Other government agencies may also impose controls on certain products, for example cosmetics.\n\n \n\nThe requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers.  Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation. \n\n \n\nPoisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by Safe Work Australia's National Code of Practice for the Labelling of Workplace Substances [NOHSC: 2012(1994)].  Note, however that this exemption does not extend to controls on supply of these poisons.\n\n \n\nThe SUSMP is presented with a view to promoting uniform:\n\n- scheduling of poisons throughout Australia;\n- signal headings on labels for poisons throughout Australia;\n- labelling and packaging requirements for poisons throughout Australia;\n- additional controls on the availability and use of poisons in Australia.\n\n \n\nThe various Commonwealth Acts, legislative instruments and other documents which integrate with the SUSMP include:\n\n- the Agricultural and Veterinary Chemicals Code Act 1994\n- the Agricultural and Veterinary Chemicals Code Regulations 1995\n- the Therapeutic Goods Act 1989\n- Therapeutic Goods Order 69 – General requirements for labels for medicines\n- Therapeutic Goods Order 80 – Child-Resistant Packaging Requirements for Medicines\n- the Required Advisory Statements for Medicine Labels (RASML).\n\n \n\n \n\n## CLASSIFICATION\n\n \n\nPoisons are classified according to the Schedules in which they are included.  The following is a general description of the Schedules.  For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.\n\n \n\nSchedule 1. This Schedule is intentionally blank.\n\n \n\n","sortOrder":0},{"sectionNumber":"Sch 2","sectionType":"schedule","heading":"Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.","content":"Schedule 2. Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.\n\n \n\n","sortOrder":1},{"sectionNumber":"Sch 3","sectionType":"schedule","heading":"Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.","content":"Schedule 3.   Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.\n\n \n\n","sortOrder":2},{"sectionNumber":"Sch 4","sectionType":"schedule","heading":"Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.","content":"Schedule 4. Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.\n\n \n\n","sortOrder":3},{"sectionNumber":"Sch 5","sectionType":"schedule","heading":"Caution – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.","content":"Schedule 5. Caution – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.\n\n \n\n","sortOrder":4},{"sectionNumber":"Sch 6","sectionType":"schedule","heading":"Poison – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.","content":"Schedule 6. Poison – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.\n\n \n\n","sortOrder":5},{"sectionNumber":"Sch 7","sectionType":"schedule","heading":"Dangerous Poison – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use.  These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely.  Special regulations restricting their availability, possession, storage or use may apply.","content":"Schedule 7. Dangerous Poison – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use.  These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely.  Special regulations restricting their availability, possession, storage or use may apply.\n\n \n\n","sortOrder":6},{"sectionNumber":"Sch 8","sectionType":"schedule","heading":"Controlled Drug – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.","content":"Schedule 8. Controlled Drug – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.\n\n \n\n","sortOrder":7},{"sectionNumber":"Sch 9","sectionType":"schedule","heading":"Prohibited Substance – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.","content":"Schedule 9.   Prohibited Substance – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.\n\n \n\n## PRINCIPLES OF SCHEDULING\n\n \n\nPoisons are not scheduled on the basis of a universal scale of toxicity.  Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.\n\n \n\nThis Standard lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.\n\n \n\nPoisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.\n\n \n\nFor some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7.  Products for domestic use must not include poisons listed in Schedule 7.\n\n \n\nSchedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities.  Although appearing as a Schedule in this Standard, the method by which it is implemented in the States and Territories may vary.\n\n \n\nSubstances in products which have been considered for scheduling, but have been exempted from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).\n\n \n\nAppendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties.  It is recommended that the provisions of this Appendix be put into effect through inclusion of the substances in appropriate State and Territory legislation.\n\n \n\n## READING THE SCHEDULES\n\nSchedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible.  As a result, they are expressed in a number of ways, though this number has been kept to a minimum.  It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.\n\n \n\nFirstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases.  Some of those are mentioned overleaf.  Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.\n\n \n\nSecondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.\n\n \n\nWhere exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.\n\n \n\nWhere the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.\n\n \n\nWhere a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.\n\n \n\nWhere a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.\n\n \n\nIt is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Part 1, Interpretation, subparagraph 1(2).\n\n \n\nIt is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria.  Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison.  However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry.  Additionally, some entries specifically exclude derivatives.  Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.\n\n \n\nFinally, when using this Standard to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index.  In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:\n\n \n\nGroup Example\n\n \n\nthe parent acid of salts  “oxalic acid” to find sodium oxalate\n\n \n\nthe radical of a salt  “chromates” to find potassium\n\n chromate\n\n \n\nthe element  “arsenic” to find arsenic trioxide\n\n \n\na chemical group with similar  “hydrocarbons, liquid” to find\n\ntoxicological or pharmacological kerosene\n\nactivity \n\n \n\na pharmacological group “anabolic steroidal agents” to find\n\n “androsterone”\n\n \n\n### Availability of poisons\n\n \n\nThe purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.\n\n \n\nThese Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons.  Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.\n\n \n\nInclusion of a poison in a Schedule indicates the degree of control required if it is marketed.  It does not indicate:\n\n- that the poison is available; nor\n- that is has been approved or is efficacious for any use that may be specified in a Schedule; nor\n- does it negate any obligation for registration of a therapeutic good, or agricultural or veterinary chemical product containing that poison.\n\n \n\n### Preparations containing poisons listed in two or more Schedules\n\n \n\nIf a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.\n\n \n\nWhere it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.\n\n \n\nThe Schedules listed in order of greatest to least restriction on access and availability are 9, 8, 4, 7, 3, 2, 6, 5.\n\nSchedule 1 is not currently in use.\n\n \n\nSome substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this Standard.  The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.\n\n \n\n| Appendix | Title | Purpose/ controls imposed |\n| --- | --- | --- |\n| Appendix A | General exemptions | List of classes of products or uses exempted from this Standard. |\n| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |\n| Appendix C | Substances, other than those included in Schedule 9, of such danger to health as to warrant prohibition of sale, supply and use | List of poisons prohibited from sale, supply or use because of their known potential for harm to human and/or animal health. |\n| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |\n| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |\n| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |\n| Appendix G | Dilute preparations | Concentration cut-offs for specified poisons, below which the requirements of the Standard do not apply |\n| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |\n| Appendix I | Uniform Paint Standard | Requirements applying to poisons included in paints or tinters. |\n| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |\n| Appendix K | Human medicines required to be labelled with a sedation warning | List of human medicines required to be labelled with a warning regarding their sedation potential. |\n| Appendix L<br> | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |\n\n \n\nThis page is intentionally blank.  \n\n# PART 1\n\n \n\n# INTERPRETATION\n\n \n\n1. (1) In this Standard, unless the contrary intention appears —\n\n \n\n  “Agricultural chemical” means a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:\n\n \n\n   (a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing;\n\n \n\n   (b) destroying a plant;\n\n \n\n   (c) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity;\n\n \n\n   (d) modifying an effect of another agricultural chemical;\n\n \n\n   (e) attracting a pest for the purpose of destroying it; or\n\n \n\n   (f) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical product;\n\n \n\n \n\n   (g) a veterinary chemical.\n\n \n\n  “Agricultural chemical product” has the meaning defined in the Agricultural and Veterinary Chemicals Code Act 1994.\n\n \n\n  “Animal” means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.\n\n \n\n  “Animal feed premix” means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.\n\n \n\n  “Appropriate authority” means:\n\n \n\n   (a) in the Australian Capital Territory, ACT Government Health Directorate;\n\n \n\n   (b) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines Authority, the Chief Executive Officer or their delegate;\n\n \n\n   (c) in New South Wales, the Director-General of the NSW Ministry of Health;\n\n \n\n   (d) in the Northern Territory, the Chief Health Officer of the Department of Health;\n\n \n\n   (e) in Queensland, the Chief Executive of Queensland Health;\n\n \n\n   (f) in South Australia, the Chief Executive of the Department for Health and Ageing;\n\n \n\n   (g) in Tasmania, the Secretary of the Department of Health and Human Services;\n\n \n\n   (h) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 of this Standard\n\n \n\n    by the Therapeutic Goods Administration, the National Manager or their delegate;\n\n \n\n   (i) in Victoria, the Secretary to the Department of Health;\n\n \n\n   (j) in Western Australia, the Chief Executive Officer of the Department of Health.\n\n  \n\n  “Approved name” means:\n\n \n\n   (a) in relation to a poison that is for human therapeutic use, the name approved for use by the Therapeutic Goods Administration; \n\n \n\n   (b) in relation to a poison that is for animal or agricultural use, the name approved for use by the Australian Pesticides and Veterinary Medicines Authority;\n\n \n\n   (c) in relation to all other poisons:\n\n \n\n    (i) the name used in an entry in these Schedules; or, if no such name is given,\n\n \n\n    (ii) the English name recommended by Standards Australia as the common name for the poison; or, if no such name is given,\n\n \n\n    (iii) the English name given to the poison by the International Organization for Standardization; or, if no such name is given,\n\n \n\n    (iv) the English name given to the poison by the British Standards Institution; or, if no such name is given,\n\n \n\n    (v) the name that would comply with the requirements of part (a) or (b) of this definition, or, if no such name is given,\n\n \n\n    (vi) the English name given to the poison by the European Committee for Standardization (CEN); or, if no such name is given,\n\n \n\n    (vii) the international non-proprietary name recommended for the poison by the World Health Organization; or, if no such name is given,\n\n \n\n    (viii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the International Cosmetic Ingredient Dictionary & Handbook published by the Personal Care Products Council of America; or, if no such name is given,\n\n \n\n    (ix) the accepted scientific name or the name descriptive of the true nature and origin of the poison.\n\n \n\n  “Australian Code for the Transport of Dangerous Goods by Road and Rail” means the seventh edition of the document of that name.\n\n \n\n  “Authorised prescriber” means a registered medical, dental or veterinary practitioner or such other person authorised by the appropriate authority.\n\n \n\n  “Blood” means whole blood extracted from human donors.\n\n \n\n  “Blood components” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.\n\n \n\n  “Child-resistant closure” means:\n\n \n\n   (a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled Child-resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2003, MOD);\n\n \n\n   (b) a closure approved by an order made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or\n\n \n\n   (c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.\n\n \n\n   See also \"Non-access packaging”.\n\n \n\n   “Child-resistant packaging” means packaging that:\n\n \n\n   (a) complies with the requirements of the Australian Standard AS 1928-2007 entitled\n\n    Child resistant packaging – Requirements and testing procedures for reclosable packages (ISO 8317:2003, MOD);\n\n \n\n   (b) is reclosable and complies with the requirements of at least one of the following Standards:\n\n \n\n    (i) the International Organization for Standardization Standard ISO 8317:2003 entitled Child-resistant packaging – Requirements and testing procedures for reclosable packages;\n\n \n\n    (ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled\n\n     Child-resistant packaging.  Requirements and testing procedures for reclosable packages;\n\n \n\n    (iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled Reclosable Child-Resistant Packages;\n\n \n\n \n\n    (iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled Poison prevention packaging standards and Section 1700.20, entitled Testing procedure for special packaging;\n\n \n\n   (c) is approved as child-resistant by any order made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or\n\n \n\n   (d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled Child-resistant packages.\n\n \n\n  See also \"Non-access packaging\".\n\n \n\n  “Compounded” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.\n\n \n\n  “Cosmetic” means:\n\n(a) a substance or preparation intended for placement in contact with any external part of the human body, including:\n\n   (i) the mucous membranes of the oral cavity; and\n\n   (ii) the teeth;\n\n       with a view to:\n\n   (iii) altering the odours of the body; or\n\n   (iv) changing its appearance; or\n\n (v) cleansing it; or\n\n (vi) maintaining it in good condition; or\n\n (vii) perfuming it; or\n\n (viii) protecting it.\n\n \n\n  “Debitterised neem seed oil” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.\n\n  \n\n  “Dermal use” means application to the skin primarily for localised effect.\n\n \n\n  “Designated solvent” means the following:\n\n   acetone\n\n   dimethylformamide\n\n   N-(N-dodecyl)-2-pyrrolidone\n\n   hydrocarbons, liquid\n\n   methanol when included in Schedule 5\n\n   methyl ethyl ketone\n\n   methyl isoamyl ketone\n\n   methyl isobutyl ketone\n\n   N-methyl-2-pyrrolidone\n\n   N-(N-octyl)-2- pyrrolidone\n\n   phenyl methyl ketone\n\n   styrene\n\n   tetrachloroethylene\n\n   1,1,1-trichloroethane\n\n \n\n  “Dispensing label” means the label attached to the immediate container of a substance for therapeutic use at the time of dispensing.\n\n \n\n  “Distributor” means a person who imports, sells or otherwise supplies a poison.\n\n \n\n  “Divided preparation” means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.\n\n \n\n  “Dosage unit” means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.\n\n \n\n  “Drug” means a poison intended for human or animal therapeutic use.\n\n \n\n  “Essential oils” means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation.  For scheduling purposes it also means:\n\n \n\n   (a) oils of equivalent composition derived through synthetic means; or\n\n \n\n   (b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.\n\n \n\n  “External” in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.\n\n \n\n  “First Schedule Paint” means a paint containing the specified proportion of any substance in the First Schedule to Appendix I of this Standard.\n\n \n\n  “Free formaldehyde” includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol.\n\n \n\n  “Graphic material” means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.\n\n \n\n  “Height” in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.\n\n \n\n  “Hemp seed oil” means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.\n\n \n\n  “Immediate container” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.\n\n \n\n  “Immediate wrapper” means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.\n\n \n\n  “Internal use” means administration:\n\n \n\n   (a) orally, except for topical effect in the mouth; or\n\n \n\n   (b) for absorption and the production of a systemic effect;\n\n    (i) by way of a body orifice other than the mouth; or\n\n    (ii)  parenterally, other than by application to unbroken skin.\n\n \n\n  “Label” means:\n\n \n\n   (a) a written statement on a container of a poison; and\n\n \n\n   (b) in relation to a therapeutic good, includes a display of printed information about the product:\n\n    (i)  on, or attached to, the good;\n\n    (ii) on, or attached to, a container or primary pack in which the good is supplied; or\n\n    (iii) supplied with such a container or pack.\n\n \n\n  “Main label” means, where there are two or more labels on a container or a label is divided into two or more portions:\n\n \n\n   (a) the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and\n\n \n\n   (b) where there are two or more labels or two or more portions of a single label – that label or portion of the label where the product name is more or most conspicuously shown; or\n\n \n\n   (c) where the product name is equally conspicuous on two or more labels or portions of a label – each such label or portion.\n\n \n\n  “Manufacturer” means a person who manufactures, produces, or packs a poison.\n\n \n\n  “Measure pack” means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.\n\n \n\n  “Medicine” means any poison for therapeutic use.\n\n   Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to human or animal use is intended.\n\n \n\n  “Name and address” means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address.  Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.\n\n \n\n  “Non-access packaging” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled Packages for chemicals not intended for access or contact with their contents by humans, in relation to products that are not intended for human therapeutic use.\n\n \n\n   See also \"Child-resistant closure\" and \"Child-resistant packaging”.”.\n\n \n\n  “Non-volatile content” in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005 entitled Paints and related materials – Methods of test – Non-volatile content by mass.\n\n \n\n  “Oromucosal use” means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.\n\n \n\n  “Paint”, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.\n\n \n\n  “Pesticide” means any substance or mixture of substances used or intended to be used:\n\n \n\n   (a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or\n\n \n\n   (b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.\n\n \n\n  “Poison” means any substance or preparation included in a Schedule to this Standard.\n\n \n\n  “Primary pack” means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.\n\n \n\n  “Required Advisory Statements for Medicine Labels” means the document made under subsection 3(5A) of the Therapeutic Goods Act 1989 by the Therapeutic Goods Administration.\n\n \n\n  “Restricted flow insert” means a restriction fitted, or moulded, in the neck of a container which:\n\n \n\n   (a) cannot readily be removed from the container by manual force; and\n\n \n\n   (b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.\n\n \n\n  “Second Schedule Paint” means a paint containing the specified proportion of any substance in the Second Schedule to Appendix I of this Standard.\n\n \n\n  “Selected container” means:\n\n \n\n   (a) an injection vial having a nominal capacity of ten millilitres or less;\n\n \n\n   (b) a single use syringe; or\n\n \n\n   (c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.\n\n \n\n  “Solid” is considered to include “powder” for the purposes of scheduling.\n\n  \n\n  “Therapeutic good” has the meaning defined in the Commonwealth Therapeutic Goods Act 1989.\n\n \n\n  “Therapeutic use” means use in or in connection with:\n\n \n\n   (a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;\n\n \n\n   (b) influencing, inhibiting or modifying a physiological process in human beings or animals;\n\n \n\n   (c) testing the susceptibility of human beings or animals to a disease or ailment;\n\n \n\n   (d) influencing, controlling or preventing conception in persons or animals;\n\n \n\n   (e) testing for pregnancy in persons or animals; or\n\n \n\n   (f) the replacement or modification of parts of the anatomy in persons or animals.\n\n \n\n  “Third Schedule Paint” means a paint containing the specified proportion of any substance in the Third Schedule to Appendix I of this Standard.\n\n \n\n  “Tinter” means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.\n\n \n\n  “Topical use” means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.\n\n \n\n  “Toy” means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.\n\n \n\n  “Transdermal use” means application to the skin primarily for systemic effect.\n\n \n\n  “Veterinary chemical” means a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:\n\n \n\n(a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest;\n\n \n\n(b) curing or alleviating an injury suffered by the animal;\n\n \n\n(c) modifying the physiology of the animal:\n\n \n\n(i) so as to alter its natural development, productivity, quality or reproductive capacity; or\n\n \n\n(ii) so as to make it more manageable;\n\n \n\n(d) modifying the effect of another veterinary chemical\n\n \n\n(e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or\n\n \n\n(f) any active ingredient included in a product declared by regulation under the Agricultural and Veterinary Chemicals Code Act 1994 to be an veterinary chemical product;\n\n \n\n \n\n   (g) an agricultural chemical.\n\n \n\n“Veterinary chemical product” has the meaning defined in the Agricultural and Veterinary Chemicals Code Act 1994.\n\n \n\n  “Writing” includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.\n\n \n\n (2) Unless the contrary intention appears a reference to a substance in a Schedule or an Appendix to this Standard includes:\n\n \n\n  (a) that substance prepared from natural sources or artificially; and\n\n \n\n  (b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and\n\n \n\n  (c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and\n\n \n\n  (d) every alkaloid of the substance and every salt of such an alkaloid; and\n\n \n\n  (e) every stereoisomer of the substance and every salt of such a stereoisomer; and\n\n \n\n  (f) every recombinant form of the substance; and \n\n \n\n  (g) a preparation or admixture containing any proportion of the substance,\n\n \n\n \n\n  (h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or\n\n \n\n  (i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or\n\n \n\n  (j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or\n\n \n\n  (k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the Standards for Active Constituents, as published by the Australian Pesticides and Veterinary Medicines Authority.\n\n \n\n (3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a Schedule or an Appendix to this Standard in respect of a substance:\n\n \n\n  (a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and\n\n \n\n  (b) the expression “one per cent” means:\n\n \n\n   (i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or\n\n \n\n   (ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and\n\n \n\n   (iii) any expression of greater or lesser percentages shall have a corresponding meaning; and\n\n \n\n  (c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.\n\n \n\n (4) A reference to a boiling or distillation temperature in the Schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).\n\n# PART 2\n\n \n\n# LABELS AND CONTAINERS\n\n \n\n## LABELS\n\n \n\n2. A person must not sell or supply a poison unless it is labelled in accordance with paragraphs 3 to 19 of this Standard.\n\n \n\n## General requirements\n\n \n\n3. Any word, expression or statement required by this Standard to be written on a label or container must be written:\n\n \n\n (1) on the outside face of the label or container; and\n\n \n\n (2) in the English language; and\n\n \n\n (3) in durable characters; and\n\n \n\n (4) in a colour or colours to provide a distinct contrast to the background colour; and\n\n \n\n (5) in letters at least 1.5 millimetres in height.\n\n \n\n4. Subparagraph 3(5) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:\n\n \n\n (1) an appropriate authority approves the use of smaller letters; and\n\n \n\n (2) the letters are at least 1 millimetre in height.\n\n \n\n5. The label must be printed on, or securely attached to:\n\n \n\n (1) the outside of the immediate container; and\n\n \n\n (2) if the immediate container is enclosed in a primary pack, the outside of that primary pack.\n\n \n\n## Immediate wrapper\n\n \n\n6. (1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with paragraph 7 of this Standard; and\n\n \n\n (2) the immediate wrapper must be conspicuously labelled with:\n\n \n\n  (a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and\n\n \n\n  (b) the approved name of the poison; and\n\n \n\n \n\n  (c) a statement of the quantity or strength of the poison in accordance with   paragraph 8 of this Standard.\n\n \n\n## Primary packs and immediate containers\n\n \n\n7. (1) The primary pack and immediate container of a poison must be labelled as follows:\n\n \n\n  (a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:\n\n \n\n Schedule Purpose Signal words required\n\n \n\n 2 for any purpose PHARMACY MEDICINE\n\n \n\n 3 for any purpose PHARMACIST ONLY MEDICINE\n\n \n\n 4 for human use PRESCRIPTION ONLY MEDICINE\n\n \n\n 4 for animal use PRESCRIPTION ANIMAL REMEDY\n\n \n\n 5 for any purpose CAUTION\n\n \n\n 6 for any purpose POISON\n\n \n\n 7 for any purpose DANGEROUS POISON\n\n \n\n 8 for any purpose CONTROLLED DRUG\n\n \n\n \n\n   (i) on the first line or lines of the main label; and\n\n \n\n \n\n   (iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:\n\n \n\n    (A) 6 millimetres on labels for packages having a nominal capacity of   2 litres or less; or\n\n \n\n    (B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and \n\n \n\n   (iv) if the poison:\n\n \n\n    (A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail or a statement of the principal hazard of the poison, written on that line; or\n\n \n\n    (B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on that line;\n\n \n\n  (b) if the poison is a Schedule 8 poison, with the cautionary statement –\n\n \n\nPOSSESSION WITHOUT AUTHORITY ILLEGAL\n\n \n\n \n\n   (i) on a separate line or lines immediately below the signal words required by subparagraph 7(1)(a); and\n\n \n\n \n\n   (iii) in letters at least four-tenths the height of the letters used for the signal words; and\n\n \n\n   (iv) with no other statement written on the same line;\n\n \n\n  (c) with the cautionary statement –\n\n \n\nKEEP OUT OF REACH OF CHILDREN\n\n \n\n \n\n   (i) on a separate line or lines:\n\n \n\n    (A) immediately below the signal word or words required by subparagraph 7(1)(a); or\n\n \n\n    (B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by subparagraph 7(1)(b), on the line immediately below that statement; and\n\n \n\n \n\n \n\n   (iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;\n\n \n\n  (d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, except for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, with the cautionary statement –\n\n \n\nFIRE AND EXPLOSION HAZARD\n\n \n\n \n\n   (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and\n\n \n\n \n\n \n\n   (iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;\n\n \n\n  (e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –\n\n \n\nBURNS SKIN AND THROAT\n\n \n\n \n\n   (i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and\n\n \n\n \n\n   (iii) in letters at least four-tenths the height of the letters used for the signal word; and\n\n \n\n   (iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line of the main label;\n\n \n\n(f) if the poison is an aqueous solution of paraquat, with the cautionary statements –\n\n \n\nCAN KILL IF SWALLOWED\n\nDO NOT PUT IN DRINK BOTTLES\n\nKEEP LOCKED UP\n\n \n\n \n\n   (i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and\n\n \n\n \n\n   (iii) in letters at least four-tenths the height of the letters used for the signal words; and\n\n \n\n   (iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same lines of the main label;\n\n \n\n  (g) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if safety directions are required on the label by subparagraph 7(1)(n), with the cautionary statement –\n\n \n\nREAD SAFETY DIRECTIONS BEFORE OPENING\n\nOR USING\n\n \n\n   or with the cautionary statement –\n\n \n\nREAD SAFETY DIRECTIONS\n\n \n\n \n\n   (i) on a separate line or lines;\n\n \n\n    (A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); or\n\n \n\n    (B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and\n\n \n\n \n\n \n\n   (iv) with nothing, other than a Class label as specified in the Australian Code for the Transport of Dangerous Goods by Road and Rail, written on the same line;\n\n \n\n  (h) if the poison meets the criteria for a ‘flammable liquid’ in the Australian Code for the Transport of Dangerous Goods by Road and Rail, with the cautionary statement –\n\n \n\nFLAMMABLE\n\n \n\n   written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the Australian Code for the Transport of Dangerous Goods by Road and Rail;\n\n \n\n(i) if the poison is for the treatment of animals, with the cautionary statement –\n\n \n\n \n\n   written on the main label in bold-face sans serif capital letters of uniform thickness;\n\n \n\n  (j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –\n\n \n\nDO NOT SWALLOW\n\n \n\n   written in sans serif capital letters on the main label or as part of the directions for use;\n\n \n\n  (k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with paragraph 8:\n\n \n\n   (i) if the poison is for human therapeutic use, written in accordance with orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act, 1989; or\n\n \n\n   (ii) if the poison is not for human therapeutic use, written in bold-face sans serif capital letters on the main label, unless:\n\n \n\n    (A) a list of approved names is required; and\n\n \n\n    (B) it is impractical to include the list on the main label; and\n\n \n\n    (C) an appropriate authority has authorised its inclusion on another part of the label; or\n\n \n\n   (iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:\n\n \n\nTABLE\n\n \n\n    Column 1 Column 2\n\n \n\n    Alkaline salts Alkaline salts\n\n \n\n     Amines for use as curing Aliphatic amines or\n\n      agents for epoxy resins aromatic amines\n\n      (unless separately specified\n\n      in the Schedules) \n\n \n\n      Epoxy resins, liquid Liquid epoxy resins\n\n \n\n      Hydrocarbons, liquid Liquid hydrocarbons\n\n \n\n      Quaternary ammonium Quaternary ammonium\n\n      compounds compound(s)\n\n \n\n   (iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:\n\n \n\n    (A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or\n\n \n\n    (B) where the designated solvent is a ketone as “ketones”; or\n\n \n\n    (C) in any other case as “solvents” or “other solvents”;\n\n \n\n  (l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –\n\n \n\nAN ANTICHOLINESTERASE COMPOUND\n\n \n\n   (i) the requirements of subparagraph 7(1)(l) do not apply to:\n\n \n\n    (A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or\n\n \n\n    (B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or\n\n \n\n    (C) an organophosphorus compound or carbamate contained in a\n\n     pressurised spray pack for household use;\n\n \n\n  (m) for any poison other than a poison for human therapeutic use labelled in accordance with Therapeutic Goods Order 69 General requirements for labels for medicines or in an agricultural or veterinary chemical product labelled in compliance with the Agricultural and Veterinary Chemicals Code Act 1994, if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:\n\n \n\n   (i) the poison is included in Schedule 4 or Schedule 8; or\n\n \n\n   (ii) it is impractical to include such directions on the label and:\n\n \n\n    (A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and\n\n \n\n    (B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and\n\n \n\n    (C) the insert is enclosed in the primary pack;\n\n \n\n  (n) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –\n\n \n\nSAFETY DIRECTIONS\n\n \n\n   written in bold-face capital letters;\n\n \n\n  (o) for any poison other than a poison for human therapeutic use labelled in accordance with the Required Advisory Statements for Medicine Labels, if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:\n\n \n\n   (i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or\n\n \n\n   (ii) if there are no safety directions, immediately preceding the directions for use;\n\n \n\n  (p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):\n\n \n\n   (i) grouped together and prefaced by the words –\n\n \n\nFIRST AID\n\n \n\n    written in bold-face capital letters; or\n\n \n\n   (ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:\n\n \n\n    (A) written on each immediate container as specified in subparagraph 7(1)(p)(i); and\n\n \n\n    (B) replaced on the primary pack with the statement –\n\n \n\nFIRST AID: See inner packs;\n\n \n\n  (q) with the name and address of the manufacturer or distributor.\n\n \n\n (2) For the purposes of subparagraph 7(1)(a)(iii) the term “largest letter or numeral” does not include:\n\n \n\n  (a) a single letter or numeral which is larger than other lettering on the label; or\n\n \n\n  (b) an affix forming part of the trade name; or\n\n \n\n  (c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.\n\n \n\n## Statements of quantity, proportion or strength\n\n \n\n8. The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:\n\n \n\n (1) if the poison is for human therapeutic use, in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989;\n\n \n\n (2) if the poison is for a purpose or purposes other than human therapeutic use and:\n\n \n\n  (a) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;\n\n \n\n  (b) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;\n\n \n\n  (c) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;\n\n \n\n  (d) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;\n\n \n\n  (e) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;\n\n \n\n  (f) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;\n\n \n\n  (g) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;\n\n \n\n  (h) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;\n\n \n\n (3) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;\n\n \n\n (4) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:\n\n \n\n   contains not more than 10 per cent of (insert name of the metal); or\n\n \n\n   contains not more than 30 per cent of (insert name of the metal); or\n\n \n\n   contains more than 30 per cent of (insert name of the metal);\n\n \n\n (5) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;\n\n \n\n (6) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;\n\n \n\n (7) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.\n\n \n\n (8) For the purposes of subparagraph 8(7) “derivative” includes alkaloid.\n\n \n\n## Exemptions\n\n \n\n### Selected containers and measure packs\n\n \n\n9. The requirements of paragraph 7 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which paragraph 10 or 11 apply) when:\n\n \n\n (1) the immediate container is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or\n\n \n\n (2) the immediate container is:\n\n \n\n \n\n   (b) labelled with:\n\n \n\n    (i) the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to subparagraph 7(1)(a); and\n\n \n\n    (ii) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and\n\n \n\n    (iii) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and\n\n \n\n    (iv) if the poison is for the treatment of animals, with the cautionary statement –\n\n \n\n \n\n      written in sans serif capital letters.\n\n \n\n### Ampoules, pre-filled syringes and injection vials\n\n \n\n10. The requirements of paragraph 7 do not apply to a selected container, or an ampoule (other than an ampoule to which paragraph 11 applies) when:\n\n \n\n (1) the selected container or ampoule is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or\n\n \n\n (2) the selected container or ampoule is:\n\n \n\n \n\n  (b) labelled with:\n\n \n\n   (i) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and\n\n \n\n   (ii) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and\n\n \n\n   (iii) if the poison is for the treatment of animals, with the cautionary statement –\n\n \n\n \n\n     written in sans serif capital letters.\n\n \n\n11. The requirements of paragraph 7 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:\n\n \n\n (1) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989; or\n\n \n\n (2) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is:             \n\n \n\n \n\n  (b) the strip is labelled in accordance with paragraph 10; and\n\n \n\n  (c) the ampoule is labelled with:\n\n \n\n   (i) the approved name of the poison or the trade name of the product; and\n\n \n\n   (ii) the quantity, proportion or strength of the poison in accordance with paragraph 8.\n\n \n\n### Transport containers and wrappings\n\n \n\n12. The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.\n\n \n\n### Dispensary, industrial, laboratory and manufacturing poisons\n\n \n\n13. The labelling requirements of this Standard do not apply to a poison that:\n\n \n\n (1) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and\n\n \n\n (2) is labelled in accordance with Safe Work Australia's National Code of Practice for the Labelling of Workplace Substances [NOHSC: 2012(1994)].\n\n \n\n### Exemptions from label requirements in certain circumstances\n\n \n\n13A. (1) The labelling requirements of paragraphs 7 to 12 do not apply to a poison where an appropriate authority has granted a labelling exemption in whole or in part for these sections for a specified product; and\n\n \n\n (2) the labelling exemption from an appropriate authority referred to in subparagraph (1) is limited to no more than 12 months from the effective date of the decision for retail supply of the product; and\n\n \n\n (3) for the avoidance of doubt this paragraph does not apply to exemptions issued under subparagraph  7(1)(m)(ii)(B) of this Standard.\n\n \n\n### Dispensed medicines\n\n \n\n14.  Unless otherwise specified by regulation:\n\n \n\n (1) The labelling requirements of this Standard do not apply to a medicine that:\n\n \n\n  (a) is supplied by an authorised prescriber or other person authorised to supply and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or\n\n \n\n  (b) is supplied on and in accordance with a prescription written by an authorised prescriber and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or\n\n \n\n  (c) is prepared and supplied by a pharmacist for an individual patient and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard.\n\n \n\n (2) A person must not supply a dispensed medicine for human use containing:\n\n \n\n  (a) a poison listed in column 1 of the table at Appendix L Part 2 of this Standard unless it is clearly labelled with the warning statement(s) specified in column 2 of that table; or\n\n \n\n  (b) a poison listed in Appendix K unless it is clearly labelled with a sedation warning (being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).\n\n \n\n### Gas cylinders\n\n \n\n15. The requirements of subparagraphs 7(1)(a)(iv), 7(1)(c)(iv), and 7(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.\n\n \n\n### Paints\n\n \n\n16. The requirements of paragraph 7 do not apply to:\n\n \n\n (1) paint (other than a paint for therapeutic or cosmetic use) which:\n\n \n\n  (a) contains only Schedule 5 poisons; or\n\n \n\n  (b) is a First Schedule or Second Schedule paint that is labelled with:\n\n \n\n   (i) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line;  and\n\n \n\n   (ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and\n\n \n\n   (iii) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and\n\n \n\n   (iv) the name and proportion of the First Schedule or Second Schedule poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or\n\n \n\n (2) a tinter which contains:\n\n \n\n  (a) only Schedule 5 poisons; or\n\n \n\n  (b) a poison included in the First Schedule or Second Schedule to Appendix I, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.\n\n \n\n### Camphor and naphthalene\n\n \n\n17. The labelling requirements of subparagraph 3(4) and paragraph 7 do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:\n\n \n\n (1) complies with paragraph 28; and\n\n \n\n (2) is sold or supplied in a primary pack labelled in accordance with paragraphs 3 and 7.\n\n \n\n### Prohibitions\n\n \n\n18. A label used in connection with any poison must not include:\n\n \n\n (1) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or\n\n \n\n (2) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or\n\n \n\n (3) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or\n\n \n\n (4) any trade name or description that:\n\n \n\n  (a) represents any single constituent of a compound preparation; or\n\n \n\n  (b) misrepresents the composition or any property or quality of the poison; or\n\n \n\n  (c) gives any false or misleading indication of origin or place of manufacture of the poison.\n\n \n\n19. A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:\n\n \n\n (1) any expression required by this Standard to be written or embossed on the container or pack; or\n\n \n\n (2) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.\n\n \n\n## CONTAINERS\n\n \n\n20. A person must not sell or supply a poison unless the immediate container complies with the requirements of paragraphs 21 to 28 of this Standard.\n\n \n\n## Containers for poisons other than Schedule 5 poisons\n\n \n\n21. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled Packaging for poisonous substances.\n\n \n\n21a. Notwithstanding subparagraph 21, a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled Packaging for poisonous substances, if:\n\n \n\n (1) the other safety factors are not diminished; and\n\n \n\n (2) the container has a restricted flow insert and a child-resistant closure.\n\n \n\n22. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:\n\n \n\n (1) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled Packaging for poisonous substances; and\n\n \n\n (2) have the word “POISON”:\n\n \n\n  (a) in sans serif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:\n\n \n\n   (i) embossed; or\n\n \n\n   (ii) indelibly written in a colour in distinct contrast to the background colour;\n\n \n\n  (b) on the side or shoulder of the container.\n\n \n\n## Containers for Schedule 5 poisons\n\n \n\n23. (1) The container in which any Schedule 5 poison is sold or supplied must:\n\n \n\n  (a) comply with the container requirements of paragraph 21 or paragraph 22; or\n\n \n\n  (b) be readily distinguishable from a container in which food, wine or other beverage is sold; and\n\n \n\n   (i) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled Packaging for poisonous substances, excluding paragraph 1.4.3;\n\n \n\n   (ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and\n\n \n\n   (iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.\n\n \n\n (2) Notwithstanding subparagraph 23(1), the following Schedule 5 poisons namely:\n\n \n\n  (a) methylated spirit(s);\n\n \n\n  (b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;\n\n \n\n  (c) petrol;\n\n \n\n  (d) toluene; or\n\n \n\n  (e) xylene,\n\n \n\n  must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in paragraph 21.\n\n \n\n## Approved containers\n\n \n\n24.  Notwithstanding subparagraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of Australian Standard AS2216-1997 entitled Packaging for poisonous substances or the requirements of subparagraphs 22(2) or 23(1)(iii) if:\n\n \n\n (1) the other safety factors are not diminished;\n\n \n\n (2) the container is for a specific purpose; and\n\n \n\n (3) an appropriate authority has approved the use of the container for that purpose.\n\n \n\n## Child-resistant closures\n\n \n\n25. (1) If a poison, other than a poison included in a therapeutic good packaged in a manner compliant with orders made under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989, listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2, it must be closed with a child-resistant closure.\n\n \n\nTABLE\n\n  ______________________________________________________________________\n\n  Column 1    Column 2\n\n  Name of the poison   Nominal capacity\n\n  ______________________________________________________________________\n\n \n\n  Alkaline salts included in Schedule 5,   All sizes  when packed and labelled as dishwashing\n\n  machine tablets.\n\n \n\n  Alkaline salts included in Schedule 5,   5 litres /kilograms or less  when packed and labelled as dishwashing\n\n  machine liquids, solids or gels.\n\n \n\n  Alkaline salts included in Schedule 5, when   2.5 litres or less\n\n  packed and labelled as a food additive.\n\n \n\n  Anise oil when included in Schedule 5.   200 millilitres or less\n\n \n\n  Basil oil when included in Schedule 5.   200 millilitres or less\n\n \n\n  Bay oil when included in Schedule 6.   200 millilitres or less\n\n \n\n  Cajuput oil when included in Schedule 6.   200 millilitres or less\n\n \n\n  Cassia oil when included in Schedule 5.   200 millilitres or less\n\n \n\n  Cineole when included in Schedule 6.   2 litres or less\n\n \n\n  Cinnamon bark oil when included   200 millilitres or less\n\n  in Schedule 5.\n\n \n\n  Cinnamon leaf oil when included in Schedule 6.  200 millilitres or less\n\n  \n\n  Clove oil when included in Schedule 6.   200 millilitres or less\n\n \n\n  Essential oils when included in Schedule 6   200 millilitres or less\n\n  because of their natural camphor component.\n\n \n\n  Ethylene glycol when included in Schedule 6.   5 litres or less\n\n  \n\n  Ethylene glycol when included in    5 litres or less\n\n  Schedule 5 in preparations containing\n\n  more than 50 per cent of ethylene glycol.\n\n \n\n  Eucalyptus oil when included in Schedule 6.   2 litres or less\n\n  \n\n  Eugenol when included in Schedule 6.   200 millilitres or less\n\n \n\n  Hydrocarbons, liquid, when packed     5 litres or less\n\n  as kerosene, lamp oil, mineral turpentine,\n\n  thinners, reducers, white petroleum spirit\n\n  or dry cleaning fluid.\n\n \n\n  Hydrochloric acid when included in Schedule 6.  5 litres or less  \n\n  \n\n  Leptospermum scoparium oil (manuka oil)   200 millilitres or less\n\n  when included in Schedule 6\n\n  \n\n  Marjoram oil when included in Schedule 5.   200 millilitres or less\n\n \n\n  Melaleuca oil (tea-tree oil) when included   200 millilitres or less\n\n  in Schedule 6.\n\n \n\n  Methylated spirit excluding preparations or   5 litres or less  \n\n  admixtures.\n\n \n\n  Methyl salicylate and preparations containing   200 millilitres or less\n\n  more than 50 per cent of methyl salicylate.\n\n \n\n  Nutmeg oil when included in Schedule 5.   200 millilitres or less\n\n \n\n  Oil of turpentine.   5 litres or less\n\n \n\n  Pennyroyal oil when included in Schedule 6.   200 millilitres or less\n\n  \n\n  Potassium hydroxide as such.   2.5 litres or less\n\n \n\n  Potassium hydroxide in oven, hot plate or   5 litres or less\n\n  drain cleaners when included in Schedule 6\n\n  except when in pressurised spray packs.\n\n \n\n  d-Pulegone when included in Schedule 6.   200 millilitres or less\n\n  \n\n  Sage oil (Dalmatian) when included   200 millilitres or less\n\n  in Schedule 6.\n\n \n\n  Sodium hydroxide as such.   2.5 litres or less\n\n \n\n  Sodium hydroxide in oven, hot plate or    5 litres or less\n\n  drain cleaners when included in Schedule 6\n\n  except when in pressurised spray packs.\n\n \n\n  Thujone when included in Schedule 6.   200 millilitres or less\n\n  \n\n  Thyme oil when included in Schedule 5.   200 millilitres or less\n\n \n\n (2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.\n\n \n\n## Schedule 8 poisons\n\n \n\n25A. (1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.\n\n \n\n (2) This paragraph does not apply to the supply of a Schedule 8 poison by an:\n\n \n\n  (a) authorised prescriber or other authorised supplier;\n\n \n\n  (b) pharmacist on the prescription of an authorised prescriber;\n\n \n\n  (c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse or midwife in charge of the ward in which the Schedule 8 poison is to be used or stored; or\n\n \n\n  (d) nurse or midwife on the direction in writing of an authorised prescriber.\n\n \n\n## Exemptions\n\n \n\n26. (1) Paragraphs 21, 22 and 23 do not apply to the immediate container of a poison prepared, packed and sold:\n\n \n\n  (a) for human internal or animal internal use; or\n\n \n\n  (b) as a solid or semi-solid preparation for human external or animal external use; or\n\n \n\n  (c) as a paint, other than a paint for therapeutic or cosmetic use; or\n\n \n\n  (d) in containers having a nominal capacity of 15 millilitres or less; or\n\n \n\n  (e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or\n\n \n\n  (f) solely for dispensary, industrial, laboratory or manufacturing purposes.\n\n \n\n (2) Paragraph 25 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.\n\n \n\n27. The tactile identification or embossing required by paragraphs 21, 22 or 23 of this Standard or Australian Standard AS 2216-1997 entitled Packaging for poisonous substances do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.\n\n \n\n## Camphor and naphthalene\n\n \n\n28. The container requirements of paragraph 21 do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:\n\n \n\n (1) in normal use, prevents removal or ingestion of its contents; and\n\n \n\n (2) is incapable of reacting with the poison; and\n\n \n\n (3) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and\n\n \n\n (4) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.\n\n \n\n## Prohibitions\n\n \n\n29.  A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.\n\n \n\n30. A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.\n\n \n\n31. A person must not sell any poison which is for internal use or any food, drink or condiment in a container prescribed by paragraph 21, 22 or 23 of this Standard.\n\n \n\n31A. A person must not sell any poison in a container used expressly for any food, drink or condiment.\n\n# PART 3\n\n \n\n# MISCELLANEOUS REGULATIONS\n\n \n\n(It is recommended that the States and Territories implement regulations which   provide controls similar to those included in this Part of the Standard.)\n\n \n\n## ADVERTISING\n\n \n\n32.  A person must not include any reference to a poison included in:\n\n \n\n (a) Schedule 3 unless included in Appendix H; or\n\n \n\n (b)  Schedule 4 or Schedule 8,\n\n \n\n of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.\n\n \n\n33. A person must not include any reference to a poison included in Schedule 9 or Appendix C of this Standard in any advertisement.\n\n \n\n## SALE OR SUPPLY\n\n \n\n## Schedule 2 poisons\n\n \n\n34. A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.\n\n \n\n35. A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:\n\n \n\n (1) he or she is carrying on the business of selling goods by retail; and\n\n \n\n (2) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy;  and\n\n \n\n (3) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.\n\n \n\n## Schedule 3 poisons\n\n \n\n36. A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.\n\n \n\n37. The person who sells or supplies a Schedule 3 poison must:\n\n \n\n (1) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and\n\n \n\n (2) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and\n\n \n\n (3) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.\n\n \n\n## Schedule 4 poisons\n\n \n\n38. A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.\n\n \n\n39. Paragraph 38 does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:\n\n \n\n (1) the patient is under medical treatment with the poison and continuation of medication is essential;  and\n\n \n\n (2) the quantity sold or supplied does not exceed 3 days' medication; and\n\n \n\n (3) the pharmacist is satisfied that an emergency exists.\n\n \n\n40. Paragraphs 34, 36, 37 and 38 do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.\n\n \n\n## Schedule 7 poisons\n\n \n\n41.  (1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.\n\n \n\n (2) A person must not sell or supply:\n\n \n\n  (a) a Schedule 7 poison for domestic or domestic garden purposes; or\n\n \n\n  (b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or\n\n \n\n  (c) a Schedule 7 poison for which an authorisation to possess or use is required by subparagraph (3) unless the purchaser produces his or her authorisation.\n\n \n\n (3) A person must not possess or use any of the following Schedule 7 poisons unless he or she is authorised to do so by the appropriate authority:\n\n \n\n  Arsenic\n\n  Cyanides\n\n  Fluoroacetic acid\n\n  Fluoroacetamide\n\n  Hydrocyanic acid\n\n  Strychnine\n\n  Thallium.\n\n \n\n (4) The appropriate authority may exempt a person or a class of persons from the requirement to hold an authorisation under subparagraph (3) and may vary or revoke the exemption by notice in writing.\n\n \n\n## Prohibitions on sale, prescribing and possession\n\n \n\n42. A person must not:\n\n \n\n (1) knowingly have in his or her possession or sell, supply or use a poison listed in Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Appendix C; or\n\n \n\n (2) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or\n\n \n\n (3) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.\n\n \n\n## STORAGE\n\n \n\n43. A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.\n\n \n\n44. A person who sells or supplies Schedule 3, Schedule 4 or Schedule 7 poisons must keep those poisons in a part of the premises to which the public does not have access.\n\nThis page is intentionally blank.\n\n \n\n# PART 4\n\n \n\n# THE SCHEDULES\n\n## SCHEDULE 1\n\n \n\nThis Schedule is intentionally blank.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n## SCHEDULE 2\n\n \n\n \n\nACETIC ACID (excluding its salts and derivatives) and preparations containing  more than 80 per cent of acetic acid (CH3COOH) for therapeutic use. \n\n \n\nACETYLCYSTEINE in preparations for oral use except when labelled with a recommended daily dose of 1 g or less of acetylcysteine.\n\n \n\nACONITUM spp. for therapeutic use in adults:\n\n \n\n (a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids; or\n\n \n\n (b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids except in packs containing 0.02 mg or less of total alkaloids.\n\n \n\nALOXIPRIN.\n\n \n\nAMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.\n\n \n\nAMOROLFINE in preparations for topical use except in preparations for the treatment of tinea pedis.\n\n \n\nANTAZOLINE in eye drops.\n\n \n\nASPIRIN except:\n\n \n\n (a) when included in Schedule 4, 5 or 6;\n\n \n\n (b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:\n\n \n\n   (i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and\n\n \n\n   (ii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:\n\n \n\n   (i) packed in blister or strip packaging or in a container with a child-resistant closure;\n\n \n\n   (ii) in a primary pack of not more than 25 tablets or capsules, each containing 325  mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and\n\n \n\n   (iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:\n\n \n\n   (i)  packed in blister or strip packaging or in a container with a child-resistant\n\n \n\n    closure;\n\n \n\n   (ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg  or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and\n\n \n\n   (iii) compliant with the requirements of the Required Advisory Statements for Medicine Labels.\n\n \n\nATROPA BELLADONNA (belladonna):\n\n \n\n (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or\n\n \n\n \n\n   (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n   (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\n \n\nATROPINE (excluding atropine methonitrate) for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\n \n\nAZELAIC ACID in dermal preparations.\n\n \n\nAZELASTINE:\n\n \n\n (a) in preparations for nasal use; or\n\n \n\n (b) in topical eye preparations containing 0.05 per cent or less of azelastine.\n\n \n\nBECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\n \n\nBENZOCAINE in preparations for topical use other than eye drops:\n\n \n\n (a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or\n\n \n\n (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\n \n\nBENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide except in preparations containing 5 per cent or less of benzoyl peroxide.\n\n \n\nBENZYDAMINE in preparations for topical use, except in preparations for dermal use.\n\n \n\nBEPHENIUM SALTS.\n\n \n\nBIFONAZOLE in preparations for dermal use except:\n\n \n\n (a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or\n\n \n\n \n\nBROMHEXINE.\n\n \n\nBROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nBUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\n \n\nCARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.\n\n \n\nCARBOCISTEINE.\n\n \n\nCETIRIZINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n1.                  in a primary pack containing not more than 5 days’ supply; and\n\n \n\n1.                 labelled with a recommended daily dose not exceeding 10 mg of cetirizine.\n\n \n\nCHLOPHEDIANOL.\n\n \n\nCHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol except in preparations containing 0.5 per cent or less of chlorbutol.\n\n \n\nCHLOROFORM in preparations for therapeutic use except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of chloroform.\n\n \n\nCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nCICLOPIROX:\n\n \n\n1.             in preparations for dermal use containing 2 per cent or less of ciclopirox except in preparations for the treatment of tinea pedis; or\n\n \n\n1.             in preparations for application to the nails containing 8 per cent or less of ciclopirox.\n\n \n\nCINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.\n\n \n\nCINNAMEDRINE.\n\n \n\nCLOTRIMAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.\n\n \n\nCODEINE in preparations for the treatment of coughs and colds when:\n\n1.           not combined with any other opiate substance;\n\n \n\n1.          compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:\n\n \n\n1.           in divided preparations containing 10 mg or less of codeine per dosage unit; or\n\n \n\n  (ii) in undivided preparations containing 0.25 per cent or less of codeine;\n\n \n\n1.           labelled with a recommended daily dose not exceeding 60 mg of codeine; and\n\n \n\n (d) in packs containing not more than 6 days' supply at the maximum dose recommended on the label.\n\n \n\nCREOSOTE derived from wood other than beechwood for human therapeutic use, except in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.\n\n \n\nDATURA spp. for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,\n\n \n\n except when separately specified in these Schedules.\n\n \n\nDATURA STRAMONIUM (stramonium) for oral use when:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,\n\n \n\n except for smoking or burning.\n\n \n\nDATURA TATULA (stramonium) for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of  0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,\n\n \n\nexcept for smoking or burning.\n\n \n\nDELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of Delphinium staphisagria.\n\n \n\nDESLORATADINE in preparations for oral use.\n\n \n\nDEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nDEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.\n\n \n\nDIBROMOPROPAMIDINE for ophthalmic use.\n\n \n\nDICLOFENAC when:\n\n \n\n1.                  in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;\n\n \n\n1.                  in preparations for dermal use containing 4 per cent or less of diclofenac except in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or\n\n \n\n1.                  in transdermal preparations for topical use containing 140 mg or less of diclofenac.\n\n \n\nDIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:\n\n \n\n (a) containing 5 mg or less of dihydrocodeine per dosage unit;\n\n \n\n (b) packed in blister or strip packaging or in a container with a child-resistant closure;\n\n \n\n (c) enclosed in primary packs containing 25 or less dosage units; and\n\n \n\n (d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.\n\n \n\nDIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.\n\n \n\nDIPHENHYDRAMINE in oral preparations:\n\n \n\n (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or\n\n \n\n (b) when combined with one or more other therapeutically active substances when:\n\n   (ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nDOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,              \n\n \n\n \n\nDUBOISIA LEICHHARDTII for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\n \n\nDUBOISIA MYOPOROIDES for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\n \n\nECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.\n\n \n\nETAFEDRINE.\n\n \n\nETHER for therapeutic use except:\n\n \n\n \n\n (b) in preparations containing 10 per cent or less of ether.\n\n \n\nETHYLMORPHINE when:\n\n \n\n (a) compounded with one or more other therapeutically active substances:\n\n \n\n   (i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or\n\n \n\n   (ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;\n\n  \n\n (b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.\n\n \n\nETOFENAMATE in preparations for external use.\n\n \n\nFAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.\n\n \n\nFELBINAC in preparations for external use.\n\n \n\nFEXOFENADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n1.                  in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and\n\n \n\n1.                  labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.\n\n \n\nFLUORIDES for human use:\n\n \n\n (a)  in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or\n\n \n\n (b)  in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:\n\n \n\n   (i) for therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of Required Advisory Statements for Medicine Labels; or\n\n \n\n   (ii) for non-therapeutic use when labelled with warnings to the following effect:\n\n \n\n \n\n    (B) Do not use [this product/name of product] in children six years of age or less,\n\n \n\n    except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:\n\n \n\n \n\n    (B) Do not use [this product/name of product] in children six years of age or less,\n\n except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.\n\n \n\nFLURBIPROFEN in preparations for topical oral use when:\n\n (a)  in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or\n\n \n\n (b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.\n\n \n\nFLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\n \n\nFOLIC ACID for human therapeutic use except:\n\n \n\n \n\n (b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.\n\n \n\nFOLINIC ACID for human therapeutic use except:\n\n \n\n \n\n (b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.\n\n \n\n† FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:\n\n \n\n (a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or\n\n \n\n (b) in other preparations containing 0.2 per cent or less of free formaldehyde.\n\n \n\nGUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled  for the treatment of children under 12 years of age.\n\n \n\nGELSEMIUM SEMPERVIRENS.\n\n \n\nGLUTARALDEHYDE for human therapeutic use.\n\n \n\nHEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane except:\n\n \n\n (a) in preparations containing 0.75 per cent or less of hexachlorophane; or\n\n \n\n (b) in preparations for use on infants, as specified in Schedule 4.\n\n \n\nHYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:\n\n \n\n (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or\n\n \n\n (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:\n\n \n\n   (i) in undivided preparations in packs of 35 g or less; or\n\n \n\n   (ii) in packs containing 12 or less suppositories.\n\n \n\nHYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone except:\n\n \n\n1.      in hair preparations containing 0.3 per cent or less of hydroquinone; or\n\n \n\n1.     in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.\n\n \n\n8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in preparations for external use containing 1 per cent or less of such substances.\n\n \n\nHYOSCINE (excluding hyoscine butylbromide):\n\n \n\n (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or\n\n \n\n  \n\n   (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n    (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.\n\n \n\nHYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.\n\n \n\nHYOSCYAMINE:\n\n \n\n (a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or\n\n \n\n \n\n   (i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n   (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2  mg or less total solanaceous alkaloids.\n\n \n\nHYOSCYAMUS NIGER for oral use:\n\n \n\n (a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or\n\n \n\n (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,\n\n \n\n except in a pack containing 0.03 mg or less of total solanaceous alkaloids.\n\n \n\nIBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:\n\n \n\n (a) in liquid preparations when sold in the manufacturer’s original pack containing 8 grams or less of ibuprofen; or\n\n \n\n (b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:\n\n \n\n  (i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);\n\n \n\n  (ii) packed in blister or strip packaging or in a container with a child-resistant closure;\n\n \n\n  (iii) in a primary pack containing not more than 25 dosage units;\n\n \n\n  (iv) compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n  (v) not labelled for the treatment of children 6 years of age or less; and\n\n \n\n  (vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.\n\n \n\nINDANAZOLINE.\n\n \n\nINDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.\n\n \n\nIODINE:\n\n \n\n (a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or\n\n \n\n (b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),\n\n \n\n except in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.\n\n \n\nIPRATROPIUM in preparations for nasal use.\n\n \n\nIRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use except:\n\n \n\n \n\n (b)  when labelled with a recommended daily dose of 24 mg or less of iron:\n\n \n\n   (i)  in undivided preparations supplied in packs each containing 750 mg or less of iron; or\n\n \n\n   (ii)  in divided preparations:\n\n \n\n    (A)  containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or\n\n \n\n    (B) containing 5 mg or less of iron per dosage unit.\n\n \n\nISOCONAZOLE for human use in dermal preparations.\n\n \n\nISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.\n\n \n\nKETOCONAZOLE in preparations for dermal use except:\n\n \n\n (a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the\n\n  scalp; or\n\n \n\n \n\nKETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.\n\n \n\nLEVOCABASTINE in topical eye or nasal preparations.\n\n \n\nLIGNOCAINE in preparations for topical use other than eye drops:\n\n \n\n (a) containing 10 per cent or less of total local anaesthetic substances, except in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or\n\n \n\n (b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\n \n\nLINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.\n\n \n\nLITHIUM in preparations for dermal use containing 1 per cent or less of lithium except:\n\n \n\n (a) when present as an excipient at 0.25 per cent or less of lithium; or\n\n \n\n (b) in preparations containing 0.01 per cent or less of lithium.\n\n \n\nLOBELIA INFLATA except for smoking or burning.\n\n \n\nLOBELINE except in preparations for smoking or burning.\n\n \n\nLODOXAMIDE in preparations for ophthalmic use.\n\n \n\nLOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.\n\n \n\nLORATADINE in preparations for oral use except in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n (a) in a primary pack containing 5 dosage units or less; and\n\n \n\n (b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.\n\n \n\nMACROGOLS in preparations for oral use as a liquid concentrate for laxative use.\n\n \n\nMEBENDAZOLE for human therapeutic use.\n\n \n\nMECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, except in preparations for the treatment of children under 2 years of age.\n\n \n\nMEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.\n\n \n\nMEPYRAMINE for dermal use.\n\n \n\nMERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome except when included in Schedule 6.\n\n \n\nMERCURY for external use in preparations containing 0.5 per cent or less of mercury.\n\n \n\nMETHOXAMINE in preparations for external use except in preparations containing 1 per cent or less of methoxamine.\n\n \n\nMETHOXYPHENAMINE.\n\n \n\nMETHYLEPHEDRINE.\n\n \n\nMICONAZOLE for human use in dermal preparations and for application to the nails except in preparations for the treatment of tinea pedis.\n\n \n\nMINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.\n\n \n\nMOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.\n\n \n\nNAPHAZOLINE.\n\n \n\nNAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.\n\n \n\nNICLOSAMIDE for human therapeutic use.\n\n \n\nNIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.\n\n \n\nNOSCAPINE.\n\n \n\nNYSTATIN in dermal preparations.\n\n \n\nOXETACAINE (oxethazaine) in preparations for internal use.\n\n \n\nOXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.\n\n \n\nOXYMETAZOLINE.\n\n \n\nPAPAVERINE except when included in Schedule 4.\n\n \n\nPARACETAMOL for therapeutic use except:\n\n \n\n(a)  when included in Schedule 4;\n\n \n\n(b)  in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesinor when combined with effervescent agents) when:\n\n \n\n1.                    enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;\n2.                 compliant with the requirements of the Required Advisory Statements  for Medicine Labels;\n3.               not labelled for the treatment of children 6 years of age or less; and\n4.               not labelled for the treatment  of children under 12 years of age when  combined with phenylephrine and/or guaiphenesin; or\n\n (c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:\n\n \n\n1.                    packed in blister or strip packaging or in a container with a child-resistant closure;\n2.                 in a primary pack containing not more than 20 tablets or capsules;\n3.               compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n4.               not labelled for the treatment of children 6 years of age or less; and\n5.                 not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.\n\n \n\n† PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:\n\n \n\n (a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or\n\n \n\n (b) in other preparations containing 0.2 per cent or less of free formaldehyde.\n\n \n\nPENCICLOVIR for external use for the treatment of herpes labialis.\n\n \n\nPHEDRAZINE.\n\n \n\nPHENAZONE for human external use.\n\n \n\nPHENIRAMINE:\n\n \n\n (a) in eye drops; or\n\n \n\n (b) when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n   (ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nPHENOL, or any homologue boiling below 220°C, for human therapeutic use except:\n\n \n\n \n\n (b) in preparations for external use containing 3 per cent or less of such substances.\n\n \n\nPHENYLEPHRINE except:\n\n \n\n \n\n (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or\n\n \n\n (c)  in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.\n\n \n\nPHOLCODINE:\n\n \n\n (a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or\n\n \n\n (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a               recommended dose not exceeding 25 mg of pholcodine.\n\n \n\nPIPERAZINE for human therapeutic use.\n\n \n\nPODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.\n\n \n\nPODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.\n\n \n\nPODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.\n\n \n\nPOTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or less of potassium chlorate.\n\n \n\nPRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.\n\n \n\nPROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.\n\n \n\nPROMETHAZINE in oral preparations:\n\n \n\n (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or\n\n \n\n (b) when combined with one or more other therapeutically active substances when:\n\n   (ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nPROPAMIDINE for ophthalmic use.\n\n \n\nPYRANTEL for human therapeutic use.\n\n \n\nPYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.\n\n \n\nPYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.\n\n \n\nRANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply except in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.\n\n \n\nSALICYLAMIDE except when included in Schedule 4.\n\n \n\nSELENIUM in preparations for human therapeutic use except:\n\n \n\n(a) for topical use containing 3.5 per cent or less of selenium sulfide;\n\n \n\n (b) when included in Schedule 4; or\n\n \n\n (c) for oral use with a recommended daily dose of 150 micrograms or less.\n\n \n\nSILVER for therapeutic use except:\n\n \n\n (a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n (b) in other preparations containing 1 per cent or less of silver.\n\n \n\nSODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.\n\n \n\nSODIUM NITRITE for therapeutic use (excluding when present as an excipient).\n\n \n\nSQUILL except in preparations containing 1 per cent or less of squill.\n\n \n\nSULCONAZOLE in preparations for dermal use.\n\n \n\nTERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.\n\n \n\nTETRACHLOROETHYLENE for human therapeutic use.\n\n \n\nTETRAHYDROZOLINE.\n\n \n\nTHIABENDAZOLE for human therapeutic use.\n\n \n\nTIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.\n\n \n\nTRAMAZOLINE.\n\n \n\nTRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.\n\n \n\nTRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses\n\n  are in the same immediate container or immediate wrapper,\n\n \n\n \n\nTRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:\n\n \n\n \n\n (b) in a day-night pack containing triprolidine in the bed-time dose where the day and night\n\n  doses are in the same immediate container or immediate wrapper,\n\n \n\n \n\nTUAMINOHEPTANE.\n\n \n\nTYMAZOLINE.\n\n \n\nXYLOMETAZOLINE.\n\n \n\nZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of zinc chloride.\n\n## SCHEDULE 3\n\n \n\nADRENALINE in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.\n\n \n\nALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing  0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.\n\n \n\nAMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.\n\n \n\nAZATADINE in oral preparations.\n\n \n\nBROMPHENIRAMINE in oral preparations except:\n\n \n\n \n\n \n\nBUCLIZINE in oral preparations.\n\n \n\nBUTOCONAZOLE in preparations for vaginal use.\n\n \n\nCHLORAMPHENICOL for ophthalmic use only.\n\n \n\nCHLORBUTOL in preparations for human use except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of chlorbutol.\n\n \n\nCHLORPHENIRAMINE in oral preparations except:\n\n \n\n \n\n \n\nCICLOPIROX in preparations for dermal use and for application to the nails except:\n\n \n\n \n\n \n\nCIMETIDINE in a primary pack containing not more than 14 days' supply.\n\n \n\nCLEMASTINE in preparations for oral use.\n\n \n\nCLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.\n\n \n\nCLOTRIMAZOLE in preparations for vaginal use.\n\n \n\nCODEINE when:\n\n \n\n (a) not combined with any other opiate substance;\n\n \n\n (b) compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:\n\n \n\n  (i) in divided preparations containing 12 mg or less of codeine per dosage unit; or\n\n \n\n  (ii) in undivided preparations containing 0.25 per cent or less of codeine;\n\n \n\n  (c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and\n\n \n\n (d) in packs containing not more than 5 days' of supply at the maximum dose recommended on the label,\n\n \n\n \n\nCYCLIZINE in preparations for oral use.\n\n \n\nCYPROHEPTADINE in oral preparations.\n\n \n\nDEXCHLORPHENIRAMINE in oral preparations except:\n\n \n\n \n\n \n\nDICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units except when included in Schedule 2.\n\n \n\nDIHYDROCODEINE when compounded with one or more other therapeutically active substances:\n\n \n\n (a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or\n\n \n\n (b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,\n\n \n\n \n\nDI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.\n\n \n\nDIMENHYDRINATE in oral preparations except when included in Schedule 2.\n\n \n\nDIMETHINDENE in oral preparations.\n\n \n\nDIPHENHYDRAMINE in oral preparations except:\n\n \n\n \n\n \n\nDIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.\n\n \n\nDITHRANOL for therapeutic use.\n\n \n\nDOXYLAMINE in oral preparations except:\n\n \n\n \n\n \n\nECONAZOLE in preparations for vaginal use.\n\n \n\nERYTHRITYL TETRANITRATE for therapeutic use.\n\n \n\nESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days supply.\n\n \n\nFAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).\n\n \n\nFLAVOXATE.\n\n \n\nFLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.\n\n \n\nFLUORIDES for human topical use:\n\n \n\n (a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure except when included in or expressly excluded from Schedule 2; or\n\n \n\n (b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except:\n\n \n\n   (i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n   (ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:\n\n \n\n \n\n    (B) Do not use [this product/name of product] in children six years of age or less; or\n\n \n\n   (iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.\n\n \n\nGLUCAGON.\n\n \n\nGLYCERYL TRINITRATE:\n\n \n\n (a) in preparations for oral use; or\n\n \n\n (b) in preparations for rectal use.\n\n \n\nGLYCOPYRRONIUM except when included in Schedule 4.\n\n \n\nHYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:\n\n \n\n (a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or\n\n \n\n (b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:\n\n \n\n   (i) in undivided preparations, in packs of 35 g or less; or\n\n \n\n   (ii) in packs containing 12 or less suppositories,\n\n \n\n \n\nIBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units when labelled:\n\n \n\n (a) with a recommended daily dose of 1200 mg or less of ibuprofen; and\n\n \n\n (b) not for the treatment of children under 12 years of age,\n\n \n\n except when included in or expressly excluded from Schedule 2.\n\n \n\nINOSITOL NICOTINATE.\n\n \n\nISOCONAZOLE in preparations for vaginal use.\n\n \n\nISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.\n\n \n\nKETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.\n\n \n\nLANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.\n\n \n\nLEVONORGESTREL for emergency post-coital contraception.\n\n \n\nMACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.\n\n \n\nMAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when containing 1.5 g or less of magnesium sulfate per recommended daily dose.\n\n \n\nMalathion in preparations for human external use except in preparations containing 2 per cent or less of malathion.\n\n \n\nMANNITYL HEXANITRATE for therapeutic use.\n\n \n\nMEPYRAMINE in oral preparations.\n\n \n\nMETHDILAZINE in oral preparations.\n\n \n\nMETOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.\n\n \n\nMICONAZOLE for human use in topical preparations:\n\n \n\n (a) for the treatment of oral candidiasis; or\n\n \n\n (b) for vaginal use.\n\n \n\nNAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit in packs of 16 or less dosage units when labelled not for the treatment of children under 12 years of age.\n\n \n\nNICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit except:\n\n \n\n (a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or\n\n \n\n (b) nicotinamide.\n\n \n\nNICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.\n\n \n\nNYSTATIN in preparations for topical use except when included in Schedule 2.\n\n \n\nOMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.\n\n \n\nORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.\n\n \n\nOXICONAZOLE in preparations for vaginal use.\n\n \n\nPANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.\n\n \n\nPARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.\n\n \n\nPHENIRAMINE in oral preparations except:\n\n \n\n \n\n \n\nPODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\n \n\nPODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\n \n\nPODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.\n\n \n\nPROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.\n\n \n\nPROMETHAZINE in oral preparations except:\n\n \n\n \n\n (b) in preparations for the treatment of children under 2 years of age.\n\n \n\nPSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:\n\n \n\n (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or\n\n \n\n (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).\n\n \n\nRABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.\n\n \n\nSALBUTAMOL as the only therapeutically active substance:\n\n \n\n (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or\n\n \n\n (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.\n\n \n\nSALICYLIC ACID in preparations for dermal use except in preparations containing 40 per cent or less of salicylic acid.\n\n \n\nSANTONIN.\n\n \n\nSODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.\n\n \n\nSODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.\n\n \n\nSULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.\n\n \n\nTERBUTALINE as the only therapeutically active substance:\n\n \n\n (a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or\n\n \n\n (b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.\n\n \n\nTHEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.\n\n \n\nTIOCONAZOLE in preparations for vaginal use.\n\n \n\nTRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.\n\n \n\nTRIMEPRAZINE:\n\n \n\n (a) in solid oral preparations except when included in Schedule 2; or\n\n \n\n (b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,\n\n \n\n \n\nTRIPROLIDINE in oral preparations except:\n\n \n\n \n\n \n\nVITAMIN D  for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose except in preparations containing 25 micrograms or less of vitamin D per recommended daily dose. \n\n \n\n## SCHEDULE 4\n\n \n\n(Substances marked # are listed in Appendix D)\n\n \n\nABACAVIR.\n\n \n\nABATACEPT.\n\n \n\nABIRATERONE ACETATE.\n\n \n\nABCIXIMAB.\n\n \n\nACAMPROSATE CALCIUM.\n\n \n\nACARBOSE.\n\n \n\nACEBUTOLOL.\n\n \n\nACEPROMAZINE.\n\n \n\nACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.\n\n \n\nACETARSOL.\n\n \n\nACETAZOLAMIDE.\n\n \n\nACETOHEXAMIDE.\n\n \n\nACETYL ISOVALERYLTYLOSIN.\n\n \n\nACETYLCARBROMAL.\n\n \n\nACETYLCHOLINE.\n\n \n\nACETYLCYSTEINE except:\n\n \n\n \n\n (b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.\n\n \n\nACETYLDIGITOXIN.\n\n \n\nACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.\n\n \n\nACETYLSTROPHANTHIDIN.\n\n \n\nACICLOVIR except in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.\n\n \n\nACIPIMOX.\n\n \n\n# ACITRETIN.\n\n \n\nACLIDINIUM BROMIDE.\n\n \n\nACOKANTHERA OUABAIO.\n\n \n\nACOKANTHERA SCHIMPERI.\n\n \n\nACONITUM spp. except:\n\n \n\n \n\n (b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or\n\n \n\n (c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.\n\n \n\nACRIVASTINE.\n\n \n\nADALIMUMAB.\n\n \n\nADAPALENE.\n\n \n\nADEFOVIR.\n\n \n\nADENOSINE for human therapeutic use in preparations for injection.\n\n \n\nADIPHENINE.\n\n \n\nADONIS VERNALIS.\n\n \n\nADRAFINIL.\n\n \n\nADRENALINE. except:\n\n \n\n(a) when included in Schedule 3; or\n\n \n\n(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.\n\n \n\nADRENOCORTICAL HORMONES except when separately specified in these Schedules.\n\n \n\nAFAMELANOTIDE.\n\n \n\nafatinib dimaleate.\n\n \n\nAFLIBERCEPT.\n\n \n\nAGALSIDASE.\n\n \n\nAGLEPRISTONE.\n\n \n\nAGOMELATINE.\n\n \n\nALATROFLOXACIN MESYLATE.\n\n \n\nALBENDAZOLE except:\n\n \n\n (a) when included in Schedule 5 or 6; or\n\n \n\n (b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.\n\n \n\nALCLOFENAC.\n\n \n\nALCLOMETASONE except when included in Schedule 3.\n\n \n\nALCURONIUM.\n\n \n\nALDESLEUKIN.\n\n \n\nALDOSTERONE.\n\n \n\n# ALEFACEPT.\n\n \n\nALEMTUZUMAB.\n\n \n\nALENDRONIC ACID.\n\n \n\nALFACALCIDOL.\n\n \n\nALFUZOSIN.\n\n \n\nALGLUCERASE.\n\n \n\nALGLUCOSIDASE.\n\n \n\nALISKIREN.\n\n \n\nALLERGENS.\n\n \n\nALLOPURINOL.\n\n \n\nALLYLOESTRENOL.\n\n \n\nALOGLIPTIN.\n\n \n\nALOSETRON.\n\n \n\nALPHA1-PROTEINASE INHIBITOR (HUMAN).\n\n \n\nALPHADOLONE.\n\n \n\nALPHAXALONE.\n\n \n\nALPRENOLOL.\n\n \n\nALPROSTADIL.\n\n \n\nALSEROXYLON.\n\n \n\nALTEPLASE.\n\n \n\nALTRENOGEST.\n\n \n\nALTRETAMINE (hexamethylmelamine).\n\n \n\nAMANTADINE.\n\n \n\nAMBENONIUM CHLORIDE.\n\n \n\n \n\n# AMBRISENTAN.\n\n \n\nAMBUCETAMIDE.\n\n \n\nAMBUTONIUM BROMIDE.\n\n \n\nAMCINONIDE.\n\n \n\nAMETHOCAINE except:\n\n \n\n \n\n (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.\n\n \n\nAMIFOSTINE.\n\n \n\nAMIKACIN.\n\n \n\nAMILORIDE.\n\n \n\nAMINOCAPROIC ACID.\n\n \n\nAMINOGLUTETHIMIDE.\n\n \n\n5-AMINOLEVULINIC ACID.\n\n \n\nAMINOMETRADINE.\n\n \n\n† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.\n\n \n\nAMINOPHYLLINE except when included in Schedule 3.\n\n \n\nAMINOPTERIN.\n\n \n\n4-AMINOPYRIDINE for therapeutic use.\n\n \n\nAMINOREX.\n\n \n\nAMINOSALICYLIC ACID.\n\n \n\nAMIODARONE.\n\n \n\nAMIPHENAZOLE.\n\n \n\nAMISOMETRADINE.\n\n \n\nAMISULPRIDE.\n\n \n\nAMITRIPTYLINE.\n\n \n\nAMLODIPINE.\n\n \n\nAMMI VISNAGA.\n\n \n\nAMMONIUM BROMIDE for therapeutic use.\n\n \n\nAMODIAQUINE.\n\n \n\nAMOROLFINE except:\n\n \n\n \n\n \n\nAMOXAPINE.\n\n \n\nAMOXYCILLIN.\n\n \n\nAMPHOMYCIN.\n\n \n\nAMPHOTERICIN.\n\n \n\nAMPICILLIN.\n\n \n\nAMPRENAVIR.\n\n \n\nAMRINONE.\n\n \n\nAMSACRINE.\n\n \n\nAMYL NITRITE.\n\n \n\nAMYLOBARBITONE when packed and labelled for injection.\n\n \n\nAMYLOCAINE.\n\n \n\n# ANABOLIC STEROIDAL AGENTS.\n\n \n\nANAGRELIDE.\n\n \n\nANAKINRA.\n\n \n\nANASTROZOLE.\n\n \n\nANCESTIM.\n\n \n\nANCROD and its immunoglobulin antidote.\n\n \n\nANECORTAVE.\n\n \n\n# ANDROGENIC STEROIDAL AGENTS.\n\n \n\n# ANDROISOXAZOLE.\n\n \n\n# ANDROSTANOLONE.\n\n \n\n# ANDROSTENEDIOL.\n\n \n\n# ANDROSTENEDIONE.\n\n \n\nANGIOTENSIN AMIDE.\n\n \n\nANIDULAFUNGIN.\n\n \n\nANISTREPLASE.\n\n \n\nANTAZOLINE except when included in Schedule 2.\n\n \n\nANTIBIOTIC SUBSTANCES except:\n\n \n\n \n\n (b) nisin.\n\n \n\nANTIGENS for human therapeutic use except when separately specified in this Schedule.\n\n \n\nANTIHISTAMINES except:\n\n \n\n \n\n \n\nANTIMONY for therapeutic use except when separately specified in these Schedules.\n\n \n\nANTISERA (immunosera) for human use by injection except when separately specified in these Schedules.\n\n \n\nAPIXABAN.\n\n \n\nAPOCYNUM spp.\n\n \n\nAPOMORPHINE.\n\n \n\nAPRACLONIDINE.\n\n \n\nAPRAMYCIN.\n\n \n\nAPREPITANT.\n\n \n\nAPRONAL.\n\n \n\nAPROTININ.\n\n \n\nARECOLINE.\n\n \n\nARIPIPRAZOLE.\n\n \n\nARSENIC for human therapeutic use except when separately specified in these Schedules.\n\n \n\nARTEMETHER.\n\n \n\nARTICAINE.\n\n \n\nASENAPINE.\n\n \n\nASPIRIN:\n\n \n\n (a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or\n\n \n\n (b) for injection.\n\n \n\nASTEMIZOLE.\n\n \n\n# ATAMESTANE.\n\n \n\nATAZANAVIR.\n\n \n\nATENOLOL.\n\n \n\nATIPAMEZOLE.\n\n \n\nATOMOXETINE.\n\n \n\nATORVASTATIN.\n\n \n\nATOSIBAN.\n\n \n\nATOVAQUONE.\n\n \n\nATRACURIUM BESYLATE.\n\n \n\nATROPA BELLADONNA (belladonna) except when included in Schedule 2.\n\n \n\nATROPINE except when included in Schedule 2.\n\n \n\nATROPINE METHONITRATE.\n\n \n\nAURANOFIN.\n\n \n\nAUROTHIOMALATE SODIUM.\n\n \n\nAVILAMYCIN except:\n\n \n\n (a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or\n\n \n\n (b) in animal feeds containing 50 mg/kg or less of avilamycin activity.\n\n \n\nAVIPTADIL.\n\n \n\nAXITINIB.\n\n \n\nAVOPARCIN.\n\n \n\nAZACITIDINE.\n\n \n\nAZACYCLONOL.\n\n \n\nAZAPERONE.\n\n \n\nAZAPROPAZONE.\n\n \n\nAZARIBINE.\n\n \n\nAZATADINE except when included in Schedule 3.\n\n \n\nAZATHIOPRINE.\n\n \n\nAZELAIC ACID except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of azelaic acid for non-human use.\n\n \n\nAZELASTINE except when included in Schedule 2.\n\n \n\nAZITHROMYCIN.\n\n \n\nAZLOCILLIN.\n\n \n\nAZTREONAM.\n\n \n\nBACAMPICILLIN.\n\n \n\nBACITRACIN.\n\n \n\nBACLOFEN.\n\n \n\nBALSALAZIDE.\n\n \n\nBAMBERMYCIN (flavophospholipol) except:\n\n \n\n \n\n (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.\n\n \n\nBAMBUTEROL.\n\n \n\nBAMETHAN.\n\n \n\nBAMIPINE.\n\n \n\nBARBITURATES except when separately specified in these Schedules.\n\n \n\nBASILIXIMAB.\n\n \n\nBAZEDOXIFENE.\n\n \n\nBECAPLERMIN.\n\n \n\nBECLAMIDE.\n\n \n\nBECLOMETHASONE except when included in Schedule 2.\n\n \n\nBELATACEPT.\n\n \n\nBELIMUMAB.\n\n \n\nBEMEGRIDE.\n\n \n\nBENACTYZINE.\n\n \n\nBENAZEPRIL.\n\n \n\nBENDROFLUAZIDE.\n\n \n\nBENETHAMINE PENICILLIN.\n\n \n\nBENORYLATE.\n\n \n\nBENOXAPROFEN.\n\n \n\nBENPERIDOL.\n\n \n\nBENSERAZIDE.\n\n \n\nBENZATHINE PENICILLIN.\n\n \n\nBENZHEXOL.\n\n \n\nBENZILONIUM.\n\n \n\nBENZOCAINE except:\n\n \n\n \n\n (b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or\n\n \n\n (c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.\n\n \n\n# BENZODIAZEPINE derivatives except when separately specified in these Schedules.\n\n \n\nBENZOYL PEROXIDE in preparations for human therapeutic use except:\n\n \n\n \n\n(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.\n\n \n\nBENZPHETAMINE.\n\n \n\nBENZTHIAZIDE.\n\n \n\nBENZTROPINE (benzatropine).\n\n \n\nBENZYDAMINE except:\n\n \n\n \n\n (b) in preparations for dermal use.\n\n \n\nBENZYLPENICILLIN.\n\n \n\nBEPRIDIL.\n\n \n\nBERACTANT.\n\n \n\nBESIFLOXACIN.\n\n \n\nBETAHISTINE.\n\n \n\nBETAMETHASONE.\n\n \n\nBETAXOLOL.\n\n \n\nBETHANECHOL CHLORIDE.\n\n \n\nBETHANIDINE.\n\n \n\nBEVACIZUMAB.\n\n \n\nBEVANTOLOL.\n\n \n\n# BEXAROTENE.\n\n \n\nBEZAFIBRATE.\n\n \n\nBICALUTAMIDE.\n\n \n\nBIFONAZOLE except:\n\n \n\n \n\n (b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or\n\n \n\n (c) in preparations for dermal use for the treatment of tinea pedis.\n\n \n\nBIMATOPROST.\n\n \n\nBIPERIDEN.\n\n \n\nBISMUTH COMPOUNDS for cosmetic use, except:\n\n \n\n (a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or\n\n \n\n (b) bismuth oxychloride.\n\n \n\nBISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.\n\n \n\nBISOPROLOL.\n\n \n\nBIVALIRUDIN.\n\n \n\nBLEOMYCIN.\n\n \n\nBOCEPREVIR.\n\n \n\n# BOLANDIOL.\n\n \n\n# BOLASTERONE.\n\n \n\n# BOLAZINE.\n\n \n\n# BOLDENONE (dehydrotestosterone).\n\n \n\n# BOLENOL.\n\n \n\n# BOLMANTALATE.\n\n \n\nBORON, including boric acid and borax, for human therapeutic use except:\n\n \n\n (a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;\n\n \n\n (b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or\n\n \n\n (c) when present as an excipient.\n\n \n\nBORTEZOMIB.\n\n \n\n# BOSENTAN.\n\n \n\nBOTULINUM TOXINS for human use except when separately specified in these Schedules.\n\n \n\nBRETYLIUM TOSYLATE.\n\n \n\nBRIMONIDINE.\n\n \n\nBRINZOLAMIDE.\n\n \n\n# BROMAZEPAM.\n\n \n\nBROMIDES, inorganic, for therapeutic use except when separately specified in\n\n these Schedules.\n\n \n\nBROMOCRIPTINE.\n\n \n\nBROMOFORM for therapeutic use.\n\n \n\nBROMPHENIRAMINE except when included in Schedule 2 or 3.\n\n \n\nBROMVALETONE.\n\n \n\nBRUGMANSIA spp.\n\n \n\nBUCLIZINE except when included in Schedule 3.\n\n \n\nBUDESONIDE except when included in Schedule 2.\n\n \n\nBUFEXAMAC except:\n\n \n\n (a) in preparations for dermal use containing 5 per cent or less of bufexamac; or\n\n \n\n (b) in suppositories.\n\n \n\nBUMETANIDE.\n\n \n\nBUPHENINE.\n\n \n\nBUPIVACAINE except when included in Schedule 5.\n\n \n\nBUPROPION.\n\n \n\nBUSERELIN.\n\n \n\nBUSPIRONE.\n\n \n\nBUSULPHAN.\n\n \n\nBUTACAINE.\n\n \n\nBUTOCONAZOLE except when included in Schedule 3.\n\n \n\nBUTRACONAZOLE.\n\n \n\nBUTYL AMINOBENZOATE except in dermal preparations containing 2 per cent or less of total local anaesthetic substances.\n\n \n\nBUTYLCHLORAL HYDRATE.\n\n \n\nBUTYL NITRITE.\n\n \n\nCABAZITAXEL.\n\n \n\nCABERGOLINE.\n\n \n\nCADMIUM COMPOUNDS for human therapeutic use.\n\n \n\nCALCIPOTRIOL.\n\n \n\nCALCITONIN.\n\n \n\nCALCITRIOL.\n\n \n\nCALCIUM CARBIMIDE for therapeutic use.\n\n \n\nCALCIUM POLYSTYRENE SULPHONATE.\n\n \n\nCALOTROPIS GIGANTEA.\n\n \n\nCALOTROPIS PROCERA.\n\n \n\n# CALUSTERONE.\n\n \n\nCAMPHORATED OIL for therapeutic use.\n\n \n\nCAMPHOTAMIDE.\n\n \n\nCANAGLIFLOZIN.\n\n \n\nCANAKINUMAB.\n\n \n\nCANDESARTAN CILEXETIL.\n\n \n\nCANDICIDIN.\n\n \n\nCANINE TICK ANTI-SERUM.\n\n \n\nCANTHARIDIN.\n\n \n\nCAPECITABINE.\n\n \n\nCAPREOMYCIN.\n\n \n\nCAPTODIAME.\n\n \n\nCAPTOPRIL.\n\n \n\nCAPURIDE.\n\n \n\nCARAMIPHEN.\n\n \n\nCARBACHOL.\n\n \n\nCARBAMAZEPINE.\n\n \n\nCARBARYL for human therapeutic use.\n\n \n\nCARBAZOCHROME.\n\n \n\nCARBENICILLIN.\n\n \n\nCARBENOXOLONE for internal use.\n\n \n\nCARBETOCIN.\n\n \n\nCARBIDOPA.\n\n \n\nCARBIMAZOLE.\n\n \n\nCARBOCROMEN.\n\n \n\nCARBOPLATIN.\n\n \n\nCARBOPROST.\n\n \n\nCARBROMAL.\n\n \n\nCARBUTAMIDE.\n\n \n\nCARBUTEROL.\n\n \n\nCARINDACILLIN.\n\n \n\nCARISOPRODOL.\n\n \n\nCARMUSTINE.\n\n \n\nCARNIDAZOLE.\n\n \n\nCARPROFEN.\n\n \n\nCARVEDILOL.\n\n \n\nCASPOFUNGIN.\n\n \n\nCATHINE.\n\n \n\nCATUMAXOMAB.\n\n \n\nCEFACETRILE.\n\n \n\nCEFACLOR.\n\n \n\nCEFADROXIL.\n\n \n\nCEFALORIDINE.\n\n \n\nCEFAMANDOLE.\n\n \n\nCEFAPIRIN.\n\n \n\nCEFAZOLIN.\n\n \n\nCEFEPIME.\n\n \n\nCEFETAMET.\n\n \n\nCEFIXIME.\n\n \n\nCEFODIZIME.\n\n \n\nCEFONICID.\n\n \n\nCEFOPERAZONE.\n\n \n\nCEFOTAXIME.\n\n \n\nCEFOTETAN.\n\n \n\nCEFOTIAM.\n\n \n\nCEFOVECIN for veterinary use.\n\n \n\nCEFOXITIN.\n\n \n\nCEFPIROME.\n\n \n\nCEFPODOXIME.\n\n \n\nCEFQUINOME.\n\n \n\nCEFTAROLINE FOSAMIL.\n\n \n\nCEFSULODIN.\n\n \n\nCEFTAZIDIME.\n\n \n\nCEFTIBUTEN.\n\n \n\nCEFTIOFUR.\n\n \n\nCEFTRIAXONE.\n\n \n\nCEFUROXIME.\n\n \n\nCELECOXIB.\n\n \n\nCELIPROLOL.\n\n \n\nCEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or less of emetine.\n\n \n\nCEPHAELIS IPECACUANHA except in preparations containing 0.2 per cent or less of emetine.\n\n \n\nCEPHALEXIN.\n\n \n\nCEPHALONIUM.\n\n \n\nCEPHALOTHIN.\n\n \n\nCEPHRADINE.\n\n \n\nCERIVASTATIN.\n\n \n\nCERTOLIZUMAB PEGOL.\n\n \n\nCERULETIDE.\n\n \n\nCETIRIZINE except\n\n \n\n \n\n (b)  in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n   (i) in a primary pack containing not more than 5 days’ supply; and\n\n \n\n   (ii)  labelled with a recommended daily dose not exceeding 10 mg  of cetirizine.\n\n \n\nCETRORELIX.\n\n \n\nCETUXIMAB.\n\n \n\nCHENODEOXYCHOLIC ACID.\n\n \n\nCHLORAL FORMAMIDE.\n\n \n\nCHLORAL HYDRATE except in preparations for topical use containing 2 per cent or less of chloral hydrate.\n\n \n\nCHLORALOSE except when included in Schedule 6.\n\n \n\nCHLORAMBUCIL.\n\n \n\nCHLORAMPHENICOL except when included in Schedule 3.\n\n \n\n# CHLORANDROSTENOLONE.\n\n \n\nCHLORAZANIL.\n\n \n\nCHLORCYCLIZINE.\n\n \n\n# CHLORDIAZEPOXIDE.\n\n \n\nCHLORMERODRIN.  \n\n \n\nCHLORMETHIAZOLE.\n\n \n\nCHLORMEZANONE.\n\n \n\nCHLOROFORM for use in anaesthesia.\n\n \n\n# 4-CHLOROMETHANDIENONE.\n\n \n\n2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.\n\n \n\nCHLOROQUINE.\n\n \n\nCHLOROTHIAZIDE.\n\n \n\nCHLOROTRIANISENE.\n\n \n\n# CHLOROXYDIENONE.\n\n \n\nCHLORPHENIRAMINE except when included in Schedule 2 or 3.\n\n \n\nCHLORPHENTERMINE.\n\n \n\nCHLORPROMAZINE.\n\n \n\nCHLORPROPAMIDE.\n\n \n\nCHLORPROTHIXENE.\n\n \n\nCHLORQUINALDOL for human topical use.\n\n \n\nCHLORTETRACYCLINE except when included in Schedule 5.\n\n \n\nCHLORTHALIDONE.\n\n \n\nCHLORZOXAZONE.\n\n \n\nCHOLERA VACCINE.\n\n \n\nCHOLESTYRAMINE (colestyramine) for human therapeutic use.\n\n \n\nCHYMOPAPAIN for human therapeutic use.\n\n \n\nCICLACILLIN.\n\n \n\nCICLESONIDE.\n\n \n\nCICLOPIROX except:\n\n \n\n1.             when included in Schedule 2 or 3; or\n\n \n\n1.            in preparations for the treatment of tinea pedis.\n\n \n\nCIDOFOVIR.\n\n \n\nCILASTATIN.\n\n \n\nCILAZAPRIL.\n\n \n\nCILOSTAZOL.\n\n \n\nCIMETIDINE except when included in Schedule 3.\n\n \n\nCINACALCET.\n\n \n\nCINCHOCAINE except when included in Schedule 2.\n\n \n\nCINOXACIN.\n\n \n\nCIPROFLOXACIN.\n\n \n\nCISAPRIDE.\n\n \n\nCISATRACURIUM BESYLATE.\n\n \n\nCISPLATIN.\n\n \n\nCITALOPRAM.\n\n \n\nCLADRIBINE.\n\n \n\nCLANOBUTIN.\n\n \n\nCLARITHROMYCIN.\n\n \n\nCLAVULANIC ACID.\n\n \n\nCLEMASTINE except when included in Schedule 3.\n\n \n\nCLEMIZOLE.\n\n \n\nCLENBUTEROL.\n\n \n\nCLEVIDIPINE.\n\n \n\nCLIDINIUM BROMIDE.\n\n \n\nCLINDAMYCIN.\n\n \n\n† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use except when separately specified in this Schedule.\n\n \n\nCLOBAZAM.\n\n \n\nCLOBETASOL.\n\n \n\nCLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.\n\n \n\nCLOCORTOLONE.\n\n \n\nCLODRONIC ACID (includes sodium clodronate).\n\n \n\nCLOFARABINE.\n\n \n\nCLOFAZIMINE.\n\n \n\nCLOFENAMIDE.\n\n \n\nCLOFIBRATE.\n\n \n\n# CLOMIPHENE.\n\n \n\nCLOMIPRAMINE.\n\n \n\nCLOMOCYCLINE.\n\n \n\n# CLONAZEPAM.\n\n \n\nCLONIDINE.\n\n \n\nCLOPAMIDE.\n\n \n\nCLOPIDOGREL.\n\n \n\nCLOPROSTENOL.\n\n \n\n# CLORAZEPATE.\n\n \n\nCLOREXOLONE.\n\n \n\nCLORPRENALINE.\n\n \n\n# CLOSTEBOL (4-chlorotestosterone).\n\n \n\nCLOTRIMAZOLE except:\n\n \n\n \n\n \n\nCLOXACILLIN.\n\n \n\n# CLOZAPINE.\n\n \n\nCOBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment of cyanide poisoning.\n\n \n\nCOBICISTAT.\n\n \n\nCODEINE when compounded with one or more other therapeutically active substances:\n\n \n\n (a) in divided preparations containing 30 mg or less of codeine per dosage unit; or\n\n \n\n (b) in undivided preparations containing 1 per cent or less of codeine,\n\n \n\n except when included in Schedule 2 or 3.\n\n \n\nCO-DERGOCRINE.\n\n \n\nCOLASPASE.\n\n \n\nCOLCHICINE.\n\n \n\nCOLCHICUM AUTUMNALE.\n\n \n\nCOLESTIPOL.\n\n \n\nCOLFOSCERIL PALMITATE for human therapeutic use.\n\n \n\nCOLISTIN.\n\n \n\nCOLLAGEN in preparations for injection or implantation:\n\n \n\n \n\n \n\nCOLLAGENASE CLOSTRIDIUM HISTOLYTICUM.\n\n \n\nCONVALLARIA KEISKI.\n\n \n\nCONVALLARIA MAJALIS.\n\n \n\nCOPPER COMPOUNDS for human use except:\n\n \n\n \n\n (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or\n\n \n\n (c) in other preparations containing 5 per cent or less of copper compounds.\n\n \n\n# CORIFOLLITROPIN ALFA.\n\n \n\nCORONILLA spp.\n\n \n\nCORTICOSTERONE.\n\n \n\nCORTICOTROPHIN.\n\n \n\nCORTISONE.\n\n \n\nCO-TRIMOXAZOLE.\n\n \n\nCOUMARIN for therapeutic use (excluding when present as an excipient).\n\n \n\nCRIZOTINIB.\n\n \n\nCROFELEMER.\n\n \n\nCRYSTAL VIOLET for human use except when used as a dermal marker.\n\n \n\nCUPRIMYXIN.\n\n \n\nCURARE.\n\n \n\nCYCLANDELATE.\n\n \n\nCYCLIZINE except when included in Schedule 3.\n\n \n\nCYCLOBENZAPRINE.\n\n \n\n# CYCLOFENIL.\n\n \n\nCYCLOHEXIMIDE.\n\n \n\nCYCLOPENTHIAZIDE.\n\n \n\nCYCLOPENTOLATE.\n\n \n\nCYCLOPHOSPHAMIDE.\n\n \n\nCYCLOPROPANE for therapeutic use.\n\n \n\nCYCLOSERINE.\n\n \n\nCYCLOSPORIN.\n\n \n\nCYCLOTHIAZIDE.\n\n \n\nCYCRIMINE.\n\n \n\nCYMARIN.\n\n \n\nCYPROHEPTADINE except when included in Schedule 3.\n\n \n\nCYPROTERONE.\n\n \n\nCYSTEAMINE for human therapeutic use.\n\n \n\nCYTARABINE.\n\n \n\nDABRAFENIB MESILATE.\n\n \n\nDABIGATRAN.\n\n \n\nDACARBAZINE.\n\n \n\nDACLIZUMAB.\n\n \n\nDACTINOMYCIN.\n\n \n\nDALFOPRISTIN.\n\n \n\nDALTEPARIN (includes dalteparin sodium).\n\n \n\nDANAPAROID (includes danaparoid sodium).\n\n \n\n# DANAZOL.\n\n \n\nDANTHRON for human use.\n\n \n\nDANTROLENE.\n\n \n\nDAPAGLIFLOZIN.\n\n \n\nDAPOXETINE.\n\n \n\nDAPSONE.\n\n \n\nDAPTOMYCIN.\n\n \n\n# DARBEPOETIN.\n\n \n\nDARIFENACIN.\n\n \n\nDARUNAVIR.\n\n \n\nDATURA spp. except:\n\n \n\n \n\n \n\nDASATINIB.\n\n \n\nDATURA STRAMONIUM (stramonium) except:\n\n \n\n \n\n (b) for smoking or burning.\n\n \n\nDATURA TATULA (stramonium) except:\n\n \n\n \n\n (b) for smoking or burning.\n\n \n\nDAUNORUBICIN.\n\n \n\nDEANOL for therapeutic use.\n\n \n\nDEBRISOQUINE.\n\n \n\nDECAMETHONIUM.\n\n \n\nDEFERASIROX.\n\n \n\nDEFERIPRONE.\n\n \n\nDEFLAZACORT.\n\n \n\nDEGARELIX.\n\n \n\n# DEHYDROCHLOROMETHYLTESTOSTERONE.\n\n \n\nDEHYDROCORTICOSTERONE.\n\n \n\nDELAVIRDINE (includes delavirdine mesylate).\n\n \n\nDEMBREXINE except when included in Schedule 5.\n\n \n\nDEMECARIUM.\n\n \n\nDEMECLOCYCLINE.\n\n \n\nDENOSUMAB.\n\n \n\nDEOXYCORTONE.\n\n \n\nDEOXYRIBONUCLEASE except:\n\n \n\n (a) when separately specified in this Schedule; or\n\n \n\n (b) for external use.\n\n \n\nDERACOXIB.\n\n \n\nDESFERRIOXAMINE.\n\n \n\nDESFLURANE.\n\n \n\nDESIPRAMINE.\n\n \n\nDESIRUDIN.\n\n \n\nDESLANOSIDE.\n\n \n\nDESLORATADINE except when included in Schedule 2.\n\n \n\nDESLORELIN.\n\n \n\nDESMOPRESSIN (D.D.A.V.P.).\n\n \n\nDESOGESTREL.\n\n \n\nDESONIDE.\n\n \n\nDESOXYMETHASONE.\n\n \n\nDESVENLAFAXINE.\n\n \n\nDETOMIDINE.\n\n \n\nDEXAMETHASONE.\n\n \n\nDEXCHLORPHENIRAMINE except when included in Schedule 2 or 3.\n\n \n\nDEXFENFLURAMINE.\n\n \n\nDEXMEDETOMIDINE.\n\n \n\nDEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.\n\n \n\n# DEXTROPROPOXYPHENE:\n\n \n\n (a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or\n\n \n\n (b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.\n\n \n\nDEXTRORPHAN (excluding its stereoisomers).\n\n \n\nDIAMTHAZOLE.\n\n \n\nDIAVERIDINE.\n\n \n\n# DIAZEPAM.\n\n \n\nDIAZOXIDE.\n\n \n\nDIBENZEPIN.\n\n \n\nDIBOTERMIN.\n\n \n\nDIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.\n\n \n\nDICHLORALPHENAZONE.\n\n \n\nDICHLOROPHEN for human therapeutic use.\n\n \n\nDICHLORPHENAMIDE.\n\n \n\nDICLOFENAC except:\n\n \n\n \n\n(b)  in preparations for dermal use unless:\n\n \n\n (i) for the treatment of solar keratosis; or\n\n \n\n  (ii) containing more than 4 per cent of diclofenac.\n\n \n\nDICLOXACILLIN.\n\n \n\nDICYCLOMINE.\n\n \n\nDIDANOSINE.\n\n \n\nDIENESTROL.\n\n \n\nDIENOGEST.\n\n \n\nDIETHAZINE.\n\n \n\nDIETHYLCARBAMAZINE for human therapeutic use.\n\n \n\nDIETHYLPROPION.\n\n \n\nDIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.\n\n \n\nDIFLORASONE.\n\n \n\nDIFLOXACIN.\n\n \n\nDIFLUCORTOLONE.\n\n \n\nDIFLUNISAL.\n\n \n\nDIGITALIS LANATA.\n\n \n\nDIGITALIS PURPUREA.\n\n \n\nDIGITOXIN.\n\n \n\nDIGOXIN.\n\n \n\nDIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).\n\n \n\nDIHYDRALAZINE.\n\n \n\nDIHYDROCODEINE when compounded with one or more other therapeutically active substances:\n\n \n\n (a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or\n\n \n\n (b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,\n\n \n\n except when included in Schedule 2 or 3.\n\n \n\nDIHYDROERGOTOXINE.\n\n \n\n# DIHYDROLONE.\n\n \n\nDIHYDROSTREPTOMYCIN.\n\n \n\nDIHYDROTACHYSTEROL.\n\n \n\n† DI-IODOHYDROXYQUINOLINE (iodoquinol) except:\n\n \n\n (a) when included in Schedule 3; or\n\n \n\n (b) for human internal use.\n\n \n\nDIISOPROPYLAMINE DICHLOROACETATE.\n\n \n\nDILTIAZEM.\n\n \n\nDIMENHYDRINATE except when included in Schedule 2 or 3.\n\n \n\nDIMERCAPROL.\n\n \n\n# DIMETHANDROSTANOLONE.\n\n \n\n# DIMETHAZINE.\n\n \n\nDIMETHINDENE except when included in Schedule 3.\n\n \n\nDIMETHOTHIAZINE.\n\n \n\nDIMETHOXANATE.\n\n \n\nDIMETHYL FUMARATE.\n\n \n\nDIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:\n\n \n\n \n\n (b) in in vitro test kits.\n\n \n\nDIMETRIDAZOLE.\n\n \n\n2,4-DINITROCHLOROBENZENE for therapeutic use.\n\n \n\nDINITROCRESOLS for therapeutic use except when separately specified in these Schedules.\n\n \n\nDINITRONAPHTHOLS for therapeutic use except when separately specified in these Schedules.\n\n \n\nDINITROPHENOLS for therapeutic use.\n\n \n\nDINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.\n\n \n\n# DINOPROST.\n\n \n\n# DINOPROSTONE.\n\n \n\nDIPERODON.\n\n \n\nDIPHEMANIL except in preparations for dermal use.\n\n \n\nDIPHENHYDRAMINE except when included in Schedule 2 or 3.\n\n \n\nDIPHENIDOL.\n\n \n\nDIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate except when included in Schedule 3.\n\n \n\nDIPHENYLPYRALINE.\n\n \n\nDIPHTHERIA TOXOID.\n\n \n\nDIPIVEFRIN.\n\n \n\nDIPYRIDAMOLE.\n\n \n\nDIRITHROMYCIN.\n\n \n\nDIRLOTAPIDE.\n\n \n\nDISOPHENOL.\n\n \n\nDISOPYRAMIDE.\n\n \n\nDISTIGMINE.\n\n \n\nDISULFIRAM for therapeutic use.\n\n \n\nDISULPHAMIDE.\n\n \n\nDITHIAZANINE except when included in Schedule 6.\n\n \n\nDITIOCARB.\n\n \n\nDOBUTAMINE.\n\n \n\nDOCETAXEL.\n\n \n\nDOFETILIDE.\n\n \n\nDOLASETRON.\n\n \n\nDOLUTEGRAVIR.\n\n \n\nDOMPERIDONE.\n\n \n\nDONEPEZIL.\n\n \n\nDOPAMINE.\n\n \n\nDOPEXAMINE.\n\n \n\nDORIPENEM.\n\n \n\nDORNASE.\n\n \n\nDORZOLAMIDE.\n\n \n\nDOTHIEPIN.\n\n \n\nDOXANTRAZOLE.\n\n \n\nDOXAPRAM.\n\n \n\nDOXAZOSIN.\n\n \n\nDOXEPIN.\n\n \n\nDOXORUBICIN.\n\n \n\nDOXYCYCLINE.\n\n \n\nDOXYLAMINE except when included in Schedule 2 or 3.\n\n \n\nDRONEDARONE.\n\n \n\nDROPERIDOL.\n\n \n\nDROSPIRENONE.\n\n \n\n# DROSTANOLONE.\n\n \n\nDROTRECOGIN.\n\n \n\nDUBOISIA LEICHHARDTII except when included in Schedule 2.\n\n \n\nDUBOISIA MYOPOROIDES except when included in Schedule 2.\n\n \n\nDULOXETINE.\n\n \n\nDUTASTERIDE.\n\n \n\nDYDROGESTERONE.\n\n \n\nECONAZOLE except:\n\n \n\n \n\n \n\nECOTHIOPATE (includes ecothiopate iodide).\n\n \n\nECTYLUREA.\n\n \n\nECULIZUMAB.\n\n \n\nEDETIC ACID for human therapeutic use except:\n\n \n\n (a) in preparations containing 0.25 per cent or less of edetic acid;\n\n \n\n (b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or\n\n \n\n (c) in contact lens preparations.\n\n \n\nEDOXUDINE.\n\n \n\nEDROPHONIUM.\n\n \n\nEFALIZUMAB.\n\n \n\nEFAVIRENZ.\n\n \n\nEFLORNITHINE.\n\n \n\nEFORMOTEROL.\n\n \n\nELETRIPTAN.\n\n \n\nELTENAC.\n\n \n\nELTROMBOPAG.\n\n \n\nELVITEGRAVIR.\n\n \n\nEMEPRONIUM.\n\n \n\nEMETINE except in preparations containing 0.2 per cent or less of emetine.\n\n \n\nEMPAGLIFLOZIN.\n\n \n\nEMTRICITABINE.\n\n \n\nENALAPRIL.\n\n \n\n# ENESTEBOL.\n\n \n\nENFLURANE for therapeutic use.\n\n \n\nENFUVIRTIDE.\n\n \n\n# ENOBOSARM.\n\n \n\nENOXACIN.\n\n \n\nENOXAPARIN.\n\n \n\nENOXIMONE.\n\n \n\nENPROSTIL.\n\n \n\nENROFLOXACIN.\n\n \n\nENTACAPONE.\n\n \n\nENTECAVIR.\n\n \n\nEPHEDRA spp. except in preparations containing 0.001 per cent or less of ephedrine.\n\n \n\n# EPHEDRINE.\n\n \n\nEPICILLIN.\n\n \n\nEPINASTINE.\n\n \n\nEPIRUBICIN.\n\n \n\n# EPITIOSTANOL.\n\n \n\nEPLERENONE.\n\n \n\n# EPOETINS.\n\n \n\nEPOPROSTENOL.\n\n \n\nEPROSARTAN.\n\n \n\nEPTIFIBATIDE.\n\n \n\nERGOMETRINE.\n\n \n\nERGOT.\n\n \n\nERGOTAMINE.\n\n \n\nERGOTOXINE.\n\n \n\nERIBULIN MESYLATE.\n\n \n\nERLOTINIB.\n\n \n\nERTAPENEM.\n\n \n\nERYSIMUM spp.\n\n \n\nERYTHROMYCIN.\n\n \n\n# ERYTHROPOIETIN.\n\n \n\n# ERYTHROPOIETINS except when separately specified in these Schedules.\n\n \n\nESCITALOPRAM.\n\n \n\nESMOLOL.\n\n \n\nESOMEPRAZOLE except when included in Schedule 3.\n\n \n\nESTRAMUSTINE.\n\n \n\nESTROPIPATE (piperazine oestrone sulfate).\n\n \n\nETANERCEPT.\n\n \n\nETHACRYNIC ACID.\n\n \n\nETHAMBUTOL.\n\n \n\nETHAMIVAN.\n\n \n\nETHANOLAMINE in preparations for injection.\n\n \n\nETHCHLORVYNOL.\n\n \n\nETHER for use in anaesthesia.\n\n \n\nETHINAMATE.\n\n \n\nETHINYLOESTRADIOL.\n\n \n\nETHIONAMIDE.\n\n \n\nETHISTERONE.\n\n \n\nETHOGLUCID.\n\n \n\nETHOHEPTAZINE.\n\n \n\nETHOPROPAZINE.\n\n \n\nETHOSUXIMIDE.\n\n \n\nETHOTOIN.\n\n \n\nETHOXZOLAMIDE.\n\n \n\nETHYL CHLORIDE for human therapeutic use.\n\n \n\n# ETHYLDIENOLONE.\n\n \n\n† ETHYLHEXANEDIOL for animal use.\n\n \n\nETHYLMORPHINE when compounded with one or more other therapeutically active substances:\n\n \n\n (a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or\n\n \n\n (b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;\n\n \n\n \n\n# ETHYLOESTRENOL.\n\n \n\nETHYNODIOL.\n\n \n\nETIDOCAINE.\n\n \n\nETIDRONIC ACID (includes disodium etidronate):\n\n \n\n (a) for internal use; or\n\n \n\n(b) in topical preparations except in preparations containing 1 per cent or less of etidronic acid.\n\n \n\nETILEFRIN.\n\n \n\nETIPROSTON.\n\n \n\nETODOLAC.\n\n \n\nETOFENAMATE except when included in Schedule 2.\n\n \n\nETONOGESTREL.\n\n \n\nETOPOSIDE.\n\n \n\nETORICOXIB.\n\n \n\nETRAVIRINE.\n\n \n\n# ETRETINATE.\n\n \n\nEVEROLIMUS.\n\n \n\nEXEMESTANE.\n\n \n\nEXENATIDE.\n\n \n\nEZETIMIBE.\n\n \n\nFAMCICLOVIR except when included in Schedule 3.\n\n \n\nFAMOTIDINE except when included in Schedule 2.\n\n \n\nFEBUXOSTAT.\n\n \n\nFELBINAC except when included in Schedule 2.\n\n \n\nFELODIPINE.\n\n \n\nFELYPRESSIN.\n\n \n\nFENBUFEN.\n\n \n\nFENCAMFAMIN.\n\n \n\nFENCLOFENAC.\n\n \n\nFENFLURAMINE.\n\n \n\nFENOFIBRATE.\n\n \n\nFENOLDOPAM.\n\n \n\nFENOPROFEN.\n\n \n\nFENOTEROL.\n\n \n\nFENPIPRAMIDE.\n\n \n\nFENPIPRANE.\n\n \n\nFENPROPOREX.\n\n \n\nFENPROSTALENE.\n\n \n\nFEXOFENADINE except:\n\n \n\n \n\n(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n(i) in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and\n\n \n\n(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.\n\n \n\nFIBRINOLYSIN except for external use.\n\n \n\nFIDAXOMICIN.\n\n \n\nFILGRASTIM.\n\n \n\nFINASTERIDE.\n\n \n\nFINGOLIMOD.\n\n \n\nFIROCOXIB.\n\n \n\nFLECAINIDE.\n\n \n\nFLEROXACIN.\n\n \n\nFLOCTAFENINE.\n\n \n\nFLORFENICOL.\n\n \n\nFLUANISONE.\n\n \n\nFLUCLOROLONE.\n\n \n\nFLUCLOXACILLIN.\n\n \n\nFLUCONAZOLE except when included in Schedule 3.\n\n \n\nFLUCYTOSINE.\n\n \n\nFLUDARABINE.\n\n \n\nFLUDROCORTISONE.\n\n \n\nFLUFENAMIC ACID.\n\n \n\nFLUMAZENIL.\n\n \n\nFLUMETHASONE.\n\n \n\nFLUMETHIAZIDE.\n\n \n\nFLUNISOLIDE.\n\n \n\nFLUNIXIN MEGLUMINE.\n\n  \n\nFLUOCINOLONE.\n\n \n\nFLUOCINONIDE.\n\n \n\nFLUOCORTIN.\n\n \n\nFLUOCORTOLONE.\n\n \n\nFLUORESCEIN in preparations for injection.\n\n \n\nFLUORIDES in preparations for human use except when included in or expressly excluded from Schedule 2 or 3.\n\n \n\nFLUOROMETHOLONE.\n\n \n\nFLUOROURACIL.\n\n \n\nFLUOXETINE.\n\n \n\n# FLUOXYMESTERONE.\n\n \n\nFLUPENTHIXOL.\n\n \n\nFLUPHENAZINE.\n\n \n\nFLUPROSTENOL.\n\n \n\nFLURANDRENOLONE.\n\n \n\n# FLURAZEPAM.\n\n \n\nFLURBIPROFEN except when included in Schedule 2.\n\n \n\nFLUROXENE for human therapeutic use.\n\n \n\nFLUSPIRILENE.\n\n \n\nFLUTAMIDE.\n\n \n\nFLUTICASONE except when included in Schedule 2.\n\n \n\nFLUVASTATIN.\n\n \n\nFLUVOXAMINE.\n\n \n\nFOLIC ACID in preparations for human use for injection.\n\n \n\nFOLINIC ACID in preparations for human use for injection.\n\n \n\nFOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.\n\n \n\n# FOLLISTATIN.\n\n \n\n# FOLLITROPIN ALPHA.\n\n \n\n# FOLLITROPIN BETA.\n\n \n\nFOMIVIRSEN.\n\n \n\nFONDAPARINUX.\n\n \n\n# FORMEBOLONE.\n\n \n\nFORMESTANE.\n\n \n\nFOSAMPRENAVIR.\n\n \n\nFOSAPREPITANT.\n\n \n\nFOSCARNET.\n\n \n\nFOSFESTROL (diethylstilboestrol diphosphate).\n\n \n\nFOSINOPRIL.\n\n \n\nFOSPHENYTOIN.\n\n \n\nFOTEMUSTINE.\n\n \n\nFRAMYCETIN.\n\n \n\nFULVESTRANT.\n\n \n\nFURALTADONE.\n\n \n\n# FURAZABOL.\n\n \n\nFURAZOLIDONE.\n\n \n\nFUROSEMIDE (frusemide).\n\n \n\nFUSIDIC ACID.\n\n \n\nGABAPENTIN.\n\n \n\nGALANTAMINE.\n\n \n\nGALANTHUS spp.\n\n \n\nGALLAMINE.\n\n \n\nGALSULFASE.\n\n \n\nGANCICLOVIR.\n\n \n\nGANIRELIX.\n\n \n\nGATIFLOXACIN.\n\n \n\nGEFITINIB.\n\n \n\nGEMCITABINE.\n\n \n\nGEMEPROST.\n\n \n\nGEMFIBROZIL.\n\n \n\nGEMIFLOXACIN.\n\n \n\nGEMTUZUMAB OZOGAMICIN.\n\n \n\nGENTAMICIN.\n\n \n\nGESTODENE.\n\n \n\nGESTONORONE.\n\n \n\nGESTRINONE.\n\n \n\nGHRH INJECTABLE PLASMID.\n\n \n\nGITALIN.\n\n \n\nGLATIRAMER ACETATE.\n\n \n\nGLIBENCLAMIDE.\n\n \n\nGLIBORNURIDE.\n\n \n\nGLICLAZIDE.\n\n \n\nGLIMEPIRIDE.\n\n \n\nGLIPIZIDE.\n\n \n\nGLISOXEPIDE.\n\n \n\nGLUTATHIONE for parenteral use.\n\n \n\n# GLUTETHIMIDE.\n\n \n\nGLYCERYL TRINITRATE except when included in Schedule 3.\n\n \n\nGLYCOPYRRONIUM in preparations for injection.\n\n \n\nGLYMIDINE.\n\n \n\nGnRH VACCINE.\n\n \n\nGOLIMUMAB.\n\n \n\nGONADORELIN.\n\n \n\nGONADOTROPHIC HORMONES except when separately specified in this Schedule.\n\n \n\nGOSERELIN.\n\n \n\nGRAMICIDIN.\n\n \n\nGRANISETRON.\n\n \n\nGREPAFLOXACIN.\n\n \n\nGRISEOFULVIN.\n\n \n\nGUAIPHENESIN for human therapeutic use except:\n\n \n\n \n\n (b) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or\n\n \n\n (c) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.\n\n \n\nGUANABENZ.\n\n \n\nGUANACLINE.\n\n \n\nGUANETHIDINE.\n\n \n\nGUANIDINE for therapeutic use.\n\n \n\nHACHIMYCIN.\n\n \n\nHAEMATIN.\n\n \n\nHAEMOPHILUS INFLUENZAE VACCINE.\n\n \n\nHALCINONIDE.\n\n \n\nHALOFANTRINE.\n\n \n\nHALOFENATE.\n\n \n\nHALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.\n\n \n\nHALOPERIDOL.\n\n \n\nHALOTHANE for therapeutic use.\n\n \n\nHEMEROCALLIS (Hemerocallis flava).\n\n \n\nHEPARINS for internal use except when separately specified in this Schedule.\n\n \n\nHEPATITIS A VACCINE.\n\n \n\nHEPATITIS B VACCINE.\n\n \n\nHETACILLIN.\n\n \n\nHEXACHLOROPHANE:\n\n \n\n (a) in preparations for use on infants; or\n\n \n\n (b) in other preparations except:\n\n \n\n   (i) when included in Schedule 2 or 6; or\n\n \n\n   (ii) in preparations containing 0.75 per cent or less of hexachlorophane.\n\n \n\nHEXAMETHONIUM.\n\n \n\nHEXETIDINE for human internal use.\n\n \n\nHEXOBENDINE.\n\n \n\nHEXOCYCLIUM.\n\n \n\nHEXOPRENALINE.\n\n \n\nHISTAMINE for therapeutic use except in preparations containing 0.5 per cent or less of histamine.\n\n \n\nHMG-CoA REDUCTASE INHIBITORS (including \"statins\") except when separately specified in these Schedules.\n\n \n\nHOMATROPINE.\n\n \n\nHUMAN CHORIONIC GONADATROPHIN except in pregnancy test kits.\n\n \n\nHUMAN PAPILLOMAVIRUS VACCINE.\n\n \n\nHYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:\n\n \n\n (a) for tissue augmentation;\n\n \n\n (b) for cosmetic use; or\n\n \n\n (c) for the treatment of animals.\n\n \n\nHYDRALAZINE.\n\n \n\nHYDRARGAPHEN.\n\n \n\nHYDROCHLOROTHIAZIDE.\n\n \n\nHYDROCORTISONE:\n\n \n\n (a) for human use except when included in Schedule 2 or 3; or\n\n \n\n (b) for the treatment of animals.\n\n \n\nHYDROCYANIC ACID for therapeutic use.\n\n \n\nHYDROFLUMETHIAZIDE.\n\n \n\nHYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use except:\n\n \n\n1.              when included in Schedule 2; or\n\n \n\n1.             in hair preparations containing 0.3 per cent or less of hydroquinone; or\n\n \n\n1.             in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.\n\n \n\nHYDROXYCHLOROQUINE.\n\n \n\nHYDROXYEPHEDRINE.\n\n \n\nHYDROXYPHENAMATE.\n\n \n\nHYDROXYPROGESTERONE.\n\n \n\n# HYDROXYSTENOZOL.\n\n \n\nHYDROXYUREA.\n\n \n\nHYDROXYZINE.\n\n \n\nHYGROMYCIN.\n\n \n\nHYOSCINE except when included in Schedule 2.\n\n \n\nHYOSCYAMINE except when included in Schedule 2.\n\n \n\nHYOSCYAMUS NIGER except:\n\n \n\n \n\n (b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.\n\n \n\nHYPOTHALAMIC RELEASING FACTORS except when separately specified in this Schedule.\n\n \n\nHYPROMELLOSE in preparations for injection.\n\n \n\nIBAFLOXACIN for veterinary use.\n\n \n\nIBANDRONIC ACID.\n\n \n\nIBOGAINE.\n\n \n\nIBRITUMOMAB.\n\n \n\nIBUFENAC.\n\n \n\nIBUPROFEN except:\n\n \n\n (a) when included in or expressly excluded from Schedule 2 or 3; or\n\n \n\n (b) in preparations for dermal use.\n\n \n\nIBUTEROL.\n\n \n\nIBUTILIDE.\n\n \n\nICATIBANT.\n\n \n\nIDARUBICIN.\n\n \n\nIDOXURIDINE except in preparations containing 0.5 per cent or less of idoxuridine for dermal use.\n\n \n\nIDURSULFASE.\n\n \n\nIFOSFAMIDE.\n\n \n\nILOPROST.\n\n \n\nIMATINIB.\n\n \n\nIMEPITOIN.\n\n \n\nIMIDAPRIL.\n\n \n\nIMIGLUCERASE.\n\n \n\nIMIPENIM.\n\n \n\nIMIPRAMINE.\n\n \n\nIMIQUIMOD.\n\n \n\nIMMUNOGLOBULINS for human parenteral use except when separately specified in these Schedules.\n\n \n\nINDACATEROL.\n\n \n\nINDAPAMIDE.\n\n \n\nINDINAVIR.\n\n \n\nINDOMETHACIN except when included in Schedule 2.\n\n \n\nINDOPROFEN.\n\n \n\nINDORAMIN.\n\n \n\nINFLIXIMAB.\n\n \n\nINFLUENZA AND CORYZA VACCINES:\n\n \n\n (a) for parenteral use; or\n\n \n\n (b) for nasal administration.\n\n \n\nINGENOL MEBUTATE.\n\n \n\nINSULIN GLARGINE.\n\n \n\n# INSULIN-LIKE GROWTH FACTOR I.\n\n \n\n# INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule.\n\n \n\nINSULINS.\n\n \n\nINTERFERONS.\n\n \n\nINTERLEUKINS except when separately specified in these Schedules.\n\n \n\nIODOTHIOURACIL.\n\n \n\nIPILIMUMAB.\n\n \n\nIPRATROPIUM except when included in Schedule 2.\n\n \n\nIPRIFLAVONE.\n\n \n\nIPRINDOLE.\n\n \n\nIPRONIAZID.\n\n \n\nIRBESARTAN.\n\n \n\nIRINOTECAN.\n\n \n\nIRON COMPOUNDS in injectable preparations for human use.\n\n \n\nISOAMINILE.\n\n \n\nISOAMYL NITRITE.\n\n \n\nISOBUTYL NITRITE.\n\n \n\nISOCARBOXAZID.\n\n \n\nISOCONAZOLE except when included in Schedule 2, 3 or 6.\n\n \n\nISOETARINE.\n\n \n\nISOFLURANE for therapeutic use.\n\n \n\nISOMETHEPTENE.\n\n \n\nISONIAZID.\n\n \n\nISOPRENALINE.\n\n \n\nISOPRINOSINE.\n\n \n\nISOPROPAMIDE except when included in Schedule 2.\n\n \n\nISOSORBIDE DINITRATE except when included in Schedule 3.\n\n \n\nISOSORBIDE MONONITRATE.\n\n \n\n# ISOTRETINOIN.\n\n \n\nISOXICAM.\n\n \n\nISOXSUPRINE.\n\n \n\nISRADIPINE.\n\n \n\nITRACONAZOLE.\n\n \n\nIVABRADINE.\n\n \n\nIVACAFTOR.\n\n \n\nIVERMECTIN:\n\n \n\n (a) for human use; or\n\n \n\n (b) for the treatment of mange in dogs.\n\n \n\nIXABEPILONE.\n\n \n\nJAPANESE ENCEPHALITIS VACCINE.\n\n \n\nKANAMYCIN.\n\n \n\nKETANSERIN except in topical veterinary preparations containing 0.5 per cent or less of ketanserin.\n\n \n\n# KETAZOLAM.\n\n \n\nKETOCONAZOLE except:\n\n \n\n \n\n (b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or\n\n \n\n (c) in preparations for dermal use for the treatment of tinea pedis.\n\n \n\nKETOPROFEN except:\n\n \n\n (a) in preparations for dermal use; or\n\n \n\n (b) when included in Schedule 3.\n\n \n\nKETOROLAC (includes ketoralac trometamol).\n\n \n\nKETOTIFEN except when included in Schedule 2.\n\n \n\nKHELLIN.\n\n \n\nKITASAMYCIN except:\n\n \n\n (a) when included in Schedule 5 ; or\n\n \n\n (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.\n\n \n\nLABETALOL.\n\n \n\nLACIDIPINE.\n\n \n\nLACOSAMIDE.\n\n \n\nLAMIVUDINE.\n\n \n\nLAMOTRIGINE.\n\n \n\nLANATOSIDES.\n\n \n\nLANREOTIDE.\n\n \n\nLANSOPRAZOLE except when included in Schedule 3.\n\n \n\nLANTHANUM for therapeutic use.\n\n \n\nLAPATINIB.\n\n \n\nLARONIDASE.\n\n \n\nLAROPIPRANT.\n\n \n\nLATAMOXEF.\n\n \n\nLATANOPROST.\n\n \n\nLAUDEXIUM.\n\n \n\nLAUROMACROGOLS in preparations for injection except:\n\n \n\n (a) when present as an excipient; or\n\n \n\n \n\n† LEAD for human therapeutic use.\n\n \n\nLEFETAMINE.\n\n \n\nLEFLUNOMIDE.\n\n \n\n# LENALIDOMIDE.\n\n \n\nLENOGRASTIM.\n\n \n\nLEPIRUDIN.\n\n \n\nLEPTAZOL.\n\n \n\nLERCANIDIPINE.\n\n \n\nLETROZOLE.\n\n \n\nLEUPRORELIN.\n\n \n\nLEVALLORPHAN.\n\n \n\nLEVAMISOLE:\n\n \n\n (a) for human therapeutic use; or\n\n \n\n (b) in preparations for the prevention or treatment of heartworm in dogs.\n\n \n\nLEVETIRACETAM.\n\n  \n\nLEVOBUNOLOL.\n\n \n\nLEVOBUPIVACAINE.\n\n \n\nLEVOCABASTINE except when included in Schedule 2.\n\n \n\nLEVODOPA.\n\n \n\nLEVOMEPROMAZINE.\n\n \n\nLEVONORGESTREL except when included in Schedule 3.\n\n \n\nLEVOSIMENDAN.\n\n \n\nLIDOFLAZINE.\n\n \n\nLIGNOCAINE except:\n\n \n\n(a) when included in Schedules 2 or 5;\n\n \n\n(b)  in dermal preparations containing 2 per cent or less of total local anaesthetic substances per dosage unit; or\n\n \n\n(c)  in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.\n\n \n\nLINAGLIPTIN.\n\n \n\nLINCOMYCIN.\n\n \n\nLINDANE for human therapeutic use except when included in Schedule 2.\n\n \n\nLINEZOLID.\n\n \n\nLIOTHYRONINE.\n\n \n\nLIRAGLUTIDE.\n\n \n\nLISINOPRIL.\n\n \n\nLISURIDE.\n\n \n\nLITHIUM for therapeutic use except:\n\n \n\n \n\n (b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or\n\n \n\n (c) in preparations containing 0.01 per cent or less of lithium.\n\n \n\nLIXISENATIDE.\n\n \n\nLODOXAMIDE except when included in Schedule 2.\n\n \n\nLOFEXIDINE.\n\n \n\nLOGIPARIN for internal use.\n\n \n\nLOMEFLOXACIN.\n\n \n\nLOMUSTINE.\n\n \n\nLOPERAMIDE except:\n\n \n\n \n\n (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.\n\n \n\nLOPINAVIR.\n\n \n\n# LOPRAZOLAM.\n\n \n\nLORACARBEF.\n\n \n\nLORATADINE except:\n\n \n\n1.           when included in Schedule 2; or\n\n \n\n1.          in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:\n\n \n\n1.                   in a primary pack containing 5 dosage units or less; and\n2.                 labelled with a recommended daily dose not exceeding 10 mg of loratadine.\n\n \n\n# LORAZEPAM.\n\n \n\n# LORMETAZEPAM.\n\n \n\nLOSARTAN.\n\n \n\nLOTEPREDNOL.\n\n \n\nLOXAPINE.\n\n \n\nLUMEFANTRINE.\n\n \n\nLUMIRACOXIB.\n\n \n\nLURASIDONE.\n\n \n\n# LUTEINISING HORMONE except in ovulation test kits.\n\n \n\nLYMECYCLINE.\n\n \n\nMAFENIDE except when included in Schedule 6.\n\n \n\nMANDRAGORA OFFICINARUM.\n\n \n\nMANNOMUSTINE.\n\n \n\nMAPROTILINE.\n\n \n\nMARAVIROC.\n\n \n\nMARBOFLOXACIN.\n\n \n\nMAROPITANT.\n\n \n\nMAVACOXIB.\n\n \n\nMAZINDOL.\n\n \n\nMEASLES VACCINE.\n\n \n\nMEBANAZINE.\n\n \n\nMEBEVERINE.\n\n \n\nMEBHYDROLIN.\n\n \n\n# MEBOLAZINE.\n\n \n\nMEBUTAMATE.\n\n \n\nMECAMYLAMINE.\n\n \n\nMECASERMIN.\n\n \n\nMECILLINAM.\n\n \n\nMECLOCYCLINE.\n\n \n\nMECLOFENAMATE.\n\n \n\nMECLOFENOXATE.\n\n \n\nMECLOZINE except when included in Schedule 2.\n\n \n\n# MEDAZEPAM.\n\n \n\nMEDETOMIDINE.\n\n \n\nMEDIGOXIN (methyldigoxin).\n\n \n\nMEDROXYPROGESTERONE.\n\n \n\nMEDRYSONE.\n\n \n\nMEFENAMIC ACID except when included in Schedule 2.\n\n \n\nMEFENOREX.\n\n \n\nMEFLOQUINE.\n\n \n\nMEFRUSIDE.\n\n \n\nMEGESTROL.\n\n \n\nMELAGATRAN.\n\n \n\nMELATONIN for human use.\n\n \n\nMELENGESTROL except when included in Schedule 6.\n\n \n\nMELOXICAM.\n\n \n\nMELPHALAN.\n\n \n\nMEMANTINE.\n\n \n\nMENINGOCOCCAL VACCINE.\n\n \n\nMENOTROPHIN.\n\n \n\nMEPACRINE.\n\n \n\nMEPENZOLATE.\n\n \n\nMEPHENESIN.\n\n \n\nMEPHENTERMINE.\n\n \n\nMEPINDOLOL.\n\n \n\n# MEPITIOSTANE.\n\n \n\nMEPIVACAINE.\n\n \n\nMEPROBAMATE.\n\n \n\nMEPTAZINOL.\n\n \n\nMEPYRAMINE except when included in Schedule 2 or 3.\n\n \n\nMEQUITAZINE.\n\n \n\nMERCAPTOMERIN.\n\n \n\nMERCAPTOPURINE.\n\n \n\nMERCUROCHROME except when included in Schedule 2 or 6.\n\n \n\nMERCURY for cosmetic or therapeutic use except:\n\n \n\n \n\n (b) in a sealed device which prevents access to the mercury.\n\n \n\nMEROPENEM.\n\n \n\nMERSALYL.\n\n \n\n# MESABOLONE.\n\n \n\nMESALAZINE.\n\n \n\nMESNA.\n\n \n\n# MESTANOLONE (androstalone).\n\n \n\n# MESTEROLONE.\n\n \n\nMESTRANOL.\n\n \n\n# METANDIENONE.\n\n \n\nMETARAMINOL.\n\n \n\n# METENOLONE.\n\n \n\nMETERGOLINE.\n\n \n\nMETFORMIN.\n\n \n\nMETHACHOLINE.\n\n \n\nMETHACYCLINE.\n\n \n\nMETHALLENOESTRIL.\n\n \n\n# METHANDRIOL.\n\n \n\nMETHANTHELINIUM.\n\n \n\nMETHAZOLAMIDE.\n\n \n\nMETHDILAZINE except when included in Schedule 3.\n\n \n\n# METHENOLONE.\n\n \n\nMETHICILLIN.\n\n \n\nMETHIMAZOLE.\n\n \n\nMETHISAZONE.\n\n \n\nMETHIXENE.\n\n \n\nMETHOCARBAMOL.\n\n \n\nMETHOHEXITONE.\n\n \n\nMETHOIN.\n\n \n\nMETHOTREXATE.\n\n \n\nMETHOXAMINE except:\n\n \n\n \n\n (b) in preparations for external use containing 1 per cent or less of methoxamine.\n\n \n\nMETHOXSALEN.\n\n \n\nMETHOXYFLURANE.\n\n \n\nMETHSUXIMIDE.\n\n \n\nMETHYCLOTHIAZIDE.\n\n \n\nMETHYL AMINOLEVULINATE.\n\n \n\n#METHYLANDROSTANOLONE.\n\n \n\n# METHYLCLOSTEBOL.\n\n \n\nMETHYLDOPA.\n\n \n\nMETHYLENE BLUE in preparations for injection.\n\n \n\nMETHYLERGOMETRINE.\n\n \n\nMETHYL MERCURY for therapeutic use.\n\n \n\nMETHYLNALTREXONE.\n\n \n\nMETHYLPENTYNOL.\n\n \n\nMETHYLPHENOBARBITONE.\n\n \n\nMETHYLPREDNISOLONE.\n\n \n\nMETHYL SALICYLATE in preparations for internal therapeutic use.\n\n \n\n# METHYLTESTOSTERONE.\n\n \n\nMETHYLTHIOURACIL.\n\n \n\n# METHYLTRIENOLONE.\n\n \n\nMETHYPRYLONE.\n\n \n\nMETHYSERGIDE.\n\n \n\nMETOCLOPRAMIDE except when included in Schedule 3.\n\n \n\nMETOLAZONE.\n\n \n\nMETOPROLOL.\n\n \n\n# METRIBOLONE.\n\n \n\nMETRIFONATE (trichlorfon) for human therapeutic use.\n\n \n\nMETRONIDAZOLE.\n\n \n\nMETYRAPONE.\n\n \n\nMEXILETINE.\n\n \n\nMEZLOCILLIN.\n\n \n\nMIANSERIN.\n\n \n\nMIBEFRADIL.\n\n \n\n# MIBOLERONE.\n\n \n\nMICAFUNGIN.\n\n \n\nMICONAZOLE except:\n\n \n\n \n\n \n\n# MIDAZOLAM.\n\n \n\nMIDODRINE.\n\n \n\nMIFEPRISTONE.\n\n \n\nMIGLITOL.\n\n \n\nMIGLUSTAT.\n\n \n\nMILBEMYCIN OXIME except when included in Schedule 5.\n\n \n\nMILRINONE.\n\n \n\nMINOCYCLINE.\n\n \n\nMINOXIDIL except when included in Schedule 2.\n\n \n\nMIRABEGRON.\n\n \n\nMIRTAZAPINE.\n\n \n\nMISOPROSTOL.\n\n \n\nMITOBRONITOL.\n\n \n\nMITOMYCIN.\n\n \n\nMITOTANE.\n\n \n\nMITOXANTRONE.\n\n \n\nMITRATAPIDE.\n\n \n\nMIVACURIUM CHLORIDE.\n\n \n\nMOCLOBEMIDE.\n\n \n\nMODAFINIL.\n\n \n\nMOLGRAMOSTIM.\n\n \n\nMOLINDONE.\n\n \n\nMOMETASONE except when included in Schedule 2.\n\n \n\nMONENSIN except:\n\n \n\n (a) when included in Schedule 5 or 6; or\n\n \n\n (b) in animal feeds containing 360 mg/kg or less of antibiotic substances.\n\n \n\nMONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use except in cosmetic nail preparations containing 0.02 per cent or less of monobenzone or alkyl ethers of hydroquinone.\n\n \n\nMONOCLONAL ANTIBODIES for therapeutic use except:\n\n \n\n (a) in diagnostic test kits; or\n\n \n\n \n\nMONTELUKAST.\n\n \n\nMOPERONE.\n\n \n\nMORAZONE.\n\n \n\nMORICIZINE.\n\n \n\nMOTRAZEPAM.\n\n \n\nMOTRETINIDE.\n\n \n\nMOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin except when included in Schedule 5.\n\n \n\nMOXIFLOXACIN.\n\n \n\nMOXONIDINE.\n\n \n\nMUMPS VACCINE.\n\n \n\nMUPIROCIN.\n\n \n\nMURAGLITAZAR.\n\n \n\nMUROMONAB.\n\n \n\nMUSTINE (nitrogen mustard).\n\n \n\nMYCOPHENOLIC ACID (includes mycophenolate mofetil).\n\n \n\nNABUMETONE.\n\n \n\nNADOLOL.\n\n \n\nNADROPARIN.\n\n \n\nNAFARELIN.\n\n \n\nNAFTIDROFURYL.\n\n \n\nNALBUPHINE.\n\n \n\nNALIDIXIC ACID.\n\n \n\nNALMEFENE.\n\n \n\nNALORPHINE.\n\n \n\nNALOXONE.\n\n \n\nNALTREXONE.\n\n \n\n# NANDROLONE.\n\n \n\nNAPROXEN except when included in Schedule 3 or in Schedule 2.\n\n \n\nNARASIN except:\n\n \n\n \n\n (b) in animal feeds containing 100 mg/kg or less of antibiotic substances.\n\n \n\nNARATRIPTAN.\n\n \n\nNATALIZUMAB.\n\n \n\nNATAMYCIN except for use as a food additive.\n\n \n\nNATEGLINIDE.\n\n \n\nNEBACUMAB.\n\n \n\nNEBIVOLOL.\n\n \n\nNEDOCROMIL.\n\n \n\nNEFAZODONE.\n\n \n\nNEFOPAM.\n\n \n\nNELFINAVIR (includes nelfinavir mesylate).\n\n \n\nNEOMYCIN.\n\n \n\nNEOSTIGMINE.\n\n \n\nNEPAFENAC.\n\n \n\nNERIUM OLEANDER.\n\n \n\nNESIRITIDE.\n\n \n\nNETILMICIN.\n\n \n\nNEVIRAPINE.\n\n \n\nNIALAMIDE.\n\n \n\nNICARDIPINE.\n\n \n\nNICERGOLINE.\n\n \n\nNICOFURANOSE.\n\n \n\nNICORANDIL.\n\n \n\nNICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.\n\n \n\nNICOTINIC ACID for human therapeutic use except:\n\n \n\n (b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or\n\n \n\n (c) nicotinamide.\n\n \n\nNICOUMALONE.\n\n \n\nNIFEDIPINE.\n\n \n\nNIFENAZONE.\n\n \n\nNIKETHAMIDE.\n\n \n\nNILOTINIB.\n\n \n\nNILUTAMIDE.\n\n \n\nNIMESULIDE.\n\n \n\nNIMODIPINE.\n\n \n\nNIMORAZOLE.\n\n \n\nNIRIDAZOLE.\n\n \n\nNISOLDIPINE.\n\n \n\nNITISINONE.\n\n \n\n# NITRAZEPAM.\n\n \n\nNITRENDIPINE.\n\n \n\nNITRIC OXIDE for human therapeutic use.\n\n \n\nNITROFURANTOIN.\n\n \n\nNITROFURAZONE.\n\n \n\nNITROUS OXIDE for therapeutic use.\n\n \n\nNITROXOLINE.\n\n \n\nNIZATIDINE except when included in Schedule 2.\n\n \n\nNOMEGESTROL.\n\n \n\nNOMIFENSINE.\n\n \n\nNORADRENALINE.\n\n \n\n# 19-NORANDROSTENEDIOL.\n\n    \n\n# 19-NORANDROSTENEDIONE.\n\n \n\n# NORANDROSTENOLONE.\n\n \n\n# NORBOLETHONE.\n\n \n\n# NORCLOSTEBOL.\n\n \n\nNORELGESTROMIN.\n\n \n\n# NORETHANDROLONE.\n\n \n\nNORETHISTERONE.\n\n \n\nNORFLOXACIN.\n\n \n\nNORGESTREL.\n\n \n\nNORIBOGAINE.\n\n \n\nNORMAL HUMAN IMMUNOGLOBULIN.\n\n \n\n# NORMETHANDRONE.\n\n \n\nNORTRIPTYLINE.\n\n \n\nNOVOBIOCIN.\n\n \n\nNOXIPTYLINE.\n\n \n\nNYSTATIN except when included in Schedule 2 or 3.\n\n \n\nOCRIPLASMIN.\n\n \n\nOCTAMYLAMINE.\n\n \n\nOCTATROPINE.\n\n \n\nOCTREOTIDE.\n\n \n\nOCTYL NITRITE.\n\n \n\nOESTRADIOL except when included in Schedule 5.\n\n \n\nOESTRIOL.\n\n \n\nOESTROGENS except when separately specified in these Schedules.\n\n \n\nOESTRONE.\n\n \n\nOFATUMUMAB.\n\n \n\nOFLOXACIN.\n\n \n\nOLANZAPINE.\n\n \n\nOLEANDOMYCIN except:\n\n \n\n \n\n (b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.\n\n \n\nOLEANDRIN.\n\n \n\nOLMESARTAN.\n\n \n\nOLODATEROL.\n\n \n\nOLOPATADINE.\n\n \n\nOLSALAZINE.\n\n \n\nOMALIZUMAB.\n\n \n\nOMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.\n\n \n\nOMEPRAZOLE except when included in Schedule 3.\n\n \n\nONDANSETRON.\n\n \n\nOPIPRAMOL.\n\n \n\nORBIFLOXACIN.\n\n \n\nORCIPRENALINE.\n\n \n\nORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:\n\n \n\n \n\n (b) in preparations containing 2 per cent or less of malathion for external use.\n\n \n\nORLISTAT except when included in Schedule 3.\n\n \n\nORNIDAZOLE.\n\n \n\nORNIPRESSIN.\n\n \n\nORPHENADRINE.\n\n \n\nORTHOPTERIN.\n\n \n\nOSELTAMIVIR.\n\n \n\nOUABAIN.\n\n \n\n# OVANDROTONE.\n\n \n\n# OXABOLONE.\n\n \n\nOXACILLIN.\n\n \n\nOXALIPLATIN.\n\n \n\n# OXANDROLONE.\n\n \n\nOXAPROZIN.\n\n \n\n# OXAZEPAM.\n\n \n\nOXCARBAZEPINE.\n\n \n\nOXEDRINE for human internal use except in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.\n\n \n\nOXETACAINE (oxethazaine) except when included in Schedule 2.\n\n \n\nOXICONAZOLE except:\n\n \n\n \n\n \n\nOXITROPIUM.\n\n \n\nOXOLAMINE.\n\n \n\nOXOLINIC ACID.\n\n \n\nOXPENTIFYLLINE (pentoxifylline).\n\n \n\nOXPRENOLOL.\n\n \n\nOXYBUPROCAINE.\n\n \n\nOXYBUTYNIN.\n\n \n\n# OXYMESTERONE.\n\n \n\n# OXYMETHOLONE.\n\n \n\nOXYPHENBUTAZONE.\n\n \n\nOXYPHENCYCLIMINE.\n\n \n\nOXYPHENONIUM.\n\n \n\nOXYTETRACYCLINE except when included in Schedule 5.\n\n \n\nOXYTOCIN.\n\n \n\nPACLITAXEL.\n\n \n\nPALIFERMIN.\n\n \n\nPALIPERIDONE.\n\n \n\nPALIVIZUMAB.\n\n \n\nPALONOSETRON.\n\n \n\nPAMAQUIN.\n\n \n\nPAMIDRONIC ACID (includes disodium pamidronate).\n\n \n\nPANCREATIC ENZYMES except:\n\n \n\n (a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or\n\n \n\n \n\nPANCURONIUM.\n\n \n\nPANITUMUMAB.\n\n \n\nPANTOPRAZOLE except when included in Schedule 3.\n\n \n\nPAPAVERINE in preparations for injection.\n\n \n\nPARACETAMOL:\n\n \n\n (a) when combined with aspirin or salicylamide or any derivative of these substances except when separately specified in these Schedules;\n\n \n\n (b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;\n\n \n\n (c) in slow release tablets or capsules containing more than 665 mg of paracetamol;\n\n \n\n (d) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;\n\n \n\n (e) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or\n\n \n\n (f) for injection.\n\n \n\nPARALDEHYDE.\n\n \n\nPARAMETHADIONE.\n\n \n\nPARAMETHASONE.\n\n \n\nPARECOXIB.\n\n \n\nPARICALCITOL.\n\n \n\nPAROMOMYCIN.\n\n \n\nPAROXETINE.\n\n \n\nPASIREOTIDE.\n\n \n\nPAZOPANIB.\n\n \n\nPECAZINE.\n\n \n\nPEFLOXACIN.\n\n \n\nPEGAPTANIB.\n\n \n\nPEGFILGRASTIM.\n\n \n\nPEGINTERFERON.\n\n \n\nPEGVISOMANT.\n\n \n\nPEMETREXED.\n\n \n\nPEMOLINE.\n\n \n\nPEMPIDINE.\n\n \n\nPENBUTOLOL.\n\n \n\nPENCICLOVIR except when included in Schedule 2.\n\n \n\nPENETHAMATE.\n\n \n\nPENICILLAMINE.\n\n \n\nPENTAERYTHRITYL TETRANITRATE.\n\n \n\nPENTAGASTRIN.\n\n \n\nPENTAMETHONIUM.\n\n \n\nPENTAMIDINE (includes pentamidine isethionate).\n\n \n\nPENTHIENATE.\n\n \n\nPENTOBARBITONE when packed and labelled for injection.\n\n \n\nPENTOLINIUM.\n\n \n\nPENTOSAN POLYSULFATE SODIUM.\n\n \n\n# PERAMPANEL.\n\n \n\nPERGOLIDE.\n\n \n\nPERHEXILINE.\n\n \n\nPERICYAZINE.\n\n \n\nPERINDOPRIL.\n\n \n\nPERMETHRIN for human therapeutic use except in preparations containing 5 per cent or less of permethrin.\n\n \n\nPERPHENAZINE.\n\n \n\nPERTUSSIS ANTIGEN.\n\n \n\nPERTUZUMAB.\n\nPHENACEMIDE.\n\n \n\nPHENACETIN for therapeutic use (excluding when present as an excipient).\n\n \n\nPHENAGLYCODOL.\n\n \n\nPHENAZONE except when included in Schedule 2 or 5.\n\n \n\nPHENAZOPYRIDINE.\n\n \n\nPHENELZINE.\n\n \n\nPHENETICILLIN.\n\n \n\nPHENFORMIN.\n\n \n\nPHENGLUTARIMIDE.\n\n \n\nPHENINDIONE.\n\n \n\nPHENIRAMINE except when included in Schedule 2 or 3.\n\n \n\nPHENISATIN.\n\n \n\nPHENOBARBITONE.\n\n \n\nPHENOL in preparations for injection.\n\n \n\nPHENOLPHTHALEIN for human therapeutic use.\n\n \n\nPHENOXYBENZAMINE.\n\n \n\nPHENOXYMETHYLPENICILLIN.\n\n \n\nPHENSUXIMIDE.\n\n \n\n# PHENTERMINE.\n\n \n\nPHENTHIMENTONIUM.\n\n \n\nPHENTOLAMINE.\n\n \n\nPHENYLBUTAZONE.\n\n \n\nPHENYLEPHRINE:\n\n \n\n (a) in preparations for injection; or\n\n \n\n (b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.\n\n \n\nPHENYLPROPANOLAMINE.\n\n \n\nPHENYLTOLOXAMINE.\n\n \n\nPHENYTOIN.\n\n \n\nPHOLCODINE:\n\n \n\n (a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or\n\n \n\n (b) in undivided preparations containing 2.5 per cent or less of pholcodine,\n\n \n\n \n\nPHOSPHODIESTERASE TYPE 5 INHIBITORS except:\n\n \n\n \n\n (b) when present as an unmodified, naturally occurring substance.\n\n \n\nPHTHALYLSULFATHIAZOLE.\n\n \n\nPHYSOSTIGMINE.\n\n \n\nPICROTOXIN.\n\n \n\nPILOCARPINE except in preparations containing 0.025 per cent or less of pilocarpine.\n\n \n\nPIMECROLIMUS.\n\n \n\nPIMOBENDAN.\n\n \n\nPIMOZIDE.\n\n \n\nPINACIDIL.\n\n \n\nPINDOLOL.\n\n \n\nPIOGLITAZONE.\n\n \n\nPIPECURONIUM.\n\n \n\nPIPEMIDIC ACID.\n\n \n\nPIPENZOLATE.\n\n \n\nPIPER METHYSTICUM (kava) in preparations for human use except when included on the Australian Register of Therapeutic Goods in preparations:\n\n \n\n (a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:\n\n \n\n   (i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or\n\n \n\n   (ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;\n\n \n\n  and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or\n\n \n\n (c) in dermal preparations.\n\n \n\nPIPERACILLIN.\n\n \n\nPIPERIDINE.\n\n \n\nPIPERIDOLATE.\n\n \n\nPIPOBROMAN.\n\n \n\nPIPOTHIAZINE.\n\n \n\nPIPRADROL.\n\n \n\nPIRACETAM.\n\n \n\nPIRBUTEROL.\n\n \n\nPIRENOXINE (catalin).\n\n \n\nPIRENZEPINE.\n\n \n\nPIRETANIDE.\n\n \n\nPIROXICAM except in preparations for dermal use.\n\n \n\nPIRPROFEN.\n\n \n\nPITAVASTATIN.\n\n \n\nPITUITARY HORMONES except when separately specified in these Schedules.\n\n \n\nPIVAMPICILLIN.\n\n \n\nPIZOTIFEN.\n\n \n\nPLICAMYCIN.\n\n \n\nPLERIXAFOR.\n\n \n\nPNEUMOCOCCAL VACCINE.\n\n \n\nPODOPHYLLOTOXIN for human use:\n\n \n\n \n\n \n\n \n\nPODOPHYLLUM EMODI (podophyllin) for human use:\n\n \n\n \n\n \n\n \n\nPODOPHYLLUM PELTATUM (podophyllin) for human use:\n\n \n\n \n\n \n\n \n\nPOLIDEXIDE.\n\n \n\nPOLIOMYELITIS VACCINE.\n\n \n\nPOLYACRYLAMIDE in preparations for injection or implantation:\n\n \n\n \n\n \n\nPOLYESTRADIOL.\n\n \n\nPOLYLACTIC ACID in preparations for injection or implantation:\n\n \n\n \n\n \n\nPOLYMYXIN.\n\n \n\nPOLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when separately specified in these Schedules.\n\n \n\nPOLYTHIAZIDE.\n\n \n\nPORACTANT.\n\n \n\nPOSACONAZOLE.\n\n \n\nPOTASSIUM BROMIDE for therapeutic use.\n\n \n\nPOTASSIUM CHLORIDE in oral preparations for human therapeutic use except:\n\n \n\n (a) when containing less than 550 mg of potassium chloride per dosage unit;\n\n \n\n (b) in preparations for oral rehydration therapy;\n\n \n\n (c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or\n\n \n\n (d) in preparations for enteral feeding.\n\n \n\nPOTASSIUM PERCHLORATE for therapeutic use.\n\n \n\nPRACTOLOL.\n\n \n\nPRADOFLOXACIN.\n\n \n\nPRALATREXATE.\n\n \n\nPRALIDOXIME.\n\n \n\nPRAMIPEXOLE.\n\n \n\nPRAMOCAINE.\n\n \n\nPRAMPINE.\n\n \n\n# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).\n\n \n\nPRASUGREL.\n\n \n\nPRAVASTATIN.\n\n \n\n# PRAZEPAM.\n\n \n\nPRAZIQUANTEL for human therapeutic use.\n\n \n\nPRAZOSIN.\n\n \n\nPREDNISOLONE.\n\n \n\nPREDNISONE.\n\n \n\nPREGABALIN.\n\n \n\nPREGNENOLONE.\n\n \n\nPRENALTEROL.\n\n \n\nPRENYLAMINE.\n\n \n\nPRILOCAINE except when included in Schedule 2.\n\n \n\nPRIMAQUINE.\n\n \n\nPRIMIDONE.\n\n \n\nPROBENECID.\n\n \n\nPROBUCOL.\n\n \n\nPROCAINAMIDE.\n\n \n\nPROCAINE.\n\n \n\nPROCAINE PENICILLIN.\n\n \n\nPROCARBAZINE.\n\n \n\nPROCHLORPERAZINE except when included in Schedule 3.\n\n \n\nPROCYCLIDINE except when included in Schedule 2.\n\n \n\nPROGESTERONE except when included in Schedule 5.\n\n \n\nPROGESTOGENS except when separately specified in these Schedules.\n\n \n\nPROGLUMIDE.\n\n \n\nPROGUANIL.\n\n \n\nPROLINTANE.\n\n \n\nPROMAZINE.\n\n \n\nPROMETHAZINE except when included in Schedule 2 or 3.\n\n \n\nPROMOXOLANE.\n\n \n\nPROPAFENONE.\n\n \n\nPROPAMIDINE for therapeutic use except when included in Schedule 2.\n\n \n\nPROPANIDID.\n\n \n\nPROPANTHELINE.\n\n \n\nPROPENTOFYLLINE.\n\n \n\n# PROPETANDROL.\n\n \n\nPROPIONIBACTERIUM ACNES for therapeutic use.\n\n \n\nPROPOFOL.\n\n \n\nPROPRANOLOL.\n\n \n\nPROPYLHEXEDRINE.\n\n \n\nPROPYLTHIOURACIL.\n\n \n\nPROPYPHENAZONE.\n\n \n\nPROQUAZONE.\n\n \n\nPROSCILLARIDIN.\n\n \n\nPROSTAGLANDINS except when separately specified in this Schedule.\n\n \n\nPROSTIANOL.\n\n \n\nPROTAMINE.\n\n \n\nPROTHIONAMIDE.\n\n \n\nPROTHIPENDYL.\n\n \n\nPROTIRELIN.\n\n \n\nPROTOVERATRINES.\n\n \n\nPROTRIPTYLINE.\n\n \n\nPROXYMETACAINE.\n\n \n\nPRUCALOPRIDE.\n\n \n\nPSEUDOEPHEDRINE except when included in Schedule 3.\n\n \n\nPYRAZINAMIDE.\n\n \n\nPYRIDINOLCARBAMATE.\n\n \n\nPYRIDOSTIGMINE.\n\n \n\nPYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:\n\n \n\n (a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n (b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.\n\n \n\nPYRIMETHAMINE.\n\n \n\nPYROVALERONE.\n\n \n\nPYRVINIUM.\n\n \n\n# QUAZEPAM.\n\n \n\nQUETIAPINE.\n\n \n\nQUINAGOLIDE.\n\n \n\nQUINAPRIL.\n\n \n\n# QUINBOLONE.\n\n \n\nQUINETHAZONE.\n\n \n\nQUINIDINE.\n\n \n\nQUININE for human therapeutic use except when the maximum recommended daily dose is 50 mg or less of quinine.\n\n \n\nQUINISOCAINE (dimethisoquin).\n\n \n\nQUINUPRISTIN.\n\n \n\nRABEPRAZOLE except when included in Schedule 3.\n\n \n\nRABIES VACCINE.\n\n \n\nRACTOPAMINE except when included in Schedule 5.\n\n \n\nRALOXIFENE.\n\n \n\nRALTEGRAVIR.\n\n \n\nRALTITREXED.\n\n \n\nRAMIPRIL.\n\n \n\nRANIBIZUMAB.\n\n \n\nRANITIDINE except:\n\n \n\n (a) when included in Schedule 2;  or\n\n \n\n (b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units.\n\n \n\nRAPACURONIUM.\n\n \n\nRASAGILINE.\n\n \n\nRASBURICASE.\n\n \n\nRAUWOLFIA SERPENTINA.\n\n \n\nRAUWOLFIA VOMITORIA.\n\n \n\nRAZOXANE.\n\n \n\nREBOXETINE.\n\n \n\nRED YEAST RICE for human therapeutic use.\n\n \n\nREGORAFENIB.\n\n \n\nREMOXIPRIDE.\n\n \n\nREPAGLINIDE.\n\n \n\nRESERPINE.\n\n \n\nRETAPAMULIN.\n\n \n\nRETEPLASE.\n\n \n\nRETIGABINE.\n\n \n\nRIBAVIRIN.\n\n \n\nRIDAFOROLIMUS.\n\n \n\nRIFABUTIN.\n\n \n\nRIFAMPICIN.\n\n \n\nRIFAMYCIN.\n\n \n\nRIFAPENTINE.\n\n \n\nRIFAXIMIN.\n\n \n\nRILPIVIRINE.\n\n \n\nRILUZOLE.\n\n \n\nRIMEXOLONE.\n\n \n\nRIMITEROL.\n\n \n\nRIMONABANT.\n\n \n\nRISEDRONIC ACID.\n\n \n\nRISPERIDONE.\n\n \n\nRITODRINE.\n\n \n\nRITONAVIR.\n\n \n\nRITUXIMAB.\n\n \n\nRIVAROXABAN.\n\n \n\nRIVASTIGMINE.\n\n \n\nRIZATRIPTAN.\n\n \n\nROBENACOXIB.\n\n \n\nROCURONIUM.\n\n \n\nROFECOXIB.\n\n \n\nROFLUMILAST.\n\n \n\nROLITETRACYCLINE.\n\n \n\nromidepsin.\n\n \n\nROMIFIDINE.\n\n \n\nROMIPLOSTIM.\n\n \n\nRONIDAZOLE.\n\n \n\nROPINIROLE.\n\n \n\nROPIVACAINE.\n\n \n\nROSIGLITAZONE.\n\n \n\nROSOXACIN.\n\n \n\nROSUVASTATIN.\n\n \n\nROTIGOTINE.\n\n \n\n# ROXIBOLONE.\n\n \n\nROXITHROMYCIN.\n\n \n\nRUBELLA VACCINE.\n\n \n\nRUBOXISTAURIN.\n\n \n\nRUPATADINE.\n\n \n\nRUXOLITINIB.\n\n \n\nSALBUTAMOL except when included in Schedule 3.\n\n \n\nSALCATONIN.\n\n \n\nSALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.\n\n \n\nSALINOMYCIN except:\n\n \n\n (a) when included in Schedule 6;  or\n\n \n\n (b) in animal feeds containing 60 mg/kg or less of antibiotic substances.\n\n \n\nSALMETEROL.\n\n \n\nSAPROPTERIN.\n\n \n\nSAQUINAVIR.\n\n \n\nSAXAGLIPTIN.\n\n \n\nSCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of Schoenocaulon officinale.\n\n \n\nSCOPOLIA CARNIOLICA for therapeutic use.\n\n \n\n# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).\n\n \n\nSELEGILINE.\n\n \n\nSELENIUM:\n\n \n\n (a) for human oral use with a recommended daily dose of more than 300 micrograms; or\n\n \n\n (b) for the treatment of animals except:\n\n \n\n   (i) when included in Schedule 6 or 7;\n\n \n\n   (ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;\n\n \n\n   (iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;\n\n \n\n   (iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or\n\n \n\n   (v) in feeds containing 1 g/tonne or less of selenium.\n\n \n\nSERELAXIN.\n\n \n\nSERMORELIN.\n\n \n\nSERTINDOLE.\n\n \n\nSERTRALINE.\n\n \n\nSEVELAMER.\n\n \n\nSEVOFLURANE.\n\n \n\nSEX HORMONES and all substances having sex hormonal activity except when separately specified in these Schedules.\n\n \n\nSIBUTRAMINE.\n\n \n\n# SILANDRONE.\n\n \n\nSILDENAFIL.\n\n \n\nSILICONES for intra-ocular use. \n\n \n\nSILVER SULFADIAZINE.\n\n \n\nSIMEPREVIR.\n\n \n\nSIMVASTATIN.\n\n \n\nSIROLIMUS.\n\n \n\nSISOMICIN (sisomycin).\n\n \n\nSITAGLIPTIN.\n\n \n\n# SITAXENTAN.\n\n \n\nSODIUM BROMIDE for therapeutic use.\n\n \n\nSODIUM CELLULOSE PHOSPHATE for human internal use.\n\n \n\nSODIUM CROMOGLYCATE except when included in Schedule 2.\n\n \n\nSODIUM MORRHUATE in preparations for injection.\n\n \n\nSODIUM NITROPRUSSIDE for human therapeutic use.\n\n \n\nSODIUM PHOSPHATE in preparations for oral laxative use.\n\n \n\nSODIUM POLYSTYRENE SULPHONATE for human therapeutic use.\n\n \n\nSODIUM SALICYLATE in preparations for injection for the treatment of animals.\n\n \n\nSODIUM TETRADECYLSULFATE in preparations for injection.\n\n \n\nSOFOSBUVIR.\n\n \n\nSOLASODINE.\n\n \n\nSOLIFENACIN.\n\n \n\nSOMATOSTATIN.\n\n \n\nSOMATOTROPIN EQUINE.\n\n \n\n# SOMATROPIN (human growth hormone).\n\n \n\nSONTOQUINE.\n\n \n\nSORAFENIB.\n\n \n\nSOTALOL.\n\n \n\nSPARFLOXACIN.\n\n \n\nSPARTEINE.\n\n \n\nSPECTINOMYCIN.\n\n \n\nSPIRAMYCIN.\n\n \n\nSPIRAPRIL.\n\n \n\nSPIRONOLACTONE.\n\n \n\n# STANOLONE.\n\n \n\n# STANOZOLOL.\n\n \n\nSTAVUDINE.\n\n \n\n# STENBOLONE.\n\n \n\nSTEROID HORMONES except when separately specified in these Schedules.\n\n \n\nSTILBOESTROL (diethylstilboestrol).\n\n \n\nSTREPTODORNASE.\n\n \n\nSTREPTOKINASE.\n\n \n\nSTREPTOMYCIN.\n\n \n\nSTRONTIUM RANELATE.\n\n \n\nSTROPHANTHINS.\n\n \n\nSTROPHANTHUS spp.\n\n \n\nSTRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.\n\n \n\nSTRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of strychnine.\n\n \n\nSTYRAMATE.\n\n \n\nSUCCIMER.\n\n \n\nSUGAMMADEX.\n\n \n\nSULBACTAM.\n\n \n\nSULCONAZOLE except when included in Schedule 2.\n\n \n\nSULFACETAMIDE except when included in Schedule 3 or 5.\n\n \n\nSULFADIAZINE except when included in Schedule 5.\n\n \n\nSULFADIMETHOXINE.\n\n \n\nSULFADIMIDINE except when included in Schedule 5.\n\n \n\nSULFADOXINE.\n\n \n\nSULFAFURAZOLE.\n\n \n\nSULFAGUANIDINE.\n\n \n\nSULFAMERAZINE except when included in Schedule 5.\n\n \n\nSULFAMETHIZOLE.\n\n \n\nSULFAMETHOXAZOLE.\n\n \n\nSULFAMETHOXYDIAZINE.\n\n \n\nSULFAMETHOXYPYRIDAZINE.\n\n \n\nSULFAMETROLE.\n\n \n\nSULFAMONOMETHOXINE.\n\n \n\nSULFAMOXOLE.\n\n \n\nSULFAPHENAZOLE.\n\n \n\nSULFAPYRIDINE.\n\n \n\nSULFAQUINOXALINE.\n\n \n\nSULFASALAZINE.\n\n \n\nSULFATHIAZOLE except when included in Schedule 5.\n\n \n\nSULFATROXAZOLE.\n\n \n\nSULFINPYRAZONE.\n\n \n\nSULFOMYXIN.\n\n \n\nSULFONAMIDES except:\n\n \n\n \n\n (b) when included in Schedule 3, 5 or 6; or\n\n \n\n (c) when packed and labelled solely for use as a herbicide. \n\n \n\nSULFONMETHANE (sulfonal and alkyl sulfonals).\n\n \n\nSULINDAC.\n\n \n\nSULTAMICILLIN.\n\n \n\nSULTHIAME.\n\n \n\nSUMATRIPTAN.\n\n \n\nSUNITINIB.\n\n \n\nSUPROFEN.\n\n \n\nSUTILAINS.\n\n \n\nSUXAMETHONIUM.\n\n \n\nSUXETHONIUM.\n\n \n\nTACRINE.\n\n \n\nTACROLIMUS.\n\n \n\nTADALAFIL.\n\n \n\nTAFLUPROST.\n\n \n\nTALIGLUCERASE ALFA.\n\n \n\nTAMOXIFEN.\n\n \n\nTAMSULOSIN.\n\n \n\nTANACETUM VULGARE except in preparations containing 0.8 per cent or less of oil of tansy.\n\n \n\nTASONERMIN.\n\n \n\nTAZAROTENE.\n\n \n\nTAZOBACTAM.\n\n \n\nT-CELL RECEPTOR ANTIBODY.\n\n \n\nTEGAFUR.\n\n \n\nTEGASEROD.\n\n \n\nTELAPREVIR.\n\n \n\nTELITHROMYCIN.\n\n \n\nTEICOPLANIN.\n\n \n\nTELBIVUDINE.\n\n \n\nTELMISARTAN.\n\n \n\n# TEMAZEPAM.\n\n \n\nTEMOZOLOMIDE.\n\n \n\nTEMSIROLIMUS.\n\n \n\nTENECTEPLASE.\n\n \n\nTENIPOSIDE.\n\n \n\nTENOFOVIR.\n\n \n\nTENOXICAM.\n\n \n\nTEPOXALIN.\n\n \n\nTERAZOSIN.\n\n \n\nTERBINAFINE except:\n\n \n\n \n\n \n\nTERBUTALINE except when included in Schedule 3.\n\n \n\nTERFENADINE.\n\n \n\nTERIFLUNOMIDE.\n\n \n\n# TERIPARATIDE.\n\n \n\nTERLIPRESSIN.\n\n \n\nTERODILINE.\n\n \n\nTEROPTERIN.\n\n \n\n# TESTOLACTONE.\n\n \n\n# TESTOSTERONE except when included in Schedule 6.\n\n \n\nTETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in animals.\n\n \n\nTETANUS TOXOID for human use.\n\n \n\nTETRABENAZINE.\n\n \n\nTETRACOSACTRIN.\n\n \n\nTETRACYCLINE except when included in Schedule 5.\n\n \n\nTETRAETHYLAMMONIUM.\n\n \n\nTETROXOPRIM.\n\n \n\n# THALIDOMIDE.\n\n \n\nTHENYLDIAMINE.\n\n \n\nTHEOPHYLLINE except when included in Schedule 3.\n\n \n\nTHEVETIA PERUVIANA.\n\n \n\nTHEVETIN.\n\n \n\nTHIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.\n\n \n\nTHIAMBUTOSINE.\n\n \n\nTHIAZOSULFONE.\n\n \n\nTHIETHYLPERAZINE.\n\n \n\nTHIOACETAZONE.\n\n \n\nTHIOCARLIDE.\n\n \n\nTHIOGUANINE.\n\n \n\n# THIOMESTERONE (tiomesterone).\n\n \n\nTHIOPENTONE.\n\n \n\nTHIOPROPAZATE.\n\n \n\nTHIOPROPERAZINE.\n\n \n\nTHIORIDAZINE.\n\n \n\nTHIOSTREPTON.\n\n \n\nTHIOTEPA.\n\n \n\nTHIOTHIXENE.\n\n \n\nTHIOURACIL.\n\n \n\nTHIOUREA for therapeutic use except in preparations containing 0.1 per cent or less of thiourea.\n\n \n\nTHYMOXAMINE (includes thymoxamine hydrochloride).\n\n \n\nTHYROID except when separately specified in this Schedule.\n\n \n\nTHYROTROPHIN.\n\n \n\nTHYROXINE (includes thyroxine sodium).\n\n \n\nTIAGABINE.\n\n \n\nTIAMULIN.\n\n \n\nTIAPROFENIC ACID.\n\n \n\nTIARAMIDE.\n\n \n\nTIBOLONE.\n\n \n\nTICAGRELOR.\n\n \n\nTICARCILLIN.\n\n \n\nTICLOPIDINE.\n\n \n\nTIEMONIUM.\n\n \n\nTIENILIC ACID.\n\n \n\nTIGECYCLINE.\n\n \n\nTIGLOIDINE.\n\n \n\nTILDIPIROSIN.\n\n \n\nTILETAMINE.\n\n \n\nTILMICOSIN.\n\n \n\nTILUDRONIC ACID (includes disodium tiludronate).\n\n \n\nTIMOLOL.\n\n \n\nTINIDAZOLE.\n\n \n\nTINZAPARIN (includes tinzaparin sodium).\n\n \n\nTIOCONAZOLE except:\n\n \n\n \n\n \n\nTIOTROPIUM.\n\n \n\nTIPEPIDINE.\n\n \n\nTIPRANAVIR.\n\n \n\nTIRILAZAD.\n\n \n\nTIROFIBAN.\n\n \n\nTOBRAMYCIN.\n\n \n\nTOCAINIDE.\n\n \n\nTOCERANIB.\n\n \n\nTOCILIZUMAB.\n\n \n\nTOLAZAMIDE.\n\n \n\nTOLAZOLINE.\n\n \n\nTOLBUTAMIDE.\n\n \n\nTOLCAPONE.\n\n \n\nTOLFENAMIC ACID.\n\n \n\nTOLMETIN.\n\n \n\nTOLONIUM.\n\n \n\nTOLPROPAMINE.\n\n \n\nTOLRESTAT.\n\n \n\nTOLTERODINE.\n\n \n\nTOLVAPTAN.\n\n \n\nTOPIRAMATE.\n\n \n\nTOPOTECAN.\n\n \n\nTORASEMIDE.\n\n \n\nTOREMIFENE.\n\n \n\nTOXOIDS for human parenteral use except when separately specified in these Schedules.\n\n \n\nTRAMADOL.\n\n \n\nTRANDOLAPRIL.\n\n \n\ntrametinib dimethyl sulfoxide.\n\n \n\nTRANEXAMIC ACID except in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use. \n\n \n\nTRANYLCYPROMINE.\n\n \n\nTRASTUZUMAB.\n\n \n\nTrastuzumab emtansine.\n\n \n\nTRAVOPROST.\n\n \n\nTRAZODONE.\n\n \n\n# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.\n\n \n\nTREOSULPHAN.\n\n \n\nTREPROSTINIL.\n\n \n\n# TRESTOLONE.\n\n \n\nTRETAMINE.\n\n \n\n# TRETINOIN.\n\n \n\nTRIACETYLOLEANDOMYCIN.\n\n \n\nTRIAMCINOLONE except when included in Schedule 2 or 3.\n\n \n\nTRIAMTERENE.\n\n \n\nTRIAZIQUONE.\n\n \n\n# TRIAZOLAM.\n\n \n\nTRICHLORMETHIAZIDE.\n\n \n\nTRICHLOROACETIC ACID for human dermal use except when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.\n\n \n\nTRICHLOROETHYLENE for therapeutic use.\n\n \n\nTRICLOFOS.\n\n \n\nTRICYCLAMOL.\n\n \n\nTRIDIHEXETHYL.\n\n \n\nTRIFLUOPERAZINE.\n\n \n\nTRIFLUPERIDOL.\n\n \n\nTRIFLUPROMAZINE.\n\n \n\nTRILOSTANE.\n\n \n\nTRIMEPRAZINE except when included in Schedule 2 or 3.\n\n \n\nTRIMETAPHAN.\n\n \n\nTRIMETHOPRIM.\n\n \n\nTRIMIPRAMINE.\n\n \n\nTRIMUSTINE.\n\n \n\nTRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.\n\n \n\nTRIOXYSALEN.\n\n \n\nTRIPELENNAMINE.\n\n \n\nTRIPLE ANTIGEN VACCINE.\n\n \n\nTRIPROLIDINE except when included in Schedule 2 or 3.\n\n \n\nTRIPTORELIN.\n\n \n\nTROGLITAZONE.\n\n \n\nTROMETAMOL in preparations for injection except in preparations containing 3 per cent or less of trometamol.\n\n \n\nTROPICAMIDE.\n\n \n\nTROPISETRON.\n\n \n\nTROVAFLOXACIN.\n\n \n\nTROXIDONE.\n\n \n\nTRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.\n\n \n\nTUBERCULIN.\n\n \n\nTUBOCURARINE.\n\n \n\nTULATHROMYCIN.\n\n \n\nTULOBUTEROL.\n\n \n\nTYLOSIN.\n\n \n\nTYPHOID VACCINE.\n\n \n\nUMECLIDINIUM.\n\n \n\nUNOPROSTONE.\n\n \n\nURACIL.\n\n \n\nURAPIDIL.\n\n \n\nURETHANE (excluding its derivatives) for therapeutic use.\n\n \n\n# UROFOLLITROPIN.\n\n \n\nUROKINASE.\n\n \n\nURSODEOXYCHOLIC ACID.\n\n \n\nUSTEKINUMAB.\n\n \n\nVACCINES for human therapeutic use except when separately specified in this Schedule.\n\n \n\nVACCINES, veterinary live virus except:\n\n \n\n (a) poultry vaccines;\n\n \n\n (b) pigeon pox vaccine; or\n\n \n\n (c) scabby mouth vaccine.\n\n \n\nVACCINIA VIRUS VACCINE.\n\n \n\nVALACICLOVIR.\n\n \n\nVALDECOXIB.\n\n \n\nVALGANCICLOVIR.\n\n \n\nVALNOCTAMIDE.\n\n \n\nVALPROIC ACID.\n\n \n\nVALSARTAN.\n\n \n\nVANCOMYCIN.\n\n \n\nVANDETANIB.\n\n \n\nVARDENAFIL.\n\n \n\nVARENICLINE.\n\n \n\nVARICELLA VACCINE.\n\n \n\nVASOPRESSIN.\n\n \n\nVECURONIUM.\n\n \n\nVEDAPROFEN.\n\n \n\nvEDOLIZUMAB.\n\n \n\nVELAGLUCERASE ALFA.\n\n \n\nVEMURAFENIB.\n\n \n\nVENLAFAXINE.\n\n \n\nVERAPAMIL.\n\n \n\nVERATRUM spp. except when separately specified in this Schedule.\n\n \n\nVERNAKALANT.\n\n \n\nVERTEPORFIN.\n\n \n\nVIDARABINE.\n\n \n\nVIGABATRIN.\n\n \n\nVILANTEROL.\n\n \n\nVILDAGLIPTIN.\n\n \n\nVILOXAZINE.\n\n \n\nVINBLASTINE.\n\n \n\nVINCAMINE.\n\n \n\nVINCRISTINE.\n\n \n\nVINDESINE.\n\n \n\nVINFLUNINE.\n\n \n\nVINORELBINE.\n\n \n\nVINYL ETHER for therapeutic use.\n\n \n\nVIRGINIAMYCIN except when included in Schedule 5.\n\n \n\nVISMODEGIB.\n\n \n\nVISNADINE.\n\n \n\nVITAMIN A for human therapeutic or cosmetic use except:\n\n \n\n (a) in preparations for topical use containing 1 per cent or less of Vitamin A;\n\n \n\n (b)      in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A  per daily dose; or\n\n \n\n (c) in preparations for parenteral nutrition replacement.\n\n \n\nVITAMIN D for human internal therapeutic use except:\n\n \n\n1.         in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or\n\n \n\n1.         when included in Schedule 3.\n\n \n\nVORICONAZOLE.\n\n \n\nVORINOSTAT.\n\n \n\nVORTIOXETINE.\n\n \n\nWARFARIN for therapeutic use.\n\n \n\nXAMOTEROL.\n\n \n\nXANTHINOL NICOTINATE.\n\n \n\nXIMELAGATRAN.\n\n \n\nXIPAMIDE.\n\n \n\nXYLAZINE.\n\n \n\nYOHIMBINE.\n\n \n\nZAFIRLUKAST.\n\n \n\nZALCITABINE.\n\n \n\nZALEPLON.\n\n \n\nZANAMIVIR.\n\n \n\nZERANOL except when included in Schedule 6.\n\n \n\nZIDOVUDINE.\n\n \n\nZILPATEROL.\n\n \n\nZIMELDINE.\n\n \n\nZINC COMPOUNDS for human internal use except:\n\n \n\n (a) in preparations with a recommended daily dose of 25 mg or less of zinc; or\n\n \n\n (b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels.\n\n \n\nZIPRASIDONE.\n\n \n\nZOLAZEPAM.\n\n \n\nZOLEDRONIC ACID.\n\n \n\nZOLMITRIPTAN.\n\n \n\nZOLPIDEM.\n\n \n\nZONISAMIDE.\n\n \n\nZOPICLONE.\n\n \n\nZOXAZOLAMINE.\n\n \n\nZUCLOPENTHIXOL.\n\n## SCHEDULE 5\n\n \n\n \n\nABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.\n\n \n\nABSCISIC ACID.\n\n \n\nACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH3COOH) except:\n\n \n\n (a) when included in Schedule 2 or 6; or\n\n \n\n \n\nACETONE except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.\n\n \n\nAFOXOLANER for the treatment and prevention of flea infestations and control of ticks in dogs in oral divided preparations each containing 140 mg or less of afoxolaner per dosage unit.\n\n \n\nAKLOMIDE.\n\n \n\nALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole except in intraruminal implants each containing 3.85 g or less of albendazole.\n\n \n\n† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:\n\n \n\n (a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;\n\n \n\n (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;\n\n \n\n (c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n \n\n (d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:\n\n \n\n   (i) in food additive preparations for domestic use; or\n\n \n\n   (ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,\n\n \n\n except when separately specified in these Schedules.\n\n \n\nALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer except in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.\n\n \n\nALLETHRIN in preparations containing 10 per cent or less of allethrin except:\n\n \n\n (a) in insecticidal mats; or\n\n \n\n (b) in other preparations containing 1 per cent or less of allethrin.\n\n \n\nALLOXYDIM.\n\n \n\nALPHA-CYPERMETHRIN:\n\n \n\n (a)  in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or\n\n \n\n (b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.\n\n \n\nAMETRYN.\n\n \n\nAMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.\n\n \n\nAMINES for use as curing agents for epoxy resins except when separately specified in these Schedules.\n\n \n\nAMINOPYRALID in water soluble gel formulations containing 0.5 per cent or less of aminopyralid.\n\n \n\nAMITROLE.\n\n \n\nAMINOCYCLOPYRACHLOR.\n\n \n\nAMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia except:\n\n \n\n (a) in preparations for human internal therapeutic use;\n\n \n\n (b) in preparations for inhalation when absorbed in an inert solid material; or\n\n \n\n (c) in preparations containing 0.5 per cent or less of free ammonia.\n\n \n\nAMMONIUM THIOCYANATE except in preparations containing 10 per cent or less of ammonium thiocyanate.\n\n \n\nANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when separately specified in these Schedules.\n\n \n\nANISE OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 50 per cent or less of anise oil.\n\n \n\nASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.\n\n \n\nATRAZINE.\n\n \n\n† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.\n\n \n\nAZOXYSTROBIN.\n\n \n\nBACILLUS THURINGIENSIS delta endotoxin encapsulated in killed Pseudomonas fluorescens.\n\n \n\nBARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.\n\n \n\nBASIL OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of  25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 5 per cent or less of methyl chavicol.\n\n \n\nBEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of Beauveria bassiana.\n\n \n\nBENALAXYL.\n\n \n\nBENDIOCARB in preparations containing 2 per cent or less of bendiocarb.\n\n \n\nBENTAZONE.\n\n \n\nBENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride except in preparations containing 5 per cent or less of benzalkonium chloride.\n\n \n\nBENZOFENAP.\n\n \n\nBENZOYL PEROXIDE except:\n\n \n\n (a) when included in Schedule 2 or 4; or\n\n \n\n (b) in preparations containing 5 per cent or less of benzoyl peroxide.\n\n \n\nBERGAMOT OIL except:\n\n \n\n \n\n \n\n (c) in preparations containing 0.4 per cent or less of bergamot oil;\n\n \n\n \n\n (e) in medicines for human therapeutic use when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n \n\n \n\nBETACYFLUTHRIN:\n\n \n\n (a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or\n\n \n\n (b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.\n\n \n\nBIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3 per cent or less of total bifluorides.\n\n \n\nBIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin except in preparations containing 1 per cent or less of bioallethrin.\n\n \n\nBIORESMETHRIN except in preparations containing 10 per cent or less of bioresmethrin.\n\n \n\nBISPYRIBAC except in preparations containing 10 per cent or less of bispyribac.\n\n \n\nBORIC ACID (excluding its salts) and BORAX except:\n\n \n\n \n\n (b) in preparations, other than insect baits, containing 1 per cent or less of boron; or\n\n \n\n (c) in hand cleaning preparations.\n\n \n\nBORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF3).\n\n \n\nBROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.\n\n \n\nBUPIVACAINE   in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.\n\n \n\nBUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.\n\n \n\nBUTHIDAZOLE.\n\n \n\nBUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.\n\n \n\nBUTRALIN.\n\n \n\nBUTROXYDIM.\n\n \n\nCAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor except:\n\n \n\n (a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:\n\n \n\n \n\n \n\n (c) in rosemary oil, sage oil (Spanish), or lavandin oils; or\n\n \n\n (d) in preparations containing 2.5 per cent or less of camphor.\n\n \n\n† CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide except in preparations containing 9 per cent or less of carbamide peroxide.\n\n \n\nCARBARYL:\n\n \n\n (a) in preparations containing 10 per cent or less of carbaryl except when included in Schedule 4; or\n\n \n\n (b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.\n\n \n\nCASSIA OIL except:\n\n \n\n (a) in food additives;\n\n \n\n (b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or\n\n \n\n (c) in other preparations containing 2 per cent or less of cassia oil.\n\n \n\nCHLORFENAC.\n\n \n\nCHLORFENAPYR. in preparations containing 0.5 per cent or less of chlorfenapyr.\n\n \n\nCHLORFENSON.\n\n \n\nCHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine except:\n\n \n\n (a) in preparations containing 1 per cent or less of chlorhexidine; or\n\n \n\n (b) when in solid preparations.\n\n \n\nCHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, except:\n\n \n\n \n\n (b) sodium hypochlorite preparations with a pH of less than 11.5;\n\n \n\n (c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:\n\n \n\n  WARNING – Ensure adequate ventilation when using.  Vapour may be harmful.  May give off dangerous gas if mixed with other products;\n\n \n\n (d) liquid preparations containing less than 2 per cent of available chlorine; or\n\n \n\n (e) other preparations containing 4 per cent or less of available chlorine.\n\n \n\nCHLORNIDINE.\n\n \n\nCHLOROCRESOL except in preparations containing 3 per cent or less of chlorocresol.\n\n \n\nCHLORPROPHAM.\n\n \n\nCHLORPYRIFOS:\n\n \n\n (a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;\n\n \n\n (b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or\n\n \n\n (c) in other preparations containing 5 per cent or less of chlorpyrifos,\n\n \n\n except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic  metre.\n\n \n\nCHLORSULFURON.\n\n \n\nCHLORTETRACYCLINE in preparations:\n\n \n\n \n\n (b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\n \n\nCHLORTHAL-DIMETHYL.\n\n \n\nCINMETHYLIN. \n\n \n\nCINNAMON BARK OIL except:\n\n \n\n (a) in food additives; or\n\n \n\n (b) in preparations containing 2 per cent or less of cinnamon bark oil.\n\n \n\nCLETHODIM.\n\n \n\nCLIMBAZOLE in preparations containing 40 per cent or less of climbazole except in preparations containing 2 per cent or less of climbazole.\n\n \n\nCLOFENTEZINE.\n\n \n\nCLOPYRALID.\n\n \n\nCLOQUINTOCET-MEXYL.\n\n \n\nCLORSULON.\n\n \n\nCLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.\n\n \n\nCLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except in preparations containing 25 per cent or less of clove oil.\n\n \n\nCOPPER ACETATE in preparations containing 20 per cent or less of copper acetate except in preparations containing 5 per cent or less of copper acetate.\n\n \n\nCOPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper except in preparations containing 1 per cent or less of copper.\n\n \n\nCOPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide except in preparations containing 12.5 per cent or less of copper hydroxide.\n\n \n\nCOPPER OXIDES in preparations containing 25 per cent or less of copper oxides except:\n\n \n\n (a) in preparations for internal use;\n\n \n\n (b) in marine paints; or\n\n \n\n (c) in other preparations containing 5 per cent or less of copper oxides.\n\n \n\nCOPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride except in preparations containing 12.5 per cent or less of copper oxychloride.\n\n \n\nCOPPER SULFATE in preparations containing 15 per cent or less of copper sulfate except:\n\n \n\n (a) in preparations for internal use; or\n\n \n\n (b) in other preparations containing 5 per cent or less of copper sulfate.\n\n \n\nCOUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.\n\n \n\n4-CPA.\n\n \n\nCYANATRYN.\n\n \n\nCYANOACRYLATE ESTERS in contact adhesives except:\n\n \n\n (a) when labelled with the warning:\n\n \n\n  KEEP OUT OF REACH OF CHILDREN.  Avoid contact with skin and eyes and avoid breathing vapour.  Bonds on contact.  Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water.  Do not use solvents near eyes or open wounds.  In case of eye contact immediately flush with water; or\n\n \n\n (b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:\n\n \n\n  (i) labelled with the approved name or trade name of the poison, the quantity and the warning:\n\n \n\n   Can cause eye injury.  Instantly bonds skin; and\n\n \n\n  (ii)  enclosed in a primary pack labelled with the warning:\n\n \n\n   KEEP OUT OF REACH OF CHILDREN.  Avoid contact with skin and eyes and avoid breathing vapour.  Bonds on contact.  Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water.  Do not use solvents near eyes or open wounds.  In case of eye contact immediately flush with water.\n\n \n\nCYANURIC ACID (excluding its salts and derivatives).\n\n \n\nCYANTRANILIPROLE.\n\n \n\nCYAZOFAMID.\n\n \n\nCYCLOHEXANONE PEROXIDE.\n\n \n\nCYCLOPROTHRIN except in preparations containing 10 per cent or less of cycloprothrin.\n\n \n\nCYCLOXYDIM.\n\n \n\nCYFLUFENAMID.\n\n \n\nCYFLUTHRIN:\n\n \n\n (a) in wettable powders containing 10 per cent or less of cyfluthrin;\n\n \n\n (b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or\n\n \n\n (c) in emulsions containing 5 per cent or less of cyfluthrin.\n\n \n\ncyhalofop-butyl.\n\n \n\nCYMIAZOLE.\n\n \n\nCYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.\n\n \n\nCYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.\n\n \n\nCYPROCONAZOLE except in preparations containing 10 per cent or less of cyproconazole.\n\n \n\nCYPRODINIL.\n\n \n\nCYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine except in preparations containing 1 per cent or less of cysteamine.\n\n \n\nCYTHIOATE for the treatment of animals:\n\n \n\n (a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or\n\n \n\n (b)  in undivided preparations containing 5 per cent or less of cythioate.\n\n \n\n2,4-D in preparations containing 20 per cent or less of 2,4-D.\n\n \n\nDAMINOZIDE.\n\n \n\n2,4-DB.\n\n \n\nDECOQUINATE:\n\n \n\nDELTAMETHRIN:\n\n \n\n1.        when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;\n\n \n\n1.        in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;\n\n \n\n1.        in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;\n\n \n\n1.        in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or\n\n \n\n1.        in other preparations containing 0.5 per cent or less of deltamethrin,\n\n \n\nexcept:\n\n \n\n1.      in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or\n\n \n\n1.     in preparations containing 0.1 per cent or less of deltamethrin.\n\n \n\nDEMBREXINE in oral preparations for the treatment of animals.\n\n \n\n2,4-DES.\n\n \n\nDIAFENTHIURON.\n\n \n\nN,N-DIALLYLDICHLOROACETAMIDE except in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.\n\n \n\nDIAZINON in dust preparations containing 2 per cent or less of diazinon.\n\n \n\nDICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.\n\n \n\nDICHLONE.\n\n \n\npara-DICHLOROBENZENE.\n\n \n\nDICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, except in:\n\n \n\n (a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:\n\n \n\n  WARNING – Ensure adequate ventilation when using.  Vapour may be harmful.  May give off dangerous gas if mixed with other products;\n\n \n\n (b) liquid preparations containing less than 2 per cent of available chlorine; or\n\n \n\n (c) other preparations containing 4 per cent or less of available chlorine.\n\n \n\nDICHLOROMETHANE (methylene chloride) except:\n\n \n\n (a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane; \n\n \n\n (b) in other preparations in pressurised spray packs; or\n\n \n\n (c) in paints and tinters containing 5 per cent or less of dichloromethane.\n\n \n\nDICHLOROPHEN for the treatment of animals.\n\n \n\nDICHLORVOS:\n\n \n\n (a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;\n\n \n\n (b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or\n\n \n\n (c) in pressurised spray packs containing 10 grams or less of dichlorvos.\n\n \n\nDICLOBUTRAZOL.\n\n \n\nDICLORAN.\n\n \n\nDICOFOL.\n\n \n\nDIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine except in preparations containing 5 per cent or less of diethanolamine.\n\n \n\n† DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:\n\n \n\n (a) in paints or paint tinters;\n\n \n\n (b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or\n\n \n\n (c) in other preparations containing 2.5 per cent or less of diethylene glycol.\n\n \n\nDIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.\n\n \n\nDIETHYLTOLUAMIDE (DEET) except:\n\n \n\n (a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the Required Advisory Statements for Medicine Labels;  \n\n \n\n (b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:\n\n  \n\n  WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or\n\n \n\n  (c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.\n\n \n\nDIFENOCONAZOLE.\n\n \n\nDIFLUBENZURON.\n\n \n\nDIMETHICODIETHYLBENZALMALONATE except when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.\n\n \n\nDIMETHIRIMOL.\n\n \n\nDIMETHOMORPH except in preparations containing 10 per cent or less of dimethomorph.\n\n \n\nDIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.\n\n \n\nDIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide except in silicone rubber mastic containing 2 per cent or less of dimethylformamide.\n\n \n\nDINICONAZOLE.\n\n \n\nDI-N-PROPYL ISOCINCHOMERONATE except in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.\n\n \n\nDIPHENAMID.\n\n \n\nDITHIOPYR.\n\n \n\nN-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nDORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.\n\n \n\nEMAMECTIN in preparations containing 2 per cent or less of emamectin.\n\n \n\nEMODEPSIDE in preparations:\n\n \n\n(a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or\n\n \n\n(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.\n\n \n\nEPOXICONAZOLE.\n\n \n\nEPOXY RESINS, LIQUID.\n\n \n\nEPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.\n\n \n\nESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin except in pressurised spray packs containing 1 per cent or less of esbiothrin.\n\n \n\nESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.\n\n \n\n1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.\n\n \n\nETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of ethanolamine.\n\n \n\nETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.\n\n \n\nETHOFUMESATE.\n\n \n\nETHOXYQUIN except in preparations containing 10 per cent or less of ethoxyquin.\n\n \n\nETHOXYSULFURON.\n\n \n\n† ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent except:\n\n \n\n (a) in paints or paint tinters;\n\n \n\n (b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or\n\n \n\n (c) in other preparations containing 2.5 per cent or less of ethylene glycol.\n\n \n\nETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.\n\n \n\nETRIDIAZOLE.\n\n \n\nEUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in preparations containing 25 per cent or less of eugenol.\n\n \n\nEXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (Corymbia citriodora) , except in preparations containing 40 per cent or less of extract of lemon eucalyptus.\n\n \n\nFENARIMOL.\n\n \n\nFENBENDAZOLE for the treatment of animals.\n\n \n\nFENBUCONAZOLE.\n\n \n\nFENCHLORAZOLE-ETHYL.\n\n \n\nFENOPROP.\n\n \n\nFENOXAPROP-ETHYL.\n\n \n\nFENOXAPROP-P-ETHYL.\n\n \n\nFENSON.\n\n \n\nFENTHION:\n\n \n\n (a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or\n\n \n\n (b) in preparations containing 10 per cent or less of fenthion.\n\n \n\nFIPRONIL in preparations containing 10 per cent or less of fipronil except in preparations containing 0.05 per cent or less of fipronil.\n\n \n\nFLAMPROP-METHYL.\n\n \n\nFLAMPROP-M-METHYL.\n\n \n\nFLAZASULFURON.\n\n \n\nFLORASULAM.\n\n \n\nFLUAZURON.\n\n \n\nFLUBENDAZOLE for the treatment of animals.\n\n \n\nFLUBENDIAMIDE.\n\n \n\nFLUCHLORALIN.\n\n \n\nFLUDIOXONIL except in preparations containing 10 per cent or less of fludioxonil.\n\n \n\nFLUMETHRIN:\n\n \n\n (a) when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or\n\n \n\n (b) in oil based preparations containing 1 per cent or less of flumethrin.\n\n \n\nflumiclorac pentyl.\n\n \n\nFLUORIDES in preparations containing 3 per cent or less of fluoride ion except:\n\n \n\n (a) in preparations for human use; or\n\n \n\n \n\nFLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.\n\n \n\nFLUXAPYROXAD.\n\n \n\nFORAMSULFURON.\n\n \n\nFORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5 per cent or less of formic acid.\n\n \n\nFOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.\n\n \n\nFURALAXYL.\n\n \n\nFURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.\n\n \n\nGAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.\n\n \n\nGLUFOSINATE-AMMONIUM.\n\n \n\nGLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:\n\n \n\n \n\n \n\nGLYPHOSATE.\n\n \n\nHALOSULFURON-METHYL.\n\n \n\nHEXACONAZOLE except in preparations containing 5 per cent or less of hexaconazole.\n\n \n\nHEXAZINONE in preparations containing 25 per cent or less of hexazinone.\n\n \n\nHYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.\n\n \n\nHYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral  and paraffin oils (but excluding their derivatives), except:\n\n \n\n (a) toluene and xylene when included in Schedule 6;\n\n \n\n (b) benzene and liquid aromatic hydrocarbons  when included in Schedule 7;\n\n \n\n (c) food grade and pharmaceutical grade white mineral oils;\n\n \n\n (d) in solid or semi-solid preparations;\n\n \n\n (e)  in preparations containing 25 per cent or less of designated solvents;\n\n \n\n (f) in preparations packed in pressurised spray packs;\n\n \n\n (g) in adhesives packed in containers each containing 50 grams or less of adhesive;\n\n \n\n (h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or\n\n \n\n (i) in other preparations when packed in containers with a capacity of 2 mL or less.\n\n \n\nHYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) except:\n\n \n\n (a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or\n\n \n\n \n\nHYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.\n\n \n\n† HYDROGEN PEROXIDE (excluding its salts and derivatives):\n\n \n\n (a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide except in hair dyes containing 6 per cent or less of hydrogen peroxide; or\n\n \n\n (b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide except in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.\n\n \n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).\n\n \n\nIMAZALIL.\n\n \n\nIMAZAMOX except in preparations containing 25 per cent or less of imazamox.\n\n \n\nIMAZAPIC except in preparations containing 25 per cent or less of imazapic.\n\n \n\nIMAZAPYR except in preparations containing 25 per cent or less of imazapyr.\n\n \n\nIMAZETHAPYR except in preparations containing 25 per cent or less of imazethapyr.\n\n \n\nIMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid except in preparations containing 5 per cent or less of imidacloprid.\n\n \n\nIMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin except in preparations containing 10 per cent or less of imiprothrin.\n\n \n\nINDOXACARB  (includes the R and S enantiomers) in preparations containing 1 per cent or less of\n\n indoxacarb.\n\n \n\n3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) ) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate except:\n\n \n\n(a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-propynyl butyl carbamate; or\n\n \n\n(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.\n\n \n\nIODOSULFURON-METHYL-SODIUM.\n\n \n\nIPCONAZOLE in preparations containing 2 per cent or less of ipconazole.\n\n \n\nIRON COMPOUNDS:\n\n \n\n (a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):\n\n \n\n  (i) in preparations for injection containing 20 per cent or less of iron except in preparations containing 0.1 per cent or less of iron; or\n\n \n\n  (ii) in other preparations containing 4 per cent or less of iron except:\n\n \n\n   (A) in liquid or gel preparations containing 0.1 per cent or less of iron; or\n\n  \n\n   (B) in animal feeds or feed premixes; or\n\n \n\n (b) in garden preparations except in preparations containing 4 per cent or less of iron.\n\n \n\nISOEUGENOL in preparations containing 25 per cent or less of isoeugenol except in preparations containing 10 per cent or less of isoeugenol.\n\n \n\nISOPHORONE.\n\n \n\nISOXABEN.\n\n \n\nISOXAFLUTOLE.\n\n \n\nIVERMECTIN for use in animals:\n\n \n\n (a) in preparations for the prophylaxis of heartworm in cats and dogs;\n\n \n\n (b) in intraruminal implants containing 160 mg or less of ivermectin;\n\n \n\n (c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or\n\n \n\n (d) in other preparations containing 2 per cent or less of ivermectin.\n\n \n\nKITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.\n\n \n\nLAMBDA-CYHALOTHRIN:\n\n \n\n (a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or\n\n \n\n (b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.\n\n \n\n† LEAD COMPOUNDS in preparations for use as hair cosmetics.\n\n \n\nLEMON OIL except:\n\n \n\n \n\n \n\n (c) in preparations containing 0.05 per cent or less of lemon oil;\n\n \n\n \n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n \n\n \n\nLEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals except:\n\n \n\n \n\n (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.\n\n \n\nLIGNOCAINE   in aqueous gel preparations containing 4.5 per cent or less of lignocaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.\n\n \n\nLIME OIL except:\n\n \n\n \n\n \n\n (c) in preparations containing 0.5 per cent or less of lime oil;\n\n \n\n \n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n \n\n \n\nLINDANE in preparations containing 10 per cent or less of lindane except when included in Schedule 2 or 4.\n\n \n\nLUFENURON except:\n\n \n\n (a)  in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or\n\n \n\n (b)  in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.\n\n \n\nMADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.\n\n \n\nMAGNESIUM CHLORATE except in preparations containing 10 per cent or less of magnesium chlorate.\n\n \n\nMALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.\n\n \n\nMALATHION in preparations containing 10 per cent or less of malathion except:\n\n \n\n (a) for human therapeutic use; or\n\n \n\n (b) in dust preparations containing 2 per cent or less of malathion.\n\n \n\nMANCOZEB.\n\n \n\nMANDIPROPAMID.\n\n \n\nMARJORAM OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 50 per cent or less of marjoram oil.\n\n \n\nMCPA:\n\n \n\n (a) in preparations containing 25 per cent or less of MCPA (acid); or\n\n \n\n (b) in preparations containing 50 per cent or less of the salts and esters of MCPA.\n\n \n\nMCPB.\n\n \n\nMEBENDAZOLE for the treatment of animals:\n\n \n\n (a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or\n\n \n\n (b) in undivided preparations containing 25 per cent or less of mebendazole.\n\n \n\nMECLOFENAMIC ACID for the treatment of animals.\n\n \n\nMECOPROP in preparations containing 2 per cent or less of mecoprop.\n\n \n\nMEFENPYR-DIETHYL.\n\n \n\nMEPIQUAT.\n\n \n\nMESOTRIONE.\n\n \n\nMETAFLUMIZONE.\n\n \n\nMETALAXYL in preparations containing 35 per cent or less of metalaxyl.\n\n \n\nMETALDEHYDE in preparations containing 2 per cent or less of metaldehyde.\n\n \n\nMETHABENZTHIAZURON.\n\n \n\nMETHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol except in preparations containing 2 per cent or less of methanol.\n\n \n\nMETHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.\n\n \n\nMETHOXYCHLOR.\n\n \n\nMETHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) except:\n\n \n\n (a) when included in preparations or admixtures; or\n\n \n\n (b) when packed in containers having a capacity of more than 5 litres.\n\n \n\nMETHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.\n\n \n\nMETHYL ETHYL KETONE except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nMETHYL ETHYL KETONE PEROXIDE.\n\n \n\nMETHYL ISOAMYL KETONE except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nMETHYL ISOBUTYL KETONE except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nN-METHYL-2-PYRROLIDONE:\n\n \n\n (a) when packed in single use containers having a capacity of 2 mL or less; or\n\n \n\n (b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nMETHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:\n\n \n\n (a) in preparations for therapeutic use; or\n\n \n\n (b) in preparations containing 5 per cent or less of methyl salicylate.\n\n \n\n2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.\n\n \n\nMETIRAM.\n\n \n\nMETOLACHLOR.\n\n \n\nMETRAFENONE in preparations containing 50 per cent or less of metrafenone.\n\n \n\nMILBEMECTIN in preparations containing 1 per cent or less of milbemectin.\n\n \n\nMILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.\n\n \n\nMONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.\n\n \n\nMONEPANTEL.\n\n \n\nMORANTEL in preparations containing 25 per cent or less of morantel except in preparations containing 10 per cent or less of morantel.\n\n \n\nMOXIDECTIN:\n\n \n\n (a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;\n\n \n\n (b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or\n\n \n\n (c) for internal use for the treatment of animals:\n\n   (i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or\n\n   (ii) in other preparations containing 2 per cent or less of moxidectin.\n\n \n\nMYCLOBUTANIL.\n\n \n\nNAA except in preparations containing 25 per cent or less of NAA.\n\n \n\nNALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.\n\n \n\nNAPTALAM.\n\n \n\nNETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.\n\n \n\nNITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) except in preparations containing 0.5 per cent or less of nitric acid.\n\n \n\nNITROSCANATE for the treatment of animals.\n\n \n\nNONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 except:\n\n \n\n (a) when labelled with the statements:\n\n \n\n (b) in preparations containing 12.5 per cent or less of nonoxinol 9; or\n\n \n\n (c) in preparations for human use.\n\n \n\nNORBORMIDE.\n\n \n\nNUTMEG OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 50 per cent or less of nutmeg oil.\n\n \n\nN-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10 per cent or less of\n\n N-octyl bicycloheptene dicarboximide.\n\n \n\nN-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of:\n\n \n\n1.        N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or\n\n \n\n1.        N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of designated solvents.\n\n \n\nOESTRADIOL in implant preparations for growth promotion in animals.\n\n \n\nOLEANDOMYCIN in animal feed premixes for growth promotion.\n\n \n\nOMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.\n\n \n\nORANGE OIL (BITTER) except:\n\n \n\n \n\n \n\n (c) in preparations containing 1.4 per cent or less of orange oil (bitter);\n\n \n\n \n\n (e) in medicines for human therapeutic use, when compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n \n\n \n\nOXADIARGYL.\n\n \n\nOXADIXYL.\n\n \n\nOXANTEL EMBONATE for the treatment of animals.\n\n \n\nOXFENDAZOLE for the treatment of animals.\n\n \n\nOXIBENDAZOLE for the treatment of animals.\n\n \n\nOXYCARBOXIN.\n\n \n\nOXYTETRACYCLINE in preparations:\n\n \n\n \n\n (b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\n \n\nOXYTHIOQUINOX.\n\n \n\nPACLOBUTRAZOL.\n\n \n\nPENCONAZOLE.\n\n \n\nPENDIMETHALIN.\n\n \n\nPENFLUFEN.\n\n \n\nPENTHIOPYRAD except in preparations containing 20 per cent or less of penthiopyrad.\n\n \n\nPERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.\n\n \n\nPERMETHRIN (excluding preparations for human therapeutic use):\n\n \n\n (a) in preparations containing 25 per cent or less of permethrin; or\n\n \n\n (b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,\n\n \n\n except in preparations containing 2 per cent or less of permethrin.\n\n \n\nPETROL except preparations containing 25 per cent or less of petrol.\n\n \n\nPHENAZONE for the external treatment of animals.\n\n \n\nPHENISOPHAM.\n\n \n\nPHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, except in preparations containing 3 per cent or less of such substances.\n\n \n\nPHENYL METHYL KETONE except in preparations containing 25 per cent or less of designated solvents.\n\n \n\northo-PHENYLPHENOL except in preparations containing 5 per cent or less of o-phenylphenol.\n\n \n\nPHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10 per cent or less of phosphonic acid (H3PO3).\n\n \n\nPHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) except:\n\n \n\n (a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);\n\n \n\n (b) in solid or semi-solid preparations; or\n\n \n\n (c) in professional dental kits.\n\n \n\northo-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.\n\n \n\nPICARIDIN except in preparations containing 20 per cent or less of picaridin.\n\n \n\nPINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.\n\n \n\nPINOXADEN in preparations containing 10 per cent or less of pinoxaden.\n\n \n\nPIPERAZINE for animal use.\n\n \n\nPIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.\n\n \n\nPOLIHEXANIDE except in preparations containing 5 percent or less of polihexanide.\n\n \n\nPOLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts except in preparations containing 1 per cent or less of polixetonium salts.\n\n \n\nPOLYETHANOXY (15) TALLOW AMINE.\n\n \n\nPOLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.\n\n \n\nPOTASSIUM CHLORATE except:\n\n (b) in preparations containing 10 per cent or less of potassium chlorate.\n\n \n\n† POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:\n\n \n\n (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n \n\n (b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.\n\n \n\nPOTASSIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of potassium metabisulphite.\n\n \n\nPOTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite except:\n\n \n\n (a) in preparations containing 0.5 per cent or less of potassium nitrite;\n\n \n\n (b) when present as an excipient in preparations for therapeutic use; or\n\n \n\n (c) in aerosols.\n\n \n\nPOTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:\n\n \n\n (a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or\n\n \n\n (b) liquid or semi-solid preparations, the pH of which is less than 2.5.\n\n \n\nPOTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.\n\n \n\nPRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin except in insecticidal mats containing 1 per cent or less of prallethrin.\n\n \n\nPROFOXYDIM except in preparations containing 20 per cent or less of profoxydim.\n\n \n\nPROGESTERONE:\n\n \n\n (a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or\n\n \n\n (b) in implant preparations for growth promotion in cattle.\n\n \n\nPROHEXADIONE CALCIUM.\n\n \n\nPROMETRYN.\n\n \n\nPROPAMOCARB.\n\n \n\nPROPANIL.\n\n \n\nPROPAQUIZAFOP.\n\n \n\nPROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.\n\n \n\nPROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, except:\n\n \n\n (a) in preparations containing 30 per cent or less of propionic acid; or\n\n \n\n \n\nPROPOXUR:\n\n \n\n (a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;\n\n \n\n (b) in dust preparations containing 3 per cent or less of propoxur;\n\n \n\n (c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;\n\n \n\n (d) in pressurised spray packs containing 2 per cent or less of propoxur; or\n\n \n\n (e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.\n\n \n\nPROPYZAMIDE.\n\n \n\nPROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5 per cent or less of prothioconazole-deschloro.\n\n \n\nPROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.\n\n \n\nPYMETROZINE.\n\n \n\nPYRACLOSTROBIN.\n\n \n\nPYRAFLUFEN-ETHYL.\n\n \n\nPYRASULFOTOLE.\n\n \n\nPYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:\n\n \n\n (a) in preparations for human therapeutic use; or\n\n \n\n (b) in preparations containing 10 per cent or less of such substances.\n\n \n\nPYRIDABEN in preparations containing 25 per cent or less of pyridaben.\n\n \n\nPYRIFENOX.\n\n \n\nPYRITHIOBAC SODIUM.\n\n \n\nPYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint except in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.\n\n \n\nQUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds except:\n\n \n\n \n\n (b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or\n\n \n\n (c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.\n\n \n\nQUINCLORAC.\n\n \n\nQUININE in preparations for veterinary use containing 1 per cent or less of quinine.\n\n \n\nQUINTOZENE.\n\n \n\nQUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of\n\n quizalofop-p-ethyl.\n\n \n\nRACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.\n\n \n\nRESMETHRIN in preparations containing 10 per cent or less of resmethrin.\n\n \n\nRIMSULFURON.\n\n \n\nROBENIDINE except in preparations containing 20 per cent or less of robenidine.\n\n \n\nSAFLUFENACIL in water dispersible granule preparations.\n\n \n\nSALICYLANILIDE.\n\n \n\nSEDAXANE.\n\n \n\nSELAMECTIN except in preparations containing 12 per cent or less of selamectin.\n\n \n\nSETHOXYDIM.\n\n \n\nSIDURON.\n\n \n\nSILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion except:\n\n \n\n (a) barium silicofluoride when separately specified in this Schedule; or\n\n \n\n \n\nSINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin except in preparations containing 1 per cent or less of sinbioallethrin.\n\n \n\nSODIUM CHLORATE except in preparations containing 10 per cent or less of sodium chlorate.\n\n \n\nSODIUM DIACETATE except in preparations containing 60 per cent or less of sodium diacetate.\n\n \n\nSODIUM DODECYLBENZENE SULFONATE except in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.\n\n \n\nSODIUM HYDROGEN SULFATE except in preparations containing 10 per cent or less of sodium hydrogen sulfate.\n\n \n\nSODIUM HYDROSULFITE when packed for domestic use except in preparations containing 10 per cent or less of sodium hydrosulfite.\n\n \n\n† SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:\n\n \n\n (a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or\n\n \n\n (b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food additive preparations for domestic use.\n\n \n\nSODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.\n\n \n\nSODIUM METABISULPHITE when packed for domestic use except in preparations containing 10 per cent or less of sodium metabisulphite.\n\n \n\nSODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite except:\n\n \n\n (a) in preparations containing 0.5 per cent or less of sodium nitrite;\n\n \n\n (b) when present as an excipient in preparations for therapeutic use; or\n\n \n\n (c) in aerosols.\n\n \n\nSODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate except in preparations containing 15 per cent or less of sodium percarbonate.\n\n \n\nSODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in preparations containing 10 per cent or less of sodium polystyrene sulphonate.\n\n \n\nSODIUM STANNATE except in preparations for cosmetic use containing 1 per cent or less of sodium stannate.\n\n \n\nSODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.\n\n \n\nSPINETORAM.\n\n \n\nSPINOSAD except in aqueous suspensions containing 25 per cent or less of spinosad.\n\n \n\nSTAR ANISE OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 50 per cent or less of star anise oil.\n\n \n\nSTYRENE (excluding its derivatives).\n\n \n\nSULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\n \n\nSULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.\n\n \n\nSULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.\n\n \n\nSULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.\n\n \n\nSULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H3NO3S).\n\n \n\nSULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.\n\n \n\nSULFOMETURON-METHYL.\n\n \n\nSULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.\n\n \n\n† SYMPHYTUM spp. (Comfrey) for dermal use.\n\n \n\n2,3,6-TBA.\n\n \n\nTDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less of TDE.\n\n \n\nTEBUCONAZOLE.\n\n \n\nTEBUFENOZIDE.\n\n \n\nTEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.\n\n \n\nTEMEPHOS:\n\n \n\n (a) in liquid preparations containing 10 per cent or less of temephos;\n\n \n\n (b) in powders containing 2 per cent or less of temephos; or\n\n \n\n (c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.\n\n \n\nTEPRALOXYDIM.\n\n \n\nTERBUTRYN.\n\n \n\n1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE in cosmetic preparations, except in preparations containing 0.15 per cent or less of 1, 3, 5, 7-tetraazatricyclo [3.3.1.13,7] decane.\n\n \n\nTETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene except:\n\n \n\n \n\n (b) in preparations for the treatment of animals; or\n\n \n\n (c) when absorbed into an inert solid.\n\n \n\nTETRACHLORVINPHOS except in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.\n\n \n\nTETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.\n\n \n\nTETRACYCLINE in preparations:\n\n \n\n \n\n (b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.\n\n \n\nTETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.\n\n \n\nTHIABENDAZOLE:\n\n \n\n (a) for the treatment of animals; or\n\n \n\n (b) when packed and labelled for use as a fungicide except in preparations containing 50 per cent or less of thiabendazole.\n\n \n\nTHIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.\n\n \n\nTHIAZOPYR.\n\n \n\nTHIFENSULFURON.\n\n \n\nTHIOBENCARB.\n\n \n\nTHIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.\n\n \n\nTHIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.\n\n \n\nTHYME OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:\n\n \n\n \n\n (c) in preparations containing 50 per cent or less of thyme oil.\n\n \n\nTIOCARBAZIL.\n\n \n\nTOLCLOFOS-METHYL.\n\n \n\nTOLTRAZURIL.\n\n \n\nTRALKOXYDIM.\n\n \n\nTRENBOLONE in implant preparations for growth promotion in animals.\n\n \n\nTRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.\n\n \n\nTRIADIMENOL.\n\n \n\nTRI-ALLATE.\n\n \n\nTRIBENURON-METHYL.\n\n \n\nTRICHLOROACETIC ACID, alkali salts of.\n\n \n\n† 1,1,1-TRICHLOROETHANE except:\n\n \n\n (a) in preparations packed in pressurised spray packs;\n\n \n\n (b) in preparations containing 25 per cent or less of designated solvents;\n\n \n\n (c) in preparations, other than writing correction fluids or thinners for writing correction fluidsin containers having a capacity of 50 mL or less; or\n\n \n\n (d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:\n\n \n\n   (i) the word “Trichloroethane” written in letters not less than 1 mm in height and in\n\n \n\n    distinct contrast to the background; and\n\n \n\n   (ii) the expression:\n\n \n\n    WARNING  DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;\n\n \n\n    written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.\n\n \n\nTRIDIPHANE.\n\n \n\nTRIETAZINE.\n\n \n\nTRIETHANOLAMINE (excluding its salts and derivatives) except in preparations containing 5 per cent or less of triethanolamine.\n\n \n\nTRIFLOXYSTROBIN.\n\n \n\nTRIFLUMIZOLE.\n\n \n\nTRIFLUMURON.\n\n \n\nTRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:\n\n \n\n Avoid contact with eyes and skin; and\n\n \n\n Wash hands after handling.\n\n \n\nTRINEXAPAC-ETHYL except:\n\n \n\n (a) when packed in a sealed water-soluble measure pack; or\n\n \n\n (b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.\n\n \n\n3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5 per cent or less of\n\n 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.\n\n \n\nTRITICONAZOLE.\n\n \n\nTURPENTINE OIL except in preparations containing 25 per cent or less of turpentine oil.\n\n \n\nVIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.\n\n \n\nVERNOLATE.\n\n \n\nWARFARIN in rodent baits containing 0.1 per cent or less of warfarin.\n\n \n\nZINEB.\n\n## SCHEDULE 6\n\n \n\n \n\nABAMECTIN:\n\n \n\n1.              in preparations for pesticidal use containing 4 per cent or less of abamectin except when included in Schedule 5; or\n\n \n\n1.            in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.\n\n \n\nACEPHATE.\n\n \n\nACETAMIPRID except in preparations containing 1 per cent or less of acetamiprid.\n\n \n\nACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) except when included in Schedule 2.\n\n \n\nACETIC ANHYDRIDE excluding its derivatives.\n\n \n\nACIFLUORFEN.\n\n \n\nACINITRAZOLE except in preparations containing 20 per cent or less of acinitrazole.\n\n \n\nALBENDAZOLE for the treatment of animals except:\n\n \n\n \n\n (b) in intraruminal implants each containing 3.85 g or less of albendazole.\n\n \n\nALDRIN.\n\n \n\n† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:\n\n \n\n (a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or\n\n \n\n (b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.\n\n \n\nALKOXYLATED FATTY ALKYLAMINE POLYMER except:\n\n \n\n \n\n (b)  in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.\n\n \n\nALLETHRIN except:\n\n \n\n \n\n (b) in insecticidal mats containing 20 per cent or less of allethrin; or\n\n \n\n (c) in other preparations containing 1 per cent or less of allethrin.\n\n \n\nALPHA-CYPERMETHRIN:\n\n \n\n (a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or\n\n \n\n (b) in other preparations containing 10 per cent or less of alpha-cypermethrin,\n\n \n\n \n\nAMICARBAZONE.\n\n \n\nAMIDITHION.\n\n \n\nAMINOCARB in preparations containing 25 per cent or less of aminocarb.\n\n \n\nAMINOETHOXYVINYLGLYCINE except in preparations containing 15 per cent or less of aminoethoxyvinylglycine.\n\n \n\n1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.\n\n \n\nAMINOPYRALID except when included in Schedule 5.\n\n \n\nAMITRAZ.\n\n \n\nAMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:\n\n \n\n \n\n (b) in preparations for human internal therapeutic use;\n\n \n\n (c) in preparations for inhalation when absorbed in an inert solid material; or\n\n \n\n (d) in preparations containing 0.5 per cent or less of ammonia.\n\n \n\nAMMONIUM PERSULFATE in hair preparations.\n\n \n\nANILINE (excluding its salts and derivatives) except in preparations containing 1 per cent or less of aniline.\n\n \n\nANTIMONY COMPOUNDS except:\n\n \n\n \n\n (b) antimony chloride in polishes;\n\n \n\n (c) antimony titanate pigments in paint; or\n\n \n\n (d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.\n\n \n\nARSENIC:\n\n \n\n (a) in ant poisons containing 0.4 per cent or less of arsenic;\n\n \n\n (b) in animal feed premixes containing 4 per cent or less of arsenic; or\n\n \n\n (c) in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4,\n\n \n\n except when separately specified in this Schedule.\n\n \n\nASPIRIN for the treatment of animals except when included in Schedule 4 or 5.\n\n \n\nAZACONAZOLE except in preparations containing 1 per cent or less of azaconazole.\n\n \n\n† AZADIRACHTA INDICA (Neem) including its extracts and derivatives except:\n\n \n\n \n\n (b) in preparations for human internal use;\n\n \n\n (c) debitterised neem seed oil;\n\n \n\n (d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels; or\n\n \n\n (e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.\n\n \n\nAZAMETHIPHOS.\n\n \n\nAZOBENZENE.\n\n \n\nBAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.\n\n \n\nBARIUM SALTS except:\n\n \n\n \n\n (b) barium sulfate; or\n\n \n\n (c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.\n\n \n\n† BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:\n\n \n\n (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or\n\n \n\n (b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:\n\n \n\n  KEEP OUT OF REACH OF CHILDREN;\n\n \n\n  If in eyes wash out immediately with water; and\n\n \n\n  WARNING  This product contains ingredients which may cause skin irritation to certain individuals.  A preliminary test according to the accompanying directions should be made before use.  This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n\n \n\n \n\nBAY OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of bay oil.\n\n \n\nBEAUVERIA BASSIANA except when included in Schedule 5.\n\n \n\nBENDIOCARB:\n\n \n\n (a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;\n\n \n\n (b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;\n\n \n\n (c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or\n\n \n\n (d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,\n\n \n\n \n\nBENQUINOX.\n\n \n\nBENSULIDE.\n\n \n\nBENZALKONIUM CHLORIDE except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of benzalkonium chloride.\n\n \n\n1,2-benzenediol.\n\n \n\n6-BENZYLADENINE except in preparations containing 2 per cent or less of 6-benzyladenine.\n\n \n\nBERYLLIUM.\n\n \n\nBETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin except when included in Schedule 5.\n\n \n\nBETA-CYPERMETHRIN.\n\n \n\nBHC (excluding lindane).\n\n \n\nBIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.\n\n \n\nBIFLUORIDES (including ammonium, potassium and sodium salts)  in preparations containing 3 per cent or less of total bifluorides except when included in Schedule 5.\n\n \n\nBIOALLETHRIN except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of bioallethrin.\n\n \n\nN,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine,\n\n or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and  \n\n N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:\n\n \n\n IRRITANT;\n\n REPEATED EXPOSURE MAY CAUSE SENSITISATION;\n\n \n\n Avoid contact with skin;\n\n Wear protective gloves when mixing or using; and\n\n Ensure adequate ventilation when using.\n\n \n\nN,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine,\n\n or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and\n\n N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine,  when labelled with statements to the effect of:\n\n \n\n IRRITANT;\n\n REPEATED EXPOSURE MAY CAUSE SENSITISATION;\n\n \n\n Avoid contact with skin;\n\n Wear protective gloves when mixing or using; and\n\n Ensure adequate ventilation when using.\n\n \n\n† BITHIONOL for treatment of animals.\n\n \n\nBORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3) except when included in Schedule 5.\n\n \n\nBRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.\n\n \n\nBROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.\n\n \n\nBROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.\n\n \n\nBROMOFORM except when included in Schedule 4.\n\n \n\nBROMOPHOS.\n\n \n\nBROMOPHOS-ETHYL.\n\n \n\nBROMOXYNIL.\n\n \n\nBROMUCONAZOLE except when included in Schedule 5.\n\n \n\nBROTIANIDE.\n\n \n\nBUNAMIDINE.\n\n \n\nBUTACARB.\n\n \n\nBUTOXYCARBOXIM except when included in Schedule 5.\n\n \n\n2-BUTOXYETHANOL and its ACETATES  except in preparations containing 10 per cent or less of such substances.\n\n \n\n2-BUTOXY-2’-THIOCYANODIETHYL ETHER.\n\n \n\nBUTYRIC ACID in preparations for use as insect lures.\n\n \n\nCACODYLIC ACID:\n\n \n\n (a) in animal feed premixes containing 4 per cent or less of arsenic; or\n\n \n\n (b)  in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.\n\n \n\nCADMIUM COMPOUNDS except:\n\n \n\n \n\n (b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.\n\n \n\nCADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.\n\n \n\nCAJUPUT OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of cajuput oil; or\n\n \n\n (f) in oils containing 25 per cent or less of cajuput oil.\n\n \n\nCALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.\n\n \n\nCAMBENDAZOLE.\n\n \n\nCAMPHOR except:\n\n \n\n \n\n (b) when enclosed in an inhaler device which prevents ingestion of its contents;\n\n \n\n (c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;\n\n \n\n (d) in liquid preparations containing 2.5 per cent or less of camphor;\n\n \n\n (e) in essential oils when the camphor is present as a natural component of the oil:\n\n \n\n   (i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n   (ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n   (iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n   (iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.\n\n \n\nCAPTAN.\n\n \n\nCARBARYL except when included in Schedule 4 or 5.\n\n \n\nCARBON DISULFIDE.\n\n \n\n† CARBAMIDE PEROXIDE except:\n\n \n\n \n\n (b) in other preparations containing 9 per cent or less of carbamide peroxide.\n\n \n\nCASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use except in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.\n\n \n\nCHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.\n\n \n\nCHLORDANE.\n\n \n\nCHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr except when included in Schedule   5.\n\n \n\nCHLORFENETHOL.\n\n \n\nCHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of chlorhexidine; or\n\n \n\n (c) when in solid preparations.\n\n \n\nCHLORINATING COMPOUNDS except:\n\n \n\n \n\n (b) when separately specified in these Schedules;\n\n \n\n (c) sodium hypochlorite preparations with a pH of less than 11.5;\n\n \n\n (d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:\n\n \n\n  WARNING – Ensure adequate ventilation when using.  Vapour may be harmful.  May give off dangerous gas if mixed with other products;\n\n \n\n (e) in liquid preparations containing less than 2 per cent of available chlorine; or\n\n \n\n (f) in other preparations containing 4 per cent or less of available chlorine.\n\n \n\nCHLORMEQUAT.\n\n \n\nCHLOROFORM except:\n\n \n\n (a) when included in Schedule 2 or 4;  or\n\n \n\n (b) in preparations containing 10 per cent or less of chloroform.\n\n \n\nALPHA-CHLOROHYDRIN.\n\n \n\nCHLOROPHACINONE.\n\n \n\n(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL\n\n (uniconazole-p) except in preparations containing 5 per cent or less of\n\n (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.\n\n \n\nCHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.\n\n \n\nCHLOROTHALONIL except in water-based paint containing 0.5 per cent or less of chlorothalonil.\n\n \n\n2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.\n\n \n\nCHLORPYRIFOS except:\n\n \n\n \n\n (b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.\n\n \n\nCHLORPYRIFOS-METHYL.\n\n \n\nCHLORTHIAMID.\n\n \n\nCHROMATES (including dichromates) except in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.\n\n \n\nCHROMIUM TRIOXIDE (excluding its salts and derivatives).\n\n \n\nCINEOLE except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of cineole;\n\n \n\n (f) in oils containing 25 per cent or less of cineole; or\n\n \n\n (g) in rosemary oil or camphor oil (white).\n\n \n\nCINNAMON LEAF OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of cinnamon leaf oil.\n\n \n\nCLIMBAZOLE except:\n\n \n\n \n\n (b) in preparations containing 2 per cent or less of climbazole.\n\n \n\nCLODINAFOP-PROPARGYL.\n\n \n\nCLOMAZONE.\n\n \n\nCLOSANTEL.\n\n \n\nCLOTHIANIDIN except when included in Schedule 5.\n\n \n\nCLOTRIMAZOLE for external treatment of animals.\n\n \n\nCLOVE OIL except:\n\n \n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (f) in preparations containing 25 per cent or less of clove oil.\n\n \n\nN-COCO-1,3-DIAMINOPROPANE.\n\n \n\nCOPPER ACETATE except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of copper acetate.\n\n \n\nCOPPER COMPOUNDS except:\n\n \n\n \n\n (b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;\n\n \n\n (c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;\n\n \n\n (d) in feed additives containing 1 per cent or less of copper; or\n\n \n\n (e) in other preparations containing 5 per cent or less of copper compounds.\n\n \n\nCOPPER HYDROXIDE except:\n\n \n\n \n\n (b) in preparations containing 12.5 per cent or less of copper hydroxide.\n\n \n\nCOPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.\n\n \n\nCOPPER OXIDES except:\n\n \n\n \n\n \n\n (c) in marine paints; or\n\n \n\n (d) in other preparations containing 5 per cent or less of copper oxides.\n\n \n\n \n\n \n\nCOPPER OXYCHLORIDE except:\n\n \n\n \n\n (b) in preparations containing 12.5 per cent of less of copper oxychloride.\n\n \n\nCOPPER SULFATE except:\n\n \n\n \n\n (b) in preparations for internal use; or\n\n \n\n (c) in other preparations containing 5 per cent or less of copper sulfate.\n\n \n\nCOUMAPHOS:\n\n \n\n (a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or\n\n \n\n (b) in other preparations containing 5 per cent or less of coumaphos.\n\n \n\nCOUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl except when included in Schedule 5.\n\n \n\nCREOSOTE derived from wood other than beechwood  except:\n\n \n\n \n\n (b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or\n\n \n\n (c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.\n\n \n\nCROTOXYPHOS.\n\n \n\nCRUFOMATE.\n\n \n\nCYANAMIDE.\n\n \n\nCYANAZINE.\n\n \n\nCYCLANILIDE.\n\n \n\nN-cyclohexyldiazeniumdioxy-potassium.\n\n \n\nCYFLUTHRIN except:\n\n \n\n \n\n (b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.\n\n \n\nCYOMETRINIL.\n\n \n\nCYPERMETHRIN except when included in Schedule 5.\n\n \n\nCYPHENOTHRIN except when included in Schedule 5.\n\n \n\nCYSTEAMINE for cosmetic use except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of cysteamine.\n\n \n\nCYTHIOATE except when included in Schedule 5.\n\n \n\n2,4-D except when included in Schedule 5.\n\n \n\nDAZOMET.\n\n \n\nDELTAMETHRIN:\n\n \n\n1.        in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;\n\n \n\n1.        in wettable granular preparations containing 25 per cent or less of deltamethrin;\n\n \n\n1.        in water-dispersible tablets each containing 500 mg or less of deltamethrin;\n\n \n\n1.        in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or\n\n \n\n1.        in other preparations containing 3 per cent or less of deltamethrin,\n\n \n\nexcept:\n\n \n\n(a)       when included in Schedule 5;\n\n \n\n(b)       in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or\n\n \n\n(c)       in preparations containing 0.1 per cent or less of deltamethrin.\n\n \n\nDERQUANTEL.\n\n \n\nDIAZINON except when included in Schedule 5.\n\n \n\nDICAMBA (including its salts and derivatives) except when included in Schedule 5.\n\n \n\nDICHLOBENIL.\n\n \n\nDICHLOFENTHION.\n\n \n\nDICHLOFLUANID.\n\n \n\northo-DICHLOROBENZENE.\n\n \n\nDICHLOROETHYL ETHER.\n\n \n\nDICHLOROISOCYANURIC ACID except:\n\n \n\n \n\n (b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:\n\n \n\n  WARNING – Ensure adequate ventilation when using.  Vapour may be harmful.  May give off dangerous gas if mixed with other products;\n\n \n\n (c) in liquid preparations containing less than 2 per cent of available chlorine; or\n\n \n\n (d) in other preparations containing 4 per cent or less of available chlorine.\n\n \n\n4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.\n\n \n\nDICHLOROPHEN except:\n\n \n\n (a) when included in Schedules 4 or 5; or\n\n \n\n (b) in fabrics other than when:\n\n \n\n   (i) for human therapeutic use; or\n\n \n\n   (ii) as part of a registered pesticidal product.\n\n \n\n1,2-DICHLOROPROPANE.\n\n \n\n2,4-DICHLORPROP (including the R and S enantiomers).\n\n \n\nDICHLORVOS in preparations containing 50 per cent or less of dichlorvos except when included in Schedule 5.\n\n \n\nDICLOFOP-METHYL.\n\n \n\nDICYCLANIL except in preparations containing 5 per cent or less of dicyclanil.\n\n \n\nDIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:\n\n \n\n \n\nDIELDRIN.\n\n \n\nDIETHANOLAMINE (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of diethanolamine.\n\n \n\n† DIETHYLENE GLYCOL (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in paints or paint tinters;\n\n \n\n (c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or\n\n \n\n (d) in other preparations containing 2.5 per cent or less of diethylene glycol.\n\n \n\nDIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.\n\n \n\nDIFENZOQUAT.\n\n \n\nDIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.\n\n \n\n† 5,6-DIHYDROXYINDOLINE.\n\n \n\nDIMETHENAMID-P.\n\n \n\nDIMETHIPIN.\n\n \n\nDIMETHOATE.\n\n \n\nDIMETHYLACETAMIDE except when included in Schedule 5.\n\n \n\nDIMETHYLFORMAMIDE except:\n\n \n\n \n\n (b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.\n\n \n\nDIMETHYL SULFOXIDE (excluding dimethyl sulfone):\n\n \n\n (a) when not for therapeutic use; or\n\n \n\n (b) for the treatment of animals:\n\n \n\n   (i) when combined with no other therapeutic substance(s);\n\n \n\n   (ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or\n\n \n\n   (iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.\n\n \n\nDINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds except:\n\n \n\n \n\n \n\nDINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds except:\n\n \n\n \n\n \n\nDIOXACARB.\n\n \n\nDIOXANE.\n\n \n\nDIPHACINONE.\n\n \n\nDIQUAT in preparations containing 20 per cent or less of diquat.\n\n \n\nDISULFIRAM except when included in Schedule 4.\n\n \n\nDISULFOTON in granular preparations containing 5 per cent or less of disulfoton.\n\n \n\nDITHIANON.\n\n \n\nDITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.\n\n \n\nDIUREDOSAN.\n\n \n\nN-(N-DODECYL)-2-PYRROLIDONE except:\n\n \n\n \n\n \n\nDODINE.\n\n \n\nDORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.\n\n \n\nDSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.\n\n \n\nECONAZOLE for external treatment of animals.\n\n \n\nEMAMECTIN in preparations containing 5 per cent or less of emamectin except when included in Schedule 5.\n\n \n\nEMODEPSIDE for the treatment of animals except when included in Schedule 5.\n\n \n\nENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.\n\n \n\nENDOTHAL in preparations containing 20 per cent or less of endothal.\n\n \n\nEPTC.\n\n \n\nESBIOTHRIN except:\n\n \n\n \n\n (b) in pressurised spray packs containing 1 per cent or less of esbiothrin.\n\n \n\nESFENVALERATE except when included in Schedule 5.\n\n \n\nETHANOLAMINE (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of ethanolamine.\n\n \n\nETHEPHON (excluding its salts and derivatives).\n\n \n\nETHER except:\n\n \n\n (a) when included in Schedule 2, 4 or 5;  or\n\n \n\n (b) in preparations containing 10 per cent or less of ether.\n\n \n\nETHIOFENCARB.\n\n \n\nETHOATE-METHYL.\n\n \n\nETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.\n\n \n\nETHYL BROMIDE.\n\n \n\nEthyl formate when packed and labelled for use as a fumigant.\n\n \n\nETHYLENE CHLOROHYDRIN.\n\n \n\nETHYLENE DICHLORIDE.\n\n \n\n† ETHYLENE GLYCOL (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in paints or paint tinters;\n\n \n\n  (c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or\n\n \n\n (d) in other preparations containing 2.5 per cent or less of ethylene glycol.\n\n \n\nETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, except:\n\n \n\n \n\n (b) in preparations containing 10 per cent or less of such substances.\n\n \n\nETRIMFOS.\n\n \n\nEUCALYPTUS OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of eucalyptus oil.\n\n \n\nEUGENOL except:\n\n \n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (f) in preparations containing 25 per cent or less of eugenol.\n\n \n\nFAMPHUR in preparations containing 20 per cent or less of famphur.\n\n \n\nFEBANTEL except:\n\n \n\n (a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or\n\n \n\n (b) in undivided preparations containing 10 per cent or less of febantel.\n\n \n\nFENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.\n\n \n\nFENAZAFLOR.\n\n \n\nFENBUTATIN OXIDE.\n\n \n\nFENCHLORPHOS.\n\n \n\nFENITROTHION.\n\n \n\nFENOXACRIM in preparations for the treatment of carpets during manufacture.\n\n \n\nFENPYROXIMATE.\n\n \n\nFENTHION in preparations containing 60 per cent or less of fenthion except when included in Schedule 5.\n\n \n\nFENVALERATE.\n\n \n\nFIPRONIL except:\n\n \n\n \n\n (b) in preparations containing 0.05 per cent or less of fipronil.\n\n \n\nFLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.\n\n \n\nFLONICAMID.\n\n \n\nFLUAZIFOP-BUTYL.\n\n \n\nFLUAZIFOP-P-BUTYL.\n\n \n\nFLUAZINAM.\n\n \n\nFLUCOFURON in preparations for the treatment of carpets during manufacture.\n\n \n\nfluensulfone.\n\n \n\nFLUMETHRIN except when included in Schedule 5.\n\n \n\nFLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.\n\n \n\nFLUORIDES except:\n\n \n\n \n\n (b) in preparations for human use; or\n\n \n\n (c) in preparations containing 15 mg/kg or less of fluoride ion.\n\n \n\nFLUPROPANATE.\n\n \n\nFLUQUINCONAZOLE.\n\n \n\nFLUSILAZOL.\n\n \n\nFLUTRIAFOL except in fertilisers containing 0.5 per cent or less of flutriafol.\n\n \n\nFLUVALINATE except when included in Schedule 5.\n\n \n\n† FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:\n\n \n\n (a) for human therapeutic use;\n\n \n\n (b) in oral hygiene preparations;\n\n \n\n (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;\n\n \n\n (d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:\n\n  PROTECT CUTICLES WITH GREASE OR OIL;\n\n \n\n (e) in all other cosmetic preparations; or\n\n \n\n (f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:\n\n \n\nFORMOTHION.\n\n \n\nFOSPIRATE except when included in Schedule 5.\n\n \n\nFUMAGILLIN.\n\n \n\nFURFURAL except in preparations containing 0.1 per cent or less of furfural.\n\n \n\nGLUTARALDEHYDE except:\n\n \n\n (a) when included in Schedule 2 or 5; or\n\n \n\n (b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:\n\n \n\n \n\n \n\nGLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with directions for use that include the statement:\n\n \n\n Wear protective gloves when using.  Keep out of eyes.\n\n \n\nGLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical except:\n\n \n\n (a) in cosmetic preparations for salon use only, when labelled in accordance with Safe Work Australia’s National Code of Practice for the Labelling of Workplace Substances [NOHSC:2012(1994)];\n\n  \n\n (b) in preparations containing 5 per cent or less of glycolic acid; or\n\n \n\n (c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.\n\n \n\nGUANIDINE except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of guanidine.\n\n \n\nGUAZATINE.\n\n \n\nHALOXON.\n\n \n\nHALOXYFOP.\n\n \n\nHEPTACHLOR.\n\n \n\nHEXACHLOROPHANE in preparations for the treatment of animals.\n\n \n\nHEXAZINONE except when included in Schedule 5.\n\n \n\nHEXYLOXYETHANOL   except in preparations containing 10 per cent or less of hexyloxyethanol.\n\n \n\nHYDRAMETHYLNON except when included in Schedule 5.\n\n \n\nHYDRAZINE.\n\n \n\nHYDROCHLORIC ACID (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations for therapeutic use; or\n\n \n\n (c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).\n\n \n\nHYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride except when included in Schedule 5.\n\n \n\n† HYDROGEN PEROXIDE (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or\n\n \n\n  (c)  in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.\n\n \n\nHYDROQUINONE except:\n\n \n\n (a) when included in Schedule 2 or 4; or\n\n \n\n (b) in preparations containing 10 per cent or less of hydroquinone.\n\n \n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) except when included in Schedule 5.\n\n \n\nIMIDACLOPRID except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of imidacloprid.\n\n \n\nIMIDOCARB.\n\n \n\niminoctadine trialbesilate.\n\n \n\nIMIPROTHRIN except:\n\n \n\n \n\n (b) in preparations containing 10 per cent or less of imiprothrin.\n\n \n\nINDAZIFLAM.\n\n \n\nINDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.\n\n \n\nIODINE (excluding its salts, derivatives and iodophors) except:\n\n \n\n \n\n (b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.\n\n \n\nIODOPHORS except in preparations containing 1.5 per cent or less of available iodine.\n\n \n\n3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except:\n\n \n\n \n\n(b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or\n\n \n\n(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate. \n\n \n\nIOXYNIL.\n\n \n\nIPCONAZOLE except when included in Schedule 5.\n\n \n\nIRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals except:\n\n \n\n \n\n (b) in liquid or gel preparations containing 0.1 per cent or less of iron; or\n\n \n\n (c) in animal feeds or feed premixes.\n\n \n\nISOCONAZOLE for external treatment of animals.\n\n \n\nISOCYANATES, free organic, boiling below 300° C, except in:\n\n \n\n (a)  viscous polyurethane adhesives; or\n\n \n\n (b)  viscous polyurethane sealants;\n\n \n\n containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.\n\n \n\nISOEUGENOL except:\n\n \n\n \n\n (b) in preparations containing 10 per cent or less of isoeugenol.\n\n \n\nLAMBDA-CYHALOTHRIN:\n\n \n\n1.        in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or\n\n \n\n(b)  in other preparations containing 1.6 per cent or less of lambda-cyhalothrin\n\n \n\n except when included in Schedule 5\n\n \n\nLASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.\n\n \n\nLAURETH CARBOXYLIC ACIDS (excluding its salts and derivatives) except:\n\n \n\n (a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;\n\n \n\n (b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with a warning to the following effect:\n\n \n\n  IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or\n\n \n\n (c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with warnings to the following effect:\n\n \n\n IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and\n\n \n\n IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.\n\n \n\nLAURYL ISOQUINOLINIUM BROMIDE.\n\n \n\n† LEAD COMPOUNDS except:\n\n \n\n \n\n (b) in paints, tinters, inks or ink additives;\n\n \n\n (c)  in preparations for cosmetic use containing 100 mg/kg or less of lead;\n\n \n\n (d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or\n\n \n\n (e) in ceramic glazes when labelled with the warning statement:\n\n \n\n  CAUTION  Harmful if swallowed. Do not use on surfaces which contact food or drink.\n\n \n\n \n\nLEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n  (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:  \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;  \n\n \n\n (e) in preparations containing 25 per cent or less of Leptospermum scoparium oil.\n\n \n\nLEVAMISOLE for the treatment of animals except:\n\n \n\n \n\n (b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.\n\n \n\nLINDANE except when included in Schedule 2, 4 or 5.\n\n \n\nMAFENIDE when packed and labelled for the treatment of ornamental fish only.\n\n \n\nMALATHION except:\n\n \n\n \n\n (b) for human therapeutic use; or\n\n \n\n (c) in dust preparations containing 2 per cent or less of malathion.\n\n \n\nMCPA except when included in Schedule 5.\n\n \n\nMEBENDAZOLE for the treatment of animals except when included in Schedule 5.\n\n \n\nMECOPROP except when included in Schedule 5.\n\n \n\nMECOPROP-P.\n\n \n\nMEFLUIDIDE.\n\n \n\nMELALEUCA OIL (tea tree oil) except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:\n\n  \n\n \n\n \n\n (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (e) in preparations containing 25 per cent or less of melaleuca oil.\n\n \n\nMELENGESTROL ACETATE when used as an animal feed additive.\n\n \n\nMENAZON.\n\n \n\n2-MERCAPTOETHANOL in preparations for use as insect lures.\n\n \n\nMERCURIC OXIDE for the treatment of animals, in preparations for ocular use.\n\n \n\nMERCUROCHROME for the treatment of animals, in preparations for topical use.\n\n \n\nMETACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.\n\n \n\nMETALAXYL except when included in Schedule 5.\n\n \n\nMETALDEHYDE except when included in Schedule 5.\n\n \n\nMETHACRIFOS in preparations containing 60 per cent or less of methacrifos.\n\n \n\nMETHAM.\n\n \n\nMETHANOL (excluding its derivatives) except:\n\n \n\n (a) when included in Schedule 5;  or\n\n \n\n (b) in preparations containing 2 per cent or less of methanol.\n\n \n\nMETHIOCARB in preparations containing 20 per cent or less of methiocarb except when included in Schedule 5.\n\n \n\nMETHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.\n\n \n\nMethylcyclopentadienyl Manganese Tricarbonyl in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.\n\n \n\n† METHYLDIBROMO GLUTARONITRILE except in preparations intended to be in contact with the skin, including cosmetic use.\n\n \n\nMETHYLENE BISTHIOCYANATE except in preparations containing 1 per cent or less of methylene bisthiocyanate.\n\n \n\nMETHYLEUGENOL except in preparations containing 1 per cent or less of methyleugenol.\n\n \n\nMETHYL ETHYL KETONE OXIME except in preparations containing 1 per cent or less of methyl ethyl ketone oxime.\n\n \n\nMETHYL ISOTHIOCYANATE.\n\n \n\n† METHYL METHACRYLATE (excluding its derivatives) except:\n\n \n\n (a) for cosmetic use; or\n\n \n\n (b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.\n\n \n\nMETHYL NEODECANAMIDE except in liquid preparations containing 2 per cent or less of methyl neodecanamide.\n\n \n\nMETHYLNORBORNYLPYRIDINE.\n\n \n\nN-METHYL-2-PYRROLIDONE except:\n\n \n\n \n\n \n\nMETHYL SALICYLATE except:\n\n \n\n \n\n (b) in preparations for therapeutic use; or\n\n \n\n (c) in preparations containing 5 per cent or less of methyl salicylate.\n\n \n\nMETOFLUTHRIN.\n\n \n\nMETOSULAM.\n\n \n\nMETRAFENONE except when included in Schedule 5.\n\n \n\nMETRIBUZIN.\n\n \n\nMICONAZOLE for the external treatment of animals.\n\n \n\nMILBEMECTIN except when included in Schedule 5.\n\n \n\nMONENSIN:\n\n \n\n (a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or\n\n \n\n (b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.\n\n \n\nMORANTEL except:\n\n \n\n \n\n (b) in preparations containing 10 per cent or less of morantel.\n\n \n\nMOXIDECTIN for external use:\n\n \n\n (a)  in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or\n\n \n\n (b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,\n\n \n\n \n\nMSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.\n\n \n\nNALED except when included in Schedule 5.\n\n \n\nNAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons as an impurity.\n\n  \n\nNAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.\n\n \n\nNARASIN in animal feed premixes containing 12 per cent or less of narasin.\n\n \n\nNETOBIMIN for the treatment of animals except when included in Schedule 5.\n\n \n\nNICKEL SULFATE.\n\n \n\nNICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.\n\n \n\nNIMIDANE in preparations containing 25 per cent or less of nimidane.\n\n \n\nNITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.\n\n \n\nNITRIC ACID (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).\n\n \n\nNITROBENZENE except:\n\n \n\n (a) in solid or semi-solid polishes;\n\n \n\n (b) in soaps containing 1 per cent or less of nitrobenzene; or\n\n \n\n (c) in other preparations containing 0.1 per cent or less of nitrobenzene.\n\n \n\nNITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.\n\n \n\nNITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides except when included in Schedule 4.\n\n \n\nNITROXYNIL.\n\n \n\nNONOXINOL 9 except:\n\n \n\n \n\n (b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:\n\n \n\n \n\n \n\n (c) in preparations containing 12.5 per cent or less of nonoxinol 9; or\n\n \n\n (d) in preparations for human use.\n\n \n\n1-Octen-3-ol except in preparations containing 5 per cent or less of 1-octen-3-ol.\n\n \n\nOCTHILINONE except in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.\n\n \n\nN-(N-OCTYL)-2-PYRROLIDONE except:\n\n \n\n \n\n \n\nOLAQUINDOX except in preparations containing 10 per cent or less of olaquindox.\n\n \n\nN-OLEYL-1,3-DIAMINOPROPANE.\n\n \n\nOMETHOATE in preparations containing 30 per cent or less of omethoate except when included in Schedule 5.\n\n \n\nOXADIAZON.\n\n \n\nOXALIC ACID except its derivatives and insoluble salts.\n\n \n\nOXYCLOZANIDE.\n\n \n\nPAECILOMYCES LILACINUS Strain 251.\n\n \n\n† PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde except:\n\n \n\n (a) for human therapeutic use;\n\n \n\n (b) in oral hygiene preparations;\n\n \n\n (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;\n\n \n\n (d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:\n\n  PROTECT CUTICLES WITH GREASE OR OIL;\n\n (e) in all other cosmetic preparations; or\n\n \n\n (f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:\n\n \n\nPARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.\n\n \n\nPARBENDAZOLE.\n\n \n\nPEBULATE.\n\n \n\nPENNYROYAL OIL except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (c) in preparations containing 4 per cent or less of d-pulegone.\n\n \n\nPENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.\n\n \n\nPERACETIC ACID except when included in Schedule 5.\n\n \n\nPERFLUIDONE.\n\n \n\nPERMANGANATES except potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.\n\n \n\nPERMETHRIN except:\n\n \n\n \n\n (b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or\n\n \n\n (c) in preparations containing 2 per cent or less of permethrin.\n\n \n\n2-PHENOXYETHANOL except:\n\n \n\n(a)  in cosmetic preparations containing 1 per cent or less of 2-phenoxyethanol; or\n\n(b)  in other preparations containing 15 per cent or less of 2-phenoxyethanol.\n\n \n\nPHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, except: \n\n \n\n \n\n (b) when included in Schedule 5; or\n\n \n\n (c) in preparations containing 3 per cent or less of such substances.\n\n \n\nPHENOTHIAZINE (excluding its derivatives) except in preparations containing 10 per cent or less of phenothiazine.\n\n \n\n† PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:\n\n \n\n (a) in preparations packed and labelled for photographic purposes;\n\n \n\n (b) in preparations packed and labelled for testing water except tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;\n\n \n\n (c) in hair dye preparations except when the immediate container and primary pack are  labelled with the following statements:\n\n \n\n  KEEP OUT OF REACH OF CHILDREN, and\n\n \n\n  WARNING  This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n\n \n\n  written in letters not less than 1.5 mm in height; or\n\n \n\n (d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:\n\n \n\n  WARNING  This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.\n\n \n\n \n\nPHOSALONE.\n\n \n\nPHOSMET.\n\n \n\nPHOSPHORIC ACID (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);\n\n \n\n (c) in solid or semi-solid preparations; or\n\n \n\n (d) in professional dental kits.\n\n \n\nPHOXIM.\n\n \n\northo-PHTHALALDEHYDE except when included in Schedule 5.\n\n \n\nPINDONE.\n\n \n\nPINE OILs when packed and labelled as a herbicide except when included in Schedule 5.\n\n \n\nPINOXADEN except when included in Schedule 5.\n\n \n\nPIPEROPHOS.\n\n \n\nPIRIMICARB except when included in Schedule 5.\n\n \n\nPIRIMIPHOS-ETHYL.\n\n \n\nPIRIMIPHOS-METHYL.\n\n \n\nPOLIXETONIUM SALTS except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of polixetonium salts.\n\n \n\nPOTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.\n\n \n\nPOTASSIUM BROMATE except in preparations containing 0.5 per cent or less of potassium bromate.\n\n \n\nPOTASSIUM CYANATE.\n\n \n\n† POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of potassium hydroxide being:\n\n \n\n   (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n \n\n   (ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or\n\n \n\n (c) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.\n\n \n\nPOTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of potassium nitrite;\n\n \n\n \n\n (d) in aerosols containing 2 per cent or less of potassium nitrite.\n\n \n\nPOTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:\n\n \n\n \n\n (b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or\n\n \n\n (c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:\n\n \n\n   (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or\n\n \n\n   (ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.\n\n \n\nPOTASSIUM PERSULFATE in hair preparations.\n\n \n\nPRALLETHRIN (cis:trans=20:80) except:\n\n \n\n \n\n (b) in insecticidal mats containing 1 per cent or less of prallethrin.\n\n \n\nPROCHLORAZ.\n\n \n\nPROFENOFOS.\n\n \n\nPROMACYL.\n\n \n\nPROPACHLOR.\n\n \n\nPROPARGITE.\n\n \n\nPROPETAMPHOS.\n\n \n\nPROPICONAZOLE except when included in Schedule 5.\n\n \n\nPROPINEB.\n\n \n\nPROPIONIC ACID (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 30 per cent or less of propionic acid; or\n\n \n\n (c) for therapeutic use.\n\n \n\nPROPOXUR except when included in Schedule 5.\n\n \n\nPROQUINAZID.\n\n \n\nPROSULFOCARB.\n\n \n\nPROSULFURON.\n\n \n\nPROTHIOFOS.\n\n \n\nd-PULEGONE except in preparations containing 4 per cent or less of d- pulegone.\n\n \n\nPYRACLOFOS.\n\n \n\nPYRAZOPHOS.\n\n \n\nPYRIDABEN except when included in Schedule 5.\n\n \n\nPyridalyl.\n\n \n\nPYRIDATE.\n\n \n\nPYRIPROLE.\n\n \n\npyrithione copper.\n\n \n\nPYRITHIONE ZINC except:\n\n \n\n \n\n (b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (c) in semi-solid hair preparations for animal use;\n\n \n\n (d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”;\n\n \n\n (e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or\n\n \n\n (f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.\n\n \n\nPYROXASULFONE.\n\n \n\nPYROXSULAM.\n\n \n\nQUATERNARY AMMONIUM COMPOUNDS except:\n\n \n\n \n\n (b) when included in Schedule 5;\n\n \n\n (c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or\n\n \n\n (d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.\n\n \n\nQUIZALOFOP ETHYL.\n\n \n\nQUIZALOFOP-P-ETHYL except when included in Schedule 5.\n\n \n\nQUIZALOFOP-P-TEFURYL.\n\n \n\nRESMETHRIN except when included in Schedule 5.\n\n \n\nROTENONE except in solid or semi-solid preparations containing 2 per cent or less of rotenone.\n\n \n\n† SAFROLE except:\n\n \n\n (a)  for internal use; or\n\n \n\n (b)  in other preparations containing 1 per cent or less of safrole.\n\n \n\nSAGE OIL (Dalmatian) except:\n\n \n\n (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the Required Advisory Statements for Medicine Labels;\n\n \n\n (b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:\n\n \n\n \n\n \n\n (c) in preparations containing 4 per cent or less of thujone.\n\n \n\nSALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.\n\n \n\nSASSAFRAS OIL except:\n\n \n\n (a) for internal use; or\n\n \n\n (b) in other preparations containing 1 per cent or less of safrole.\n\n \n\nSELENIUM:\n\n \n\n (a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:\n\n \n\n   (i) for the blueing of gun barrels;\n\n \n\n   (ii) for photographic purposes; or\n\n \n\n   (iii) for the colouring of lead or lead alloys;\n\n \n\n (b) in coated granules containing 1 per cent or less of selenium for application to pasture except in fertilisers containing 200 g/tonne or less of selenium; or\n\n \n\n (c) for the treatment of animals:\n\n \n\n   (i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;\n\n \n\n   (ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;\n\n \n\n   (iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or\n\n \n\n   (iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.\n\n \n\nSEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.\n\n \n\nSILICOFLUORIDES except:\n\n \n\n \n\n \n\nSILVER NITRATE except:\n\n \n\n (a) when included in or expressly excluded from Schedule 2; or\n\n \n\n (b) in preparations containing 1 per cent or less of silver.\n\n \n\nSINBIOALLETHRIN except:\n\n \n\n \n\n (b) in preparations containing 1 per cent or less of sinbioallethrin.\n\n \n\nSODIUM ALUMINATE (excluding its salts and derivatives) except:\n\n \n\n (a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n \n\n (b) in liquid preparations, the pH of which is 11.5 or less.\n\n \n\nSODIUM BROMATE except in preparations containing 0.5 per cent or less of sodium bromate.\n\n \n\n† SODIUM HYDROXIDE (excluding its salts and derivatives) except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of sodium hydroxide being:\n\n \n\n   (i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or\n\n \n\n   (ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or\n\n \n\n (c) liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.\n\n \n\nSODIUM LAURYL SULFATE (excluding its salts and derivatives) except:\n\n \n\n (a) in wash-off preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with a warning to the following effect:\n\n \n\n  IF IN EYES WASH OUT IMMEDIATELY WITH WATER;\n\n \n\n (b)  in leave-on preparations containing 1.5 per cent or less of sodium lauryl sulfate;\n\n \n\n (c) in toothpaste and oral hygiene preparations containing 5 per cent or less of sodium lauryl sulfate;\n\n \n\n (d) in other preparations for animal use containing 2 per cent or less of sodium lauryl sulfate; or\n\n \n\n (e) in other preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with warnings to the following effect:\n\n \n\n IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and\n\n \n\n IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.\n\n \n\nSODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of sodium nitrite;\n\n \n\n \n\n (d) in aerosols containing 2 per cent or less of sodium nitrite.\n\n \n\nSODIUM PERCARBONATE (CAS No. 15630-89-4) except:\n\n \n\n \n\n (b) in preparations containing 15 per cent or less of sodium percarbonate.\n\n \n\nSODIUM PERSULFATE:\n\n \n\n (a) in hair preparations; or\n\n \n\n (b) in products for the treatment of water for swimming pools and spas.\n\n \n\nSODIUM SULFIDE in preparations for use as insect lures.\n\n \n\nSPIROTETRAMAT.\n\n \n\nSPIROXAMINE.\n\n \n\nSULCOFURON in preparations for the treatment of carpets during manufacture.\n\n \n\nSULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.\n\n \n\nSULFLURAMID.\n\n \n\nSULFOXAFLOR except when included in Schedule 5.\n\n \n\nSULFURIC ACID (excluding its salts and derivatives) except:\n\n \n\n (a) in fire extinguishers; or\n\n \n\n (b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).\n\n \n\nSULFURYL FLUORIDE.\n\n \n\nSULPROFOS.\n\n \n\n2,4,5-T.\n\n \n\nN-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.\n\n \n\nTAR ACIDS distilling within the range 230-290°C inclusive.\n\n \n\nTCMTB (2-[thiocyanomethylthio]benzothiazole).\n\n \n\nTDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane)  except when included in Schedule 5.\n\n \n\nTEBUFENPYRAD.\n\n \n\nTEBUTHIURON.\n\n \n\nTEMEPHOS except when in Schedule 5.\n\n \n\nTERBUTHYLAZINE except in preparations containing 5 per cent or less of terbuthylazine.\n\n \n\nTERPENES, CHLORINATED.\n\n \n\nTESTOSTERONE in implant preparations for use in animals.\n\n \n\nTETRACHLOROETHYLENE except:\n\n \n\n \n\n (b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or\n\n \n\n (c) in preparations for the treatment of animals.\n\n \n\nTETRACONAZOLE except when included in Schedule 5.\n\n \n\nTETRADIFON.\n\n \n\n2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.\n\n \n\nTETRAMISOLE in preparations for the treatment of animals.\n\n \n\nTHIACLOPRID.\n\n \n\nTHIAMETHOXAM except when included in Schedule 5.\n\n \n\nTHIAZAFLURON.\n\n \n\nTHIODICARB except when included in Schedule 5.\n\n \n\nTHIOMETON.\n\n \n\nTHIOPHANATE-METHYL except when included in Schedule 5.\n\n \n\nTHIOUREA AND ALKYL THIOUREAS except:\n\n \n\n \n\n \n\nTHIRAM except in paint containing 0.5 per cent or less of thiram.\n\n \n\nTHUJONE except in preparations containing 4 per cent or less of thujone.\n\n \n\nTHYMOL when packed and labelled for the control of Varroa mites in bee hives.\n\n \n\nTOLUENE (excluding its derivatives) except in preparations containing 50 per cent or less of toluene or toluene and xylene.\n\n \n\n†TOLUENEDIAMINE not elsewhere specified in these Schedules:\n\n \n\n (a) in hair dye preparations except when the immediate container and primary pack are labelled with the following statements:\n\n \n\n  KEEP OUT OF REACH OF CHILDREN, and\n\n \n\n  WARNING  This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n\n \n\n  written in letters not less than 1.5 mm in height; or\n\n \n\n (b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:\n\n \n\n  WARNING  This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.\n\n \n\n \n\nTOLYLFLUANID.\n\n \n\nTRANSFLUTHRIN except:\n\n \n\n (a) in preparations containing 1 per cent or less of transfluthrin; or\n\n \n\n (b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.\n\n \n\nTRIADIMEFON except:\n\n \n\n \n\n (b) in fertilisers containing 5 g/kg or less of triadimefon.\n\n \n\nTRICHLORFON except metrifonate included in Schedule 4.\n\n \n\nTRICHLOROACETIC ACID except:\n\n \n\n \n\n (b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.\n\n \n\nTRICHLOROETHYLENE except when included in Schedule 4.\n\n \n\nTRICHLOROPHENOL.\n\n \n\nTRICLABENDAZOLE except in preparations containing 20 per cent or less of triclabendazole.\n\n \n\nTRICLOPYR.\n\n \n\nTRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.\n\n \n\nTRIDEMORPH.\n\n \n\nTRIETHYL PHOSPHATE.\n\n \n\nTRIFLUOROMETHANESULFONIC ACID.\n\n \n\nTRINITROPHENOL (excluding its derivatives) except:\n\n \n\n (a) in preparations for human therapeutic use; or\n\n \n\n (b) in preparations containing 5 per cent or less of trinitrophenol.\n\n \n\nTRISODIUM NITRILOTRIACETATE except in preparations containing 20 per cent or less of trisodium nitrilotriacetate.\n\n \n\nVAMIDOTHION.\n\n \n\nWARFARIN except when included in Schedule 4 or 5.\n\n \n\nXYLENE (excluding its derivatives) except in preparations containing 50 per cent or less of xylene or xylene and toluene.\n\n \n\nZERANOL in ear implants for use as a growth promotant in steer cattle.\n\n \n\nZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.\n\n \n\nZINC BORATE (excluding its derivatives) for use as an agricultural chemical.\n\n \n\nZINC CHLORIDE except:\n\n \n\n \n\n (b) in preparations containing 5 per cent or less of zinc chloride.\n\n \n\nZINC para-PHENOLSULFONATE except in preparations containing 5 per cent or less of zinc para-phenolsulfonate.\n\n \n\nZINC SULFATE except:\n\n \n\n (a) when included in or expressly excluded from Schedule 4; or\n\n \n\n (b) in other preparations containing 5 per cent or less of zinc sulfate.\n\n \n\nZIRAM in granular preparations.\n\n## SCHEDULE 7\n\n \n\nABAMECTIN except when included in Schedule 5 or 6.\n\n \n\nACIBENZOLAR-S-METHYL.\n\n \n\nACRIFLAVINE for veterinary use except when in Schedule 5.\n\n \n\nACROLEIN.\n\n \n\nACRYLONITRILE.\n\n \n\nALACHLOR.\n\n \n\nALDICARB.\n\n \n\nALDOXYCARB.\n\n \n\nALLYL ALCOHOL.\n\n \n\nALPHA-CYPERMETHRIN except when included in Schedule 5 or 6.\n\n \n\nAMINACRINE for veterinary use except when included in Schedule 5.\n\n \n\nAMINOCARB except when included in Schedule 6.\n\n \n\n4-AMINOPYRIDINE except when included in Schedule 4.\n\n \n\nAMITON.\n\n \n\nARPRINOCID.\n\n \n\nARSENIC except:\n\n \n\n \n\n (b) when included in Schedule 4 or 6;\n\n \n\n (c) as selenium arsenide in photocopier drums;\n\n \n\n (d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;\n\n \n\n (e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:\n\n \n\n   (i) in contact with food stuffs, animal feeds or potable water;\n\n \n\n   (ii) of clothing and footwear in contact with the skin;\n\n \n\n   (iii) used as infant wear; or\n\n \n\n   (iv) intended for use as packaging materials;\n\n \n\n (f) in animal feeds containing 75 g/tonne or less of arsenic; or\n\n \n\n (g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.\n\n \n\nAZAFENIDIN.\n\n \n\nAZINPHOS-ETHYL.\n\n \n\nAZINPHOS-METHYL.\n\n \n\nAZOCYCLOTIN.\n\n \n\nBENDIOCARB except when included in Schedule 5 or 6.\n\n \n\nBENOMYL except in paints containing 0.5 per cent or less of benomyl.\n\n \n\nBENZENE (excluding its derivatives) except:\n\n \n\n (a) preparations containing 15 mL/L or less of benzene; or\n\n \n\n (b) petrol containing 50 mL/L or less of benzene.\n\n \n\nBENZIDINE-BASED AZO DYES being:\n\n2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide]\n\nCAS No. 94249-03-3\n\n \n\nAcid Red 85 (Acid Fast Red A)\n\n1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, disodium salt\n\nCAS No. 3567-65-5\n\n \n\nDirect Black 38\n\n2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt\n\nCAS No. 1937-37-7\n\n \n\nDirect Blue 2\n\n2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium salt\n\nCAS No. 2429-73-4\n\n \n\nDirect Blue 6\n\n2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-hydroxy-, tetrasodium salt\n\nCAS No. 2602-46-2\n\n \n\nDirect Brown 2\n\n5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxy- benzoic acid disodium salt\n\nCAS No. 2429-82-5\n\n \n\nDirect Brown 95\n\nCuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt\n\nCAS No. 16071-86-6\n\n \n\nDirect Green 1\n\n2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt\n\nCAS No. 3626-28-6\n\nDirect Green 6\n\n2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt\n\nCAS No. 4335-09-5\n\n \n\nDirect Red 28 (Congo Red)\n\n1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-, disodium salt\n\nCAS No. 573-58-0\n\n \n\nDirect Red 37\n\n1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-7-hydroxy-, disodium salt\n\nCAS No. 3530-19-6\n\n \n\nBETACYFLUTHRIN except when included in Schedule 5 or 6.\n\n \n\nBIFENTHRIN except:\n\n \n\n \n\n (b) in preparations containing 0.5 per cent or less of bifenthrin.\n\n \n\nBIFLUORIDES (including ammonium, potassium and sodium salts) except when included in Schedule 5 or 6.\n\n \n\nBORON TRIFLUORIDE except when included in Schedule 5 or 6.\n\n \n\nBRODIFACOUM except when included in Schedule 6.\n\n \n\nBROMADIOLONE except when included in Schedule 6.\n\n \n\nBROMETHALIN except when included in Schedule 6.\n\n \n\nBROMINE (excluding its salts and derivatives).\n\n \n\nBRUCINE except in alcohol containing 0.02 per cent or less of brucine as a denaturant.\n\n \n\nCACODYLIC ACID except:\n\n \n\n \n\n (b) in animal feeds containing 75 g/tonne or less of arsenic.\n\n \n\nCADUSAFOS except when included in Schedule 6.\n\n \n\nCALCIFEROL for use as a rodenticide except when included in Schedule 6.\n\n \n\nCAPTAFOL.\n\n \n\nCARBADOX.\n\n \n\nCARBENDAZIM except in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.\n\n \n\nCARBOFURAN.\n\n \n\nCARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.\n\n \n\nCARBONYL SULFIDE when packed and labelled for use as a fumigant.\n\n \n\nCARBOPHENOTHION.\n\n \n\nCARBOSULFAN.\n\n \n\nCHLORDECONE.\n\n \n\nCHLORDIMEFORM.\n\n \n\nCHLORFENAPYR except when included in Schedule 5 or 6.\n\n \n\nCHLORFENVINPHOS.\n\n \n\nCHLORINE (excluding its salts and derivatives).\n\n \n\nCHLORHEXIDINE except:\n\n \n\n (a) when included in Schedule 5 or 6;\n\n \n\n (b) in preparations containing 1 per cent or less of chlorhexidine; or\n\n \n\n (c) in solid preparations.\n\n \n\nCHLOROMETHIURON.\n\n \n\n5-CHLORO-3-METHYL-4-NITROPYRAZOLE.\n\n \n\n4-CHLORO-o-TOLUIDINE.\n\n \n\nCHLOROPICRIN except when included in Schedule 6.\n\n \n\nCHLORTHIOPHOS.\n\n \n\nCOLECALCIFEROL for use as a rodenticide.\n\n \n\nCOUMAPHOS except when included in Schedule 6.\n\n \n\nCOUMATETRALYL except when included in Schedule 5 or 6.\n\n \n\nCREOSOTE derived from coal.\n\n \n\nCREOSOTE derived from beechwood.\n\n \n\nCYANIDES, metallic except:\n\n \n\n (a) ferricyanides;\n\n \n\n (b) ferrocyanides; or\n\n \n\n (c) when separately specified in these Schedules.\n\n \n\nCYANOGEN.\n\n \n\nCYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.\n\n \n\nCYHEXATIN.\n\n \n\nDELTAMETHRIN except:\n\n \n\n(a)       when included in Schedules 5 or 6; or\n\n \n\n(b)       in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or\n\n \n\n(c)       in preparations containing 0.1 per cent or less of deltamethrin.\n\n \n\nDEMETON.\n\n \n\nDEMETON-O-METHYL.\n\n \n\nDEMETON-S-METHYL.\n\n \n\nDIALIFOS.\n\n \n\n4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).\n\n \n\n1,2-DIBROMO-3-CHLOROPROPANE.\n\n \n\n1,3-DICHLOROPROPENE.\n\n \n\nDICHLORVOS except when included in Schedule 5 or 6.\n\n \n\nDICROTOPHOS.\n\n \n\nDIFENACOUM except when included in Schedule 6.\n\n \n\nDIFETHIALONE except when included in Schedule 6.\n\n \n\nDIMEFOX.\n\n \n\n4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).\n\n \n\nDIMETHYL SULFATE.\n\n \n\nDIMETILAN.\n\n \n\nDINITROCRESOLS except when included in Schedule 4 or 6.\n\n \n\nDINITROPHENOLS except when included in Schedule 4 or 6.\n\n \n\nDINOCAP.\n\n \n\nDINOSEB.\n\n \n\nDIQUAT except when included in Schedule 6.\n\n \n\nDISULFOTON except when included in Schedule 6.\n\n \n\nDORAMECTIN except when included in Schedule 5 or 6.\n\n \n\nDSMA except when included in Schedule 6.\n\n \n\nEMAMECTIN except when included in Schedule 5 or 6.\n\n \n\nENDOSULFAN except when included in Schedule 6.\n\n \n\nENDOTHAL except when included in Schedule 6.\n\n \n\nENDRIN.\n\n \n\nEPICHLOROHYDRIN.\n\n \n\nEPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.\n\n \n\nEPRINOMECTIN except when included in Schedule 5.\n\n \n\nETACONAZOLE.\n\n \n\nETHION.\n\n \n\nETHOPROPHOS except when included in Schedule 6.\n\n \n\nETHYLENE DIBROMIDE.\n\n \n\nETHYLENE OXIDE.\n\n \n\nFAMPHUR except when included in Schedule 6.\n\n \n\nFENAMIPHOS except when included in Schedule 6.\n\n \n\nFENOXACRIM except:\n\n \n\n \n\n \n\nFENSULFOTHION.\n\n \n\nFENTHION except when included in Schedule 5 or 6.\n\n \n\nFENTHION-ETHYL.\n\n \n\nFLOCOUMAFEN except when included in Schedule 6.\n\n \n\nFLUCOFURON except:\n\n \n\n \n\n \n\nFLUCYTHRINATE.\n\n \n\nFLUMIOXAZIN except when included in Schedule 6.\n\n \n\nFLUOROACETAMIDE.\n\n \n\nFLUOROACETIC ACID.\n\n \n\nFOLPET.\n\n \n\nFORMETANATE.\n\n \n\nFURATHIOCARB except when included in Schedule 5.\n\n \n\nGAMMA-CYHALOTHRIN except when included in Schedule 5.\n\n \n\nHALOFUGINONE except when included in Schedule 4.\n\n \n\nHALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.\n\n \n\nHCB.\n\n \n\nHYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any\n\n fraction of which boils above 350°C except:\n\n \n\n (a) when in solid polymers;\n\n \n\n (b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or\n\n \n\n (c)  when having a Mutagenicity Index of zero as measured by ASTM E1687-95.\n\n \n\nHYDROCYANIC ACID except:\n\n \n\n \n\n (b) its salts and derivatives other than cyanides separately specified in this Schedule.\n\n \n\nHYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.\n\n \n\nHYDROGEN SULFIDE.\n\n \n\nHYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.\n\n \n\nIODOMETHANE.\n\n \n\nISOCARBOPHOS.\n\n \n\nISOFENPHOS.\n\n \n\nISOPROTURON.\n\n \n\nIVERMECTIN except when included in Schedule 4 or 5.\n\n \n\nLAMBDA-CYHALOTHRIN except when included in Schedule 5 or 6.\n\n \n\nLEPTOPHOS.\n\n \n\nLITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.\n\n \n\nMADURAMICIN except:\n\n \n\n \n\n (b) in animal feeds containing 5 mg/kg or less of antibiotic substances.\n\n \n\nMALACHITE GREEN for veterinary use except when included in Schedule 5.\n\n \n\nMAZIDOX.\n\n \n\nMECARBAM.\n\n \n\nMERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.\n\n \n\nMERCURY except:\n\n \n\n \n\n (b) when included in Schedule 2, 4 or 6;\n\n \n\n (c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;\n\n \n\n (d) mercury (metallic) in scientific instruments;\n\n \n\n (e) dental amalgams; or\n\n \n\n (f) in a sealed device, for therapeutic use, which prevents access to the mercury.\n\n \n\nMETHACRIFOS except when included in Schedule 6.\n\n \n\nMETHAMIDOPHOS.\n\n \n\nMETHAPYRILENE.\n\n \n\nMETHAZOLE.\n\n \n\nMETHIDATHION.\n\n \n\nMETHIOCARB except when included in Schedule 5 or 6.\n\n \n\nMETHOMYL except when included in Schedule 6.\n\n \n\nMETHOXYETHYLMERCURIC ACETATE.\n\n \n\nMETHOXYETHYLMERCURIC CHLORIDE.\n\n \n\nMETHYL BROMIDE.\n\n \n\nMethylcyclopentadienyl Manganese Tricarbonyl except:\n\n \n\n \n\n (b) when used in laboratory analysis; or\n\n \n\n (c) when packed for industrial use in containers with a nominal capacity of 100 L or more.\n\n \n\n4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).\n\n \n\nMETHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.\n\n \n\nMEVINPHOS.\n\n \n\nMIPAFOX.\n\n \n\nMIREX.\n\n \n\nMOLINATE.\n\n \n\nMONOCROTOPHOS.\n\n \n\nMOXIDECTIN except when included in Schedule 4, 5 or 6.\n\n \n\nMSMA except when included in Schedule 6.\n\n \n\nNAPHTHALOPHOS except when included in Schedule 6.\n\n \n\nNICOTINE except:\n\n \n\n \n\n (b) in preparations for human therapeutic use; or\n\n \n\n (c) in tobacco prepared and packed for smoking.\n\n \n\nNIMIDANE except when included in Schedule 6.\n\n \n\nNITROFEN.\n\n \n\nNITROPRUSSIDES except when included in Schedule 4 or 6.\n\n \n\n2-NITROTOLUENE.\n\n \n\nOMETHOATE except when included in Schedule 5 or 6.\n\n \n\nOXAMYL.\n\n \n\nOXYDEMETON METHYL.\n\n \n\nPARAQUAT.\n\n \n\nPARATHION.\n\n \n\nPARATHION-METHYL except when included in Schedule 6.\n\n \n\nPENTACHLOROPHENOL except when included in Schedule 6.\n\n \n\nPHENYLMERCURIC ACETATE except in preparations containing 0.01 per cent or less of mercury as a preservative.\n\n \n\nPHORATE.\n\n \n\nPHOSFOLAN.\n\n \n\nPHOSPHIDES, METALLIC.\n\n \n\nPHOSPHINE.\n\n \n\nPHOSPHORUS, YELLOW (excluding its salts and derivatives).\n\n \n\nPOTASSIUM NITRITE except:\n\n \n\n (a) when included in Schedule 5 or 6;\n\n \n\n (b) in preparations containing 0.5 per cent or less of potassium nitrite;\n\n \n\n \n\n (d) in aerosols containing 2 per cent or less of potassium nitrite.\n\n \n\nPROCYMIDONE.\n\n \n\nPROPYLENE OXIDE.\n\n \n\nPYRINURON.\n\n \n\nQUININE for veterinary use except when included in Schedule 5.\n\n \n\nSAFLUFENACIL except when included in Schedule 5.\n\n \n\nSCHRADAN.\n\n \n\nSELENIUM except:\n\n \n\n \n\n (b) as selenium arsenide in photocopier drums;\n\n \n\n (c) in preparations for therapeutic use other than:\n\n \n\n  (i) drench concentrates containing 2.5 per cent or less of selenium; or\n\n \n\n  (ii) pour-on preparations containing 0.5 per cent or less of selenium;\n\n \n\n (d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or\n\n \n\n (e) in fertilisers containing 200 g/tonne or less of selenium.\n\n \n\nSEMDURAMICIN except:\n\n \n\n \n\n (b) in animal feeds containing 25 mg/kg or less of antibiotic substances.\n\n \n\nSODIUM NITRITE except:\n\n \n\n (a) when included in Schedule 2, 5 or 6;\n\n \n\n (b) in preparations containing 0.5 per cent or less of sodium nitrite;\n\n \n\n \n\n (d) in aerosols containing 2 per cent or less of sodium nitrite.\n\n \n\nSTRYCHNINE except when included in Schedule 4.\n\n \n\nSULCOFURON except:\n\n \n\n \n\n \n\nSULFENTRAZONE.\n\n \n\nSULFOTEP.\n\n \n\nTEFLUTHRIN except when included in Schedule 5.\n\n \n\nTEPP.\n\n \n\nTERBUFOS.\n\n \n\nTETRACHLOROETHANE.\n\n \n\n2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in Schedule 6.\n\n \n\nTHALLIUM.\n\n \n\nTHIOFANOX.\n\n \n\nTIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl except:\n\n \n\n \n\n (b) in plastics;\n\n \n\n (c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or\n\n \n\n (d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.\n\n \n\northo-TOLIDINE except in solid-state diagnostic therapeutic reagents.\n\n \n\nTRIAMIPHOS.\n\n \n\nTRIAZBUTIL.\n\n \n\nTRIBUFOS (s,s,s-tributylphosphorotrithioate).\n\n \n\nVINCLOZOLIN.\n\n \n\nVINYL CHLORIDE.\n\n \n\nZETA-CYPERMETHRIN except when included in Schedule 6.\n\n \n\nZIRAM except when included in Schedule 6.\n\n## SCHEDULE 8\n\n \n\n(Substances marked # are listed in Appendix D.)\n\n \n\nACETYLDIHYDROCODEINE.\n\n \n\nACETYLMETHADOL.\n\n \n\nACETYLMORPHINES.\n\n \n\nALFENTANIL.\n\n \n\nALPHACETYLMETHADOL.\n\n \n\nALPHAPRODINE.\n\n \n\n# ALPRAZOLAM.\n\n \n\nAMPHETAMINE.\n\n \n\nAMYLOBARBITONE except when included in Schedule 4.\n\n \n\nANILERIDINE.\n\n \n\nBENZYLMORPHINE.\n\n \n\nBEZITRAMIDE.\n\n \n\nBUPRENORPHINE.\n\n \n\nBUTOBARBITONE.\n\n \n\nBUTORPHANOL.\n\n \n\nCARFENTANYL.\n\n \n\nCOCAINE.\n\n \n\nCODEINE except when included in Schedule 2, 3 or 4.\n\n \n\nCODEINE-N-OXIDE.\n\n \n\nCONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).\n\n \n\n4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).\n\n \n\nCYCLOBARBITONE.\n\n \n\nDEXAMPHETAMINE.\n\n \n\nDEXTROMORAMIDE.\n\n \n\nDEXTROPROPOXYPHENE except when included in Schedule 4.\n\n \n\nDIFENOXIN except when included in Schedule 4.\n\n \n\nDIHYDROCODEINE except when included in Schedule 2, 3 or 4.\n\n \n\nDIHYDROMORPHINE.\n\n \n\nDIPHENOXYLATE except when included in Schedule 3 or 4.\n\n \n\nDIPIPANONE.\n\n \n\n# DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.\n\n \n\nDROTEBANOL.\n\n \n\nETHYLAMPHETAMINE.\n\n \n\nETHYLMORPHINE except when included in Schedule 2 or 4.\n\n \n\nFENTANYL.\n\n \n\n# FLUNITRAZEPAM.\n\n \n\nHYDROCODONE.\n\n \n\nHYDROMORPHINOL.\n\n \n\nHYDROMORPHONE.\n\n \n\nKETAMINE.\n\n \n\nLEVAMPHETAMINE.\n\n \n\nLEVOMETHAMPHETAMINE.\n\n \n\nLEVOMORAMIDE.\n\n \n\nLEVORPHANOL (excluding its stereoisomers).\n\n \n\nLISDEXAMFETAMINE.\n\n \n\nMETHADONE.\n\n \n\nMETHYLAMPHETAMINE.\n\n \n\nMETHYLDIHYDROMORPHINE.\n\n \n\nMETHYLPHENIDATE.\n\n \n\n1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).\n\n \n\nMORPHINE.\n\n \n\nMORPHINE METHOBROMIDE.\n\n \n\nMORPHINE-N-OXIDE.\n\n \n\nNABILONE.\n\n \n\n# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.\n\n \n\nNORCODEINE.\n\n \n\nNORMETHADONE.\n\n \n\nOPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.\n\n \n\nOXYCODONE.\n\n \n\nOXYMORPHONE.\n\n \n\nPENTAZOCINE.\n\n \n\nPENTOBARBITONE except when included in Schedule 4.\n\n \n\nPETHIDINE.\n\n \n\nPHENDIMETRAZINE.\n\n \n\nPHENMETRAZINE.\n\n \n\nPHENOPERIDINE.\n\n \n\n4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).\n\n \n\nPHOLCODINE except when included in Schedule 2 or 4.\n\n \n\nPIRITRAMIDE.\n\n \n\nPROPIRAM.\n\n \n\nQUINALBARBITONE.\n\n \n\nRACEMORAMIDE.\n\n \n\nREMIFENTANIL.\n\n \n\nSECBUTOBARBITONE.\n\n \n\n# SODIUM OXYBATE for human therapeutic use.\n\n \n\nSUFENTANIL.\n\n \n\nTAPENTADOL.\n\n \n\nTHEBACON.\n\n \n\nTHEBAINE.\n\n \n\nTILIDINE.\n\n## SCHEDULE 9\n\n \n\n(Trivial or unofficial names are marked *)\n\n \n\nACETORPHINE.\n\n \n\nACETYL-ALPHA-METHYLFENTANYL.\n\n \n\nALKOXYAMPHETAMINES and substituted alkoxyamphetamines except when separately specified in these schedules.\n\n \n\nALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when separately specified in these Schedules.\n\n \n\nALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines except when separately specified in these schedules.\n\n \n\nALLYLPRODINE.\n\n \n\nALPHAMEPRODINE.\n\n \n\nALPHA-METHYLFENTANYL.\n\n \n\nALPHA-METHYLTHIOFENTANYL.\n\n \n\nALPHAMETHADOL.\n\n \n\n2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).\n\n \n\n5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when separately specified in these schedules.\n\n \n\nBENZETHIDINE.\n\n \n\nBENZOYLINDOLES except when separately specified in these Schedules.\n\n \n\nBENZYLPIPERAZINE *(BZP).\n\n \n\nBETACETYLMETHADOL.\n\n \n\nBETA-HYDROXYFENTANYL.\n\n \n\nBETA-HYDROXY-3-METHYLFENTANYL.\n\n \n\nBETAMEPRODINE.\n\n \n\nBETAMETHADOL.\n\n \n\nBETAPRODINE.\n\n \n\n1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-Dragonfly).\n\n \n\n4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).\n\n \n\nBUFOTENINE.\n\n \n\nCANNABIS except:\n\n \n\n \n\n (b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.\n\n \n\nCATHINONE.\n\n \n\nCLONITAZENE.\n\n \n\nCOCA LEAF.\n\n \n\nCODOXIME.\n\n \n\n4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.\n\n \n\nCYCLOHEXYLPHENOLS except when separately specified in these Schedules.\n\n \n\nDESOMORPHINE.\n\n \n\nDIAMPROMIDE.\n\n \n\nDIBENZOPYRANS except when separately specified in these Schedules.\n\n \n\n3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921).\n\n \n\nDIETHYLTHIAMBUTENE.\n\n \n\nN,N-DIETHYLTRYPTAMINE  *(DET).\n\n \n\nDIMENOXADOL.\n\n \n\nDIMEPHEPTANOL.\n\n \n\n2,5-DIMETHOXYAMPHETAMINE *(DMA).\n\n \n\n2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB).\n\n \n\n2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE *(DOET).\n\n \n\n2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).\n\n \n\n2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).\n\n \n\n2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).\n\n \n\n3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).\n\n \n\n3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN                            *(DMHP).\n\n \n\nN, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).\n\n \n\nN,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).\n\n \n\nDIMETHYLTHIAMBUTENE.\n\n \n\nN,N-DIMETHYLTRYPTAMINE *(DMT).\n\n \n\nDIOXAPHETYL BUTYRATE.\n\n \n\nECGONINE.\n\n \n\nN-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).\n\n \n\nETHYLMETHYLTHIAMBUTENE.\n\n \n\nETICYCLIDINE  *(PCE).\n\n \n\nETONITAZENE.\n\n \n\nETORPHINE.\n\n \n\nETOXERIDINE.\n\n \n\nFENETYLLINE.\n\n \n\n4-FLUORO-N-METHYLAMPHETAMINE.\n\n \n\n1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).\n\n \n\nFURETHIDINE.\n\n \n\nHARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:\n\n \n\n (a) containing 0.1 per cent or less of harmala alkaloids; or\n\n \n\n (b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.\n\n \n\nHEROIN.\n\n \n\n3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).\n\n \n\n4-HYDROYXBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8. *(GAMMA HYDROXYBUTYRATE (GHB)).\n\n \n\n2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL *(Cannabicyclohexanol or CP 47,497 C8 homologue).\n\n \n\n2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP 47,497).\n\n \n\nHYDROXYPETHIDINE.\n\n \n\nISOMETHADONE.\n\n \n\nKETOBEMIDONE.\n\n \n\nLEVOMETHORPHAN (excluding its stereoisomers).\n\n \n\nLEVOPHENACYLMORPHAN.\n\n \n\nLYSERGIC ACID.\n\n \n\nLYSERGIDE.\n\n \n\nMECLOQUALONE.\n\n \n\nMETAZOCINE.\n\n \n\nMETHAQUALONE.\n\n \n\nMETHCATHINONE.\n\n \n\n5-METHOXY- α -METHYLTRYPTAMINE *(5-MeO-AMT).\n\n \n\n5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MMDA).\n\n \n\n4-METHOXY- α -METHYLPHENYLETHYLAMINE *(PMA).\n\n \n\n2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).\n\n \n\nMETHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE              *(SALVINORIN A).\n\n \n\n4-METHYLAMINOREX.\n\n \n\nMETHYLDESORPHINE.\n\n \n\n3,4-METHYLENEDIOXYAMPHETAMINE *(MDA).\n\n \n\n3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).\n\n \n\n3-METHYLFENTANYL.\n\n \n\n4-METHYLMETHCATHINONE *(MEPHEDRONE).\n\n \n\nN- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA).\n\n \n\nN-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).\n\n \n\n2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).\n\n \n\n1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).\n\n \n\n4-METHYLTHIOAMPHETAMINE.\n\n \n\n3-METHYLTHIOFENTANYL.\n\n \n\nMETOPON. \n\n \n\nMITRAGYNA SPECIOSA.\n\n \n\nMITRAGYNINE.\n\n \n\nMORPHERIDINE.\n\n \n\n(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE *(JWH-200).\n\n \n\nMUSCIMOL.\n\n \n\nMYROPHINE.\n\n \n\nNAPHTHOYLINDOLES except when separately specified in these Schedules.\n\n \n\nNAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.\n\n \n\nNAPHTHOYLPYRROLES except when separately specified in these Schedules.\n\n \n\nNAPHTHYLMETHYLINDENES except when separately specified in these Schedules.\n\n \n\nNAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).\n\n \n\nNICOCODINE.\n\n \n\nNICODICODINE.\n\n \n\nNICOMORPHINE.\n\n \n\nNORACYMETHADOL.\n\n \n\nNORLEVORPHANOL.\n\n \n\nNORMORPHINE.\n\n \n\nNORPIPANONE.\n\n \n\nPARA-FLUOROFENTANYL.\n\n \n\n1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122).\n\n \n\n1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).\n\n \n\nPHENADOXONE.\n\n \n\nPHENAMPROMIDE.\n\n \n\nPHENAZOCINE.\n\n \n\nPHENCYCLIDINE *(PCP).\n\n \n\nN-PHENETHYL-4-PIPERIDONE.\n\n \n\nPHENOMORPHAN.\n\n \n\nPHENYLACETYLINDOLES except when separately specified in these Schedules.\n\n \n\n1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).\n\n \n\nPIMINODINE.\n\n \n\nPROHEPTAZINE.\n\n \n\nPROPERIDINE.\n\n \n\nPSILOCYBINE.\n\n \n\nRACEMETHORPHAN.\n\n \n\nRACEMORPHAN.\n\n \n\nROLICYCLIDINE  *(PHP or PCPY).\n\n \n\nSALVIA DIVINORUM.\n\n \n\nTENOCYCLIDINE  *(TCP).\n\n \n\nSYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.\n\n \n\nTETRAHYDROCANNABINOLS and their alkyl homologues except:\n\n \n\n (a)  when separately specified in this Schedule;\n\n \n\n (b) when included in Schedule 8;\n\n \n\n (c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:\n\n \n\n  Not for internal use; or\n\n \n\n  Not to be taken; or\n\n \n\n (d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.\n\n \n\nTHIOFENTANYL.\n\n \n\n1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).\n\n \n\nTRIMEPERIDINE.\n\n \n\n3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE  *(TMA).\n\n \n\n3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine except:\n\n \n\n (a) methoxyphenamine; or\n\n \n\n \n\n1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.\n\n# PART 5\n\n \n\n# THE APPENDICES\n\n## APPENDIX A\n\n \n\n## GENERAL EXEMPTIONS\n\n \n\n \n\nThis Standard does not apply to a poison in any of the following products:\n\n \n\nALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.\n\n \n\nBACTERIAL CULTURE MEDIA containing antibiotics.\n\n \n\nCERAMICS.\n\n \n\nCHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 Safety of toys entitled Part 4: Experimental sets for chemistry and related activities.\n\n \n\nCOPPER COMPOUNDS in paints.\n\n \n\nDEXTRANS, GELATIN  SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders.\n\n \n\nELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.\n\n \n\nELECTRONIC COMPONENTS.\n\n \n\nENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.\n\n \n\nEXPLOSIVES.\n\n \n\nFOOD except:\n\n \n\n (a)  food additives before incorporation into food; or\n\n \n\n (b) when used as a means of administering a poison for therapeutic use.\n\n \n\nFRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.\n\n \n\nGLASS (including CRYSTAL WARE).\n\n \n\nGLAZED POTTERY.\n\n \n\nHUMAN BLOOD PRODUCTS including:\n\n \n\n (a) whole blood;\n\n \n\n (b)  blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and\n\n \n\n(c)  the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives:\n\n \n\n    (i) albumin;\n\n \n\n   (ii)  anticoagulation complex;\n\n \n\n   (iii) C1 esterase inhibitors;\n\n \n\n   (iv) clotting factors;\n\n \n\n   (v)  fibrinogen;\n\n \n\n   (vi) protein C;\n\n \n\n   (vii) prothrombin complex concentrate (PCC) ; and\n\n \n\n   (viii) thrombin.\n\n \n\nIN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.\n\n \n\nINTRAOCULAR VISCOELASTIC PRODUCTS.\n\n \n\nLUBRICANTS except soluble oils and solvent-deposited lubricating agents.\n\n \n\nMATCHES.\n\n \n\nMEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.\n\n \n\nMEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the Therapeutic Goods (Medical Devices) Regulation 2002, except:\n\n \n\n (a) injectable tissue reconstructive, augmentation and restoration materials, including collagen;\n\n \n\n (b) medical devices which include anticoagulants;\n\n \n\n (c) artificial tears;\n\n \n\n (d) urinary catheters; or\n\n \n\n (e) intra-articular fluids.\n\n \n\nMOTOR, HEATING or FURNACE FUELS except:\n\n \n\n (a) when the contrary intention appears in any Schedule;\n\n \n\n (b) when containing methanol;\n\n \n\n (c) toy or hobby fuels; or\n\n \n\n (d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.\n\n \n\nNUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.\n\n \n\nPAPER except:\n\n \n\n (a) when prepared for pesticidal use; or\n\n \n\n (b) when containing a poison included in Schedule 8 or 9.\n\n \n\nPHOTOGRAPHIC PAPER or FILM.\n\n \n\nPIGMENTS when immobilised in a polymer.\n\n \n\nPORCELAIN.\n\n \n\nPRINTING INKS or INK ADDITIVES except:\n\n \n\n (a) when containing a pesticide; or\n\n \n\n (b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.\n\n \n\nRADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.\n\n \n\nRADIOISOTOPES for therapeutic use.\n\n \n\nSEEDS treated with seed protectants.\n\n \n\nSINGLE-USE TUBES for the estimation of alcohol content of breath.\n\n \n\nTERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.\n\n \n\nTIMBER or WALLBOARD.\n\n \n\nVITREOUS ENAMELS.\n\n \n\nWRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.\n\n## APPENDIX B\n\n \n\n## SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL  BY SCHEDULING\n\n \n\n(This Appendix should be read in conjunction with Appendix A.)\n\n \n\n## INTRODUCTION\n\n \n\nSubstances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.\n\n \n\nListing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally.  It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.\n\n \n\nSubstances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal.  Factors which are considered when determining an Appendix B entry include:\n\n \n\n• the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;\n\n \n\n• the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or\n\n \n\n• the public access was limited such that scheduling was inappropriate or unnecessary.\n\n \n\nThe list was developed from scheduling files and historical records.  For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.\n\n \n\nInclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.\n\n \n\nApplications are considered for scheduling.  Applications for inclusion in Appendix B will not be accepted.\n\n \n\nAPPENDIX B\n\n \n\n \n\nREASONS FOR ENTRY\n\n \n\na Low Toxicity.\n\nb Use pattern restricts hazard.\n\nc Presentation/packaging restricts hazard.\n\nd Industrial use only.\n\n \n\n \n\nAREAS OF USE\n\n \n\n1. Agricultural\n\n 1.1 Herbicide\n\n 1.2 Insecticide\n\n  1.2.1 Insecticide for codling moth\n\n  1.2.2 Termiticide\n\n 1.3 Fungicide\n\n  1.3.1 On seed fungicide\n\n 1.4 Bird Repellent\n\n 1.5 Fertiliser\n\n 1.6 Plant Growth Regulator\n\n 1.7 Insect Pheromone\n\n 1.8 Mushroom Bactericide\n\n 1.9 Acaricide\n\n 1.10 Biological control agent\n\n2. Veterinary\n\n 2.1 For animal use\n\n 2.2 Treatment of mastitis in cows\n\n 2.3 Coccidiostat\n\n 2.4 Feed additive\n\n 2.5 Antiseptic\n\n 2.6 Scabicide\n\n 2.7 Anthelmintic\n\n 2.8 Vitamin/Mineral\n\n 2.9 Growth Promotant\n\n 2.10 Ectoparasiticide\n\n3. Domestic\n\n 3.1 Aromatherapy\n\n 3.2 Food additive\n\n 3.3 Cosmetic\n\n 3.4 Human use\n\n 3.5 Miticide\n\n4. Industrial\n\n 4.1 Water treatment\n\n 4.2 Biological control agent\n\n5. Environmental\n\n 5.1 Mosquito control\n\n6. Human therapeutic use\n\n 6.1 Diagnostic agent\n\n 6.2 Medical device\n\n 6.3 Antiseptic\n\n 6.4 Sunscreen\n\n 6.5 External use\n\n 6.6 Laxative\n\n 6.7 Antiseborrheic\n\n 6.8 Cytoprotective\n\n 6.9 Vitamin/Mineral\n\n 6.10 Eye Drops\n\n7. General\n\n 7.1 Any use\n\n 7.2 Excipient\n\n 7.3 Synergist\n\n 7.4 Flux\n\n 7.5 Pesticide\n\n 7.6 Insect repellent\n\n 7.7 Solvent\n\n 7.8 Disinfectant\n\n 7.9 Preservative\n\n 7.10 Antioxidant\n\n 7.11 Resin activator/accelerant\n\n 7.12 Sweetener artificial\n\n 7.13 Food additive\n\nAPPENDIX B\n\n \n\n","sortOrder":8},{"sectionNumber":"Part 3","sectionType":"part","heading":null,"content":"PART 3\n\n \n\nSUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL   BY SCHEDULING\n\n \n\n   REASON AREA   DATE OF FOR OF  SUBSTANCE ENTRY LISTING USE\n\n \n\n4-[4-(ACETYLOXY)PHENYL]-2-\n\n  BUTANONE Feb 2005 b 1.7\n\nAGROBACTERIUM RADIOBACTER Nov 1989 a 1\n\nALCOHOL, DEHYDRATED Aug 2000 b 6\n\nALUM May 1997 a 7.1\n\nALUMINIUM AMMONIUM SULFATE May 1997 a 7.1\n\nALUMINIUM POTASSIUM SULFATE May 1997 a 7.1\n\nALUMINIUM SILICATE Nov 1974 a 7.1\n\nALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1\n\nAMETOCTRADIN May 2012 a 1.3\n\nAMMONIUM PHOSPHATE Nov 1974 a 7.1\n\nAMMONIUM THIOSULPHATE Nov 1974 a 7.1\n\nAMPROLIUM Jun 1969 a 2.3\n\nAMYL ACETATE Nov 1974 a 7.1\n\nα -AMYLASE derived from Aspergillus niger   Feb 2005 a 2.4\n\nANDROSTENEDIONE ALBUMEN\n\nCONJUGATE WITH DEA DEXTRAN\n\nADJUNCT Jun 2004 a 2.1\n\nASPARTIC ACID - a 6\n\nASULAM May 1986 a 1\n\nAZIMSULFURON Jun 2003 a 1.1\n\nBACILLUS SPHAERICUS STRAIN 2362 Feb 2003 a 5.1\n\nBACILLUS THURINGIENSIS  May 1992 a 5.1  (excluding endotoxin) Jun 2003 a 2.10\n\nBACILLUS TOYOI Aug 1980 a 2.9\n\nBACULOVIRUS CYDIA POMONELLA Jun 2006 a 1.2\n\nBENFLURALIN - a 1.1\n\nBENSULFURON-METHYL Aug 1987 a 1\n\nBENTONITE Jun 2002 a 7.1\n\nBENZYL BENZOATE Aug 1989 a 1.3.4\n\nBETAINE HYDROCHLORIDE Nov 1974 a 7.1\n\nBIFENAZATE Oct 2002 a 1.9\n\nBISMUTH SUBNITRATE Nov 1999 b, c 2.1\n\nBISTRIFLURON Feb 2014 a 1.2.2\n\nBIURET Nov 1974 a 2.4\n\nBOSCALID June 2003 a 1.3\n\nBOVINE SOMATOTROPHIN May 1992 a 2\n\nBROMACIL Aug 1987 a 1\n\nBROMOPROPYLATE Nov 1994 a 1\n\nBUPIRIMATE Nov 1990 a 1\n\nBUTAFENACIL May 2000 a 1\n\nBUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7\n\nn-BUTYL BUTYRATE - a 7.1\n\nn-BUTYL LACTATE - a 7.1\n\nCARBETAMIDE Aug 1991 a 1\n\nCARBOXIN Aug 1987 a 1\n\nCARFENTRAZONE-ETHYL Aug 1998 a 1\n\nCELLULASE derived from    Aspergillus niger    Feb 2005 a 2.4\n\nCETYL ALCOHOL Nov 1974 a 7.1\n\nCHAMOMILE OIL Feb 2000 a 3.1\n\nCHINA CLAY Nov 1974 a 7.1\n\nCHLORANTRANILIPROLE Sep 2008 a 1.2\n\nCHLORFLUAZURON Oct 2005 a 1.2.2\n\nCHLORFLURENOL Feb 1974 a 1.6\n\nCHLORIDAZON May 1988 a 1\n\nCHLOROXYLENOLS Feb 1975 a 7.8\n\nCITRONELLA OIL Feb 2000 a 7.1\n\nCLARY SAGE OIL Feb 2000 a 7.1\n\nCLOPIDOL Nov 1974 d 2.3\n\nCOBALT NAPHTHENATE - d 7.1\n\nCOLOPHONY Feb 1997 b 7.4\n\nCROSPOVIDONE Aug 1996 a 2\n\nCULICINOMYCES CLAVOSPORUS Nov 1982 a 5.1\n\nCYCLAMIC ACID Nov 1971 a 7.1\n\nCYCLOHEXANE Nov 1974 a 7.7\n\nCYCLOHEXANOL ACETATE - a 7.7\n\nCYROMAZINE Nov 1980 a 2\n\nDICLAZURIL Nov 2001 a 2.3\n\nDIETHYL CARBONATE - a 7.1\n\nDIFLUFENICAN Feb 1987 a 1\n\nDIKEGULAC-SODIUM Mar 1980 a 1.6\n\nDIMETHICONE  a 7.1\n\nDIMETHYL ETHER Nov 1988 d 4\n\nDIPHENYLAMINE Feb 1988 a 1\n\nDIPROPYLENE GLYCOL   MONOMETHYL ETHER Nov 1987 a 4\n\nDIURON Nov 1987 a 1\n\nDOCUSATE SODIUM   (DIOCTYL SODIUM SULFOSUCCINATE)  Feb 1970 a 7.1\n\n2,2-DPA Nov 1989 a 1\n\ndrometrizole trisiloxane Oct 2003 a 6.4\n\nEPSIPRANTEL Nov 1991 a 2\n\nETHAMETSULFURON-METHYL Nov 2000 a 1.1\n\nETHOPABATE Jun 1969 d 2.3\n\nETHYL ACETATE Nov 1974 a 7.1\n\nETHYL ALCOHOL Nov 1974 a 7.1\n\nETHYLBUTYLACETYL-  AMINOPROPRIONATE Aug 2000 a 3.4\n\nETHYL BUTYRATE - a 7.1\n\nETHYL LACTATE - a 7.1\n\nETOXAZOLE Oct 2003 a 1.2\n\nEUBACTERIUM sp. strain DSM11798  Sep 2013  a 2.4\n\nFENFURAM May 1977 a 1.3.1\n\nFENHEXAMID Feb 1999 a 1\n\nFENOXYCARB Feb 1988 a 1\n\nFLUFENOXURON Feb 1997 a 1\n\nFLUMETSULAM Feb 1992 a 1\n\nFLUOMETURON Aug 1989 a 1\n\nFLUTOLANIL Nov 2001 a 1.3\n\nFLUROXYPYR May 1986 a, c 1\n\nFORCHLORFENURON Feb 2005 a 1.6\n\nFULLERS EARTH Nov 1974 a 7.1\n\nFUNGAL PROTEASE derived from\n\n  Aspergillus niger Feb 2005 a 2.4\n\nGERANIUM OIL Feb 2000 a 7.1\n\nGIBBERELLIC ACID Nov 1974 a 1.6\n\n-GLUCANASE derived from Aspergillus niger Feb 2005 a 2.4\n\nHALAUXIFEN METHYL Oct 2014 a 1, 1.1\n\nHEXAFLURON Nov 1988 a 1\n\nHEXYL ACETATE - a 7.7\n\nHEXYTHIAZOX Feb 1988 a 1\n\nHUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2\n\nHYDROPRENE Feb 1988 a 1\n\nHYDROXYPROPYL CELLULOSE Nov 1982 a 7.1\n\nICODEXTRIN Nov 2000 b 6\n\nINDOLE-3-ACETIC ACID Feb 1985 b 1.6\n\nISOPRENE ALCOHOL - a 7.1\n\nIPRODIONE Feb 1997 a 1\n\nISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1\n\nKAOLIN Nov 1974 a 7.1\n\nKRESOXIM-METHYL Aug 1999 a 1\n\nKUNZEA OIL Feb 2000 a 7.1\n\nLAURIC ACID Oct 2005 a 7.1\n\nLAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1\n\nLAVANDIN OIL Feb 2000 a 7.1\n\nLAVENDER OIL Feb 2000 a 7.1\n\nLEAD METALLIC - a 7.1\n\nLEMONGRASS OIL Feb 2000 a 7.1\n\nLEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1\n\nLIMONENE (DIPENTENE) Jun 2002 a 7.1\n\nLINOLEIC ACID Oct 2005 a 7.1\n\nLINSEED FATTY ACIDS Aug 1990 a 2.1\n\nLINURON Feb 1990 a 1\n\nLIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1\n\nMALEIC HYDRAZIDE Nov 1992 a 1\n\nMANGANESE DIOXIDE May 1999 b 1\n\nMEGASPHAERA ELSDENII strain 41125  Sep 2013 a 2.4\n\nMESOLSULFURON-METHYL Feb 2002 a 1.1\n\nMETARHIZIUM ANISOPLIAE Feb 2000 b 4.2\n\nMETARHIZIUM ANISOPLIAE Jun 2003 a 1.10\n\nMETHOPRENE Aug 1987 a 1\n\nMETHOXYFENOZIDE Nov 2000 a 1\n\nMETHYL ACETATE - a 7.7\n\nMETHYL BENZOQUATE Nov 1974 d 2.3\n\n1-METHYLCYCLOPROPENE Jun 2003 a 1.6\n\nMETHYL p-HYDROXYBENZOATE Nov 1974 a 7.9\n\nMETSULFURONMETHYL Nov 1985 a 1.1\n\nMYRISTIC ACID Oct 2005 a 7.1\n\nNAPROPAMIDE Aug 1987 a 1\n\nNAPTHYL ACETAMIDE Nov 1974 a 1.6\n\nNEROLI OIL Feb 2000 a 7.1\n\nNICARBAZIN Jun 1969 d 2.3\n\nNISIN Jun 2003 a 3.2\n\nNORFLURAZON Nov 1983 a 1.1\n\nNOVALURON Nov 2000 a 1\n\nNuclear Polyhedrosis Virus of     Helicoverpa armigera  occlusion bodies Feb 2004 a 1.2\n\nOCTYL ALCOHOLS Nov 1974 a 7.1\n\nOLEIC ACID Oct 2005 a 7.1\n\nORANGE OIL, SWEET Aug 2000 a 7.1\n\nOXABETRINIL Feb 1987 a 1\n\nOXYFLUORFEN May 2001 a 1\n\nPALMAROSA OIL Feb 2000 a 7.1\n\nPALMITIC ACID Oct 2005 a 7.1\n\nPATCHOULI OIL Feb 2000 a 7.1\n\nPECTINASE derived from Aspergillus niger Feb 2005 a 2.4\n\nPENCYCURON Aug 1994 a 1\n\nPENTADECANOIC ACID Oct 2005 a 7.1\n\nPEPPERMINT OIL Feb 2000 a 7.1\n\nPHENMEDIPHAM May 1989 a 1.1\n\nd-PHENOTHRIN Feb 1982 a 7.5, 1.2\n\nPHYTASE Feb 1996 a 2.4\n\nPICLORAM Aug 1987 a 1\n\nPICOLINAFEN May 2000 a 1\n\nPIMELIC ACID Oct 2005 a 7.1\n\nPIPERONYL BUTOXIDE Aug 1991 a 7.5\n\nPOLOXALENE Nov 1974 a 7.1\n\nPOLY DIALLYL DIMETHYL AMMONIUM   CHLORIDE (PolyDADMAC) Nov 1997 a 4.1\n\nPOLYHEDROSIS VIRUS of     Helico zea occlusion bodies Nov 1996 a 1\n\nPOLY (GNRF) OVALBUMIN Feb 1990 a 2\n\nPOLYSORBATE 20 May 2001 a 1\n\nPORCINE SOMATOTROPHIN Nov 1991 c 2\n\npotassium sorbate Oct 2004 a 1.3\n\nPOTASSIUM BICARBONATE Jun 2004 a 1\n\nPROPYL ACETATES - a 7.1\n\nPROPYLENE GLYCOL Nov 1974 a 7.1\n\n2-PROPYLENE GLYCOL 1-MONOMETHYL   ETHER Nov 1987 a  4\n\nPROTHIOCONAZOLE June 2005 a 1.3.1\n\nPSEUDOMONAS FLUORESCENS May 1985 a 1.8\n\nPYRIMETHANIL Feb 1996 a 1\n\nPYRIPROXYFEN Aug 1994 a 1\n\nQUASSIA Nov 1974 d 6, 2.1\n\nQUINOXYFEN Nov 2001 a 1.3\n\nROSEMARY OIL Feb 2000 a 7.1\n\nSAGE OIL (Spanish) Feb 2000 a 7.1\n\nSANDALWOOD OIL Feb 2000 a 7.1\n\nSEAWEED & UNFRACTIONED   SEAWEED EXTRACTS Feb 1985 d 1.5\n\nSIMAZINE Nov 1987 a 1.1\n\nSODIUM BICARBONATE Jun 2004 a 1\n\nsodium propionate Oct 2004 a 1.3\n\nSTERIC ACID Oct 2005 a 7.1\n\nSUCRALFATE Aug 1982 a 6.8\n\nSULESOMAB Jun 2002 b 6.1\n\nSULFOSULFURON Feb 1998 a 1\n\nSULPHATED POLYSACCHARIDES - a 7.1\n\nTANNIC ACID Dec 1965 a 7.1\n\nTANNIC ACID/BENZYL ALCOHOL   PRODUCT Nov 1993 a 7.1\n\nTERBACIL Aug 1987 a 1\n\nTHAUMATIN Nov 1990 a 3.2\n\nTHIDIAZURON Nov 1989 a 1\n\nTRIASULFURON Feb 1988 a 1\n\nTRICHODERMA HARZIANUM May 1996 a 1\n\n(Z)-9-TRICOSENE Aug 1991 a 1\n\nTRIETHYLENE GLYCOL Nov 1974 a 7.1\n\nTRIFLOXYSULFURON Feb 2002 a 1.1\n\nTRIFLURALIN Aug 1990 a 1\n\nTRIFORINE Aug 1987 a 1\n\nUlocladium oudemansii Oct 2003 a 1.10\n\nUREA Nov 1974 a 7.1\n\n13C-UREA May 2001 a 6.1\n\nVETIVER OIL Feb 2000 a 7.1\n\nVINYL ETHER Nov 1987 b 6\n\nVITAMIN K Jul 1963 a 6.9, 2.8\n\nXANTHOPHYLL (lutein) Nov 1974 a 7.1\n\nXYLANASE derived from Aspergillus niger Feb 2005 a 2.4\n\nYLANG YLANG OIL Feb 2000 a 7.1\n\nZINC NAPHTHENATE - a 1.3\n\n \n\n## APPENDIX C\n\n## SUBSTANCES, OTHER THAN THOSE INCLUDED IN SCHEDULE 9,\n\n## OF SUCH DANGER TO HEALTH AS TO WARRANT\n\n## PROHIBITION OF SALE, SUPPLY AND USE\n\n \n\nABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.\n\n \n\nACORUS CALAMUS (calamus) for human therapeutic use.\n\n \n\nALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:\n\n \n\n (a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;\n\n \n\n (b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or\n\n \n\n (b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.\n\n \n\nALLYLISOPROPYLACETYLUREA for therapeutic use.\n\n \n\nAMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.\n\n \n\nAMYGDALIN for therapeutic use.\n\n \n\nANCHUSA OFFICINALIS for therapeutic use.\n\n \n\nARISTOLOCHIA spp. for therapeutic use.\n\n \n\nARISTOLOCHIC ACID(S) for human therapeutic use.\n\n \n\nASARUM spp. containing aristolochic acid(s) for human therapeutic use.\n\n \n\nAZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use except ‘debitterised neem seed oil’.\n\n \n\nBASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.\n\n \n\nBITHIONOL for human therapeutic use.\n\n \n\nBORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the seeds of Borago officinalis.\n\n \n\nBRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.\n\n \n\nBUCLOSAMIDE for therapeutic use.\n\n \n\nBUNIODYL SODIUM for therapeutic use.\n\n \n\n1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.\n\n \n\nCACALIA spp. for therapeutic use.\n\n \n\nCARBAMIDE PEROXIDE  (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.\n\n \n\nCINCHOPHEN and its derivatives for therapeutic use.\n\n \n\nCLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use except when being used solely for experimental purposes in humans and where such use:\n\n \n\n (a) is in accordance with:\n\n \n\n  (i)  an approval granted under paragraph 19(1)(b) of the Therapeutic Goods Act 1989, including any conditions specified in the notice of approval; and\n\n  (ii)  any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(1A) of the Therapeutic Goods Act 1989; and\n\n  (iii)  any conditions specified in the Therapeutic Goods Regulations 1990 for the purposes of subsection 19(4A) of the Therapeutic Goods Act 1989; or\n\n \n\n (b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic Goods Regulations 1990.\n\n \n\nCOAL TAR for cosmetic use other than in therapeutic goods.\n\n \n\nCONIUM MACULATUM (coniine) for therapeutic use.\n\n \n\nCOTARNINE for therapeutic use.\n\n \n\nCROTALARIA spp. for therapeutic use.\n\n \n\nCROTON TIGLIUM for therapeutic use.\n\n \n\nCYNOGLOSSUM spp. for therapeutic use.\n\n \n\nDIBUTYLPHTHALATE for cosmetic use.\n\n \n\nDICOPHANE (DDT) for therapeutic use.\n\n \n\nDIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of diethylene glycol.\n\n \n\nDIETHYLHEXYL PHTHALATE for cosmetic use.\n\n \n\nDIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of diethylphthalate.\n\n \n\n5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.\n\n \n\n1,3-DIMETHYLAMYLAMINE (DMAA).\n\n \n\nDIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use except in preparations containing 0.5 per cent or less of dimethylphthalate.\n\n \n\nDULCIN for therapeutic use.\n\n \n\nETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations containing 0.25 per cent or less of ethylene glycol.\n\n \n\nETHYLHEXANEDIOL for human use.\n\n \n\nEUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.\n\n  \n\nFARFUGIUM JAPONICUM for therapeutic use.\n\n \n\nFORMALDEHYDE (excluding its derivatives):\n\n \n\n1.           in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;\n\n \n\n1.          in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;\n\n \n\n1.           in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or\n\n \n\n1.          in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:\n\n \n\n \n\nHELIOTROPIUM spp. for therapeutic use.\n\n \n\nHYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.\n\n \n\nJUNIPERUS SABINE [savin(e)]  for therapeutic use.\n\n \n\nLEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.\n\n \n\nLIGULARIA DENTATA for therapeutic use.\n\n \n\nMELIA AZEDARACH including its extracts and derivatives.\n\n \n\nMETHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.\n\n \n\nMETHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.\n\n \n\nOXYPHENISATIN for therapeutic use.\n\n \n\nPARAFORMALDEHYDE (excluding its derivatives):\n\n \n\n (a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;\n\n \n\n (b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;\n\n \n\n (c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or\n\n \n\n (d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde except in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:\n\n \n\n \n\nPETASITES spp. for therapeutic use.\n\n \n\nPHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.\n\n \n\nPOTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.\n\n \n\nPTERIDIUM spp. for therapeutic use.\n\n \n\nPULMONARIA spp. for therapeutic use.\n\n \n\nSAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of safrole.\n\n \n\nSENECIO spp. for therapeutic use.\n\n \n\nSILICONES for injection or implantation except when included in Schedule 4.\n\n \n\nSODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.\n\n \n\nSYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use except when included in Schedule 5.\n\n \n\nTOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows except when included in Schedule 6.\n\n \n\n1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.\n\n \n\nTRICHODESMA AFRICANA for therapeutic use.\n\n \n\nTRIPARANOL for therapeutic use.\n\n \n\nTUSSILAGO FARFARA for therapeutic use.\n\n## APPENDIX D\n\n## ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY  OF POISONS INCLUDED IN SCHEDULE 4 OR 8\n\n \n\n(The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)\n\n \n\n1. Poisons available only from or on the prescription or order of an authorised medical practitioner.\n\n \n\n CLOMIPHENE for human use.\n\n CLOZAPINE for human use.\n\n CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.\n\n CYCLOFENIL for human use.\n\n DINOPROST for human use.\n\n DINOPROSTONE for human use.\n\n FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.\n\n FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.\n\n LUTEINISING HORMONE for human use.\n\n NABIXIMOLS. \n\n SODIUM OXYBATE for human use.\n\n TERIPARATIDE for human use.\n\n UROFOLLITROPIN (human follicle-stimulating hormone) for human use.\n\n \n\n2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:\n\n \n\n (1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and\n\n \n\n (2)  if the drug is -\n\n \n\n  (a)  acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or\n\n \n\n  (b)  bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.\n\n \n\n ACITRETIN for human use.\n\n BEXAROTENE for human use.\n\n ETRETINATE for human use.\n\n ISOTRETINOIN for human oral use.\n\n THALIDOMIDE for human use.\n\n \n\n3. Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the Therapeutic Goods Act 1989.\n\n \n\n DRONABINOL (delta-9-tetrahydrocannabinol).\n\n \n\n4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:\n\n \n\n (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and\n\n \n\n (b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.\n\n \n\n LENALIDOMIDE.\n\n TRETINOIN for human oral use.\n\n \n\n5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).\n\n \n\n ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.\n\n ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.\n\n BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8.\n\n DARBEPOETIN.\n\n DEXTROPROPOXYPHENE.\n\n EPHEDRINE.\n\n EPOETINS.\n\n ERYTHROPOIETIN.\n\n ERYTHROPOIETINS except when separately specified in this Appendix.\n\n FOLLISTATIN.\n\n GLUTETHIMIDE.\n\n INSULIN-LIKE GROWTH FACTORS. \n\n PERAMPANEL for human use.\n\n PHENTERMINE.\n\n              SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.\n\n SOMATROPIN (human growth hormone).\n\n \n\n6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:\n\n \n\n (a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and\n\n \n\n (b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.\n\n \n\n AMBRISENTAN for human use.\n\n BOSENTAN for human use.\n\n SITAXENTAN for human use.\n\n \n\n7. Poisons available only from or on the prescription or order of a dermatologist.\n\n \n\n ALEFACEPT for human use.\n\n## APPENDIX E\n\n## FIRST AID INSTRUCTIONS FOR POISONS\n\n \n\n(other than agricultural and veterinary chemicals (including pesticides) registered by the\n\nAustralian Pesticides and Veterinary Medicines Authority and medicines for human use\n\nwhen compliant with the requirements of the Required Advisory Statements for Medicine Labels)\n\n \n\nINTRODUCTION\n\n \n\nDirections for First Aid Attention\n\n \n\nUnder poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose.  Standard statements specified in this Appendix may be varied provided that the intent is not changed.\n\n \n\nThe directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product.  Any such modification should be concise and readily understood.\n\n \n\nThese First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue.  However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation.  While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.\n\n \n\nModified First Aid Instruction on Primary Pack \n\n \n\nWhere a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:\n\n (a)  each immediate container must be labelled with first aid instructions appropriate for its contents; and\n\n (b) the primary pack must be labelled with the statement:\n\n   FIRST AID: See inner packs.\n\n \n\nExempt Preparations\n\n \n\nThis Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.\n\n \n\nPoisons Information Centre Telephone Numbers\n\n \n\nCompanies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.\n\n \n\nCompanies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:\n\n \n\n1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and\n\n \n\n2. calls must be logged and submitted for incorporation into the official collection of poisoning data.\n\nAPPENDIX E\n\n \n\n \n\nSTANDARD STATEMENTS\n\n \n\nTo be grouped together and prefaced with the words “FIRST AID” (see subparagraph 7(p) of this Standard).\n\n \n\nBasic\n\n \n\n A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).\n\n \n\n Z First aid is not generally required.  If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n\n \n\nGeneral\n\n \n\n G1 Urgent hospital treatment is likely to be needed.    (Note  the words ‘at once’ to be added to instruction A).\n\n \n\n G2 If swallowed, give activated charcoal if instructed.   (Note  the words ‘at once’ to be added to instruction A).\n\n \n\n G3 If swallowed, do NOT induce vomiting.\n\n \n\n G4 Immediately give a glass of water.\n\n \n\n G5 Avoid giving milk or oils.\n\n \n\n G6 If sprayed in mouth, rinse mouth with water.\n\n \n\nEyes\n\n \n\n E1 If in eyes wash out immediately with water.\n\n \n\n E2 If in eyes, hold eyelids apart and flush the eye continuously with running water.  Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.\n\n \n\nRespiratory system\n\n \n\n R1 If inhaled, remove from contaminated area.  Apply artificial respiration if not breathing.\n\n \n\n R2 If swallowed or inhaled, remove from contaminated area.  Apply artificial respiration if not breathing.  Do not give direct mouth-to-mouth resuscitation.  To protect rescuer, use air-viva, oxy-viva or one-way mask.  Resuscitate in a well-ventilated area.\n\nSkin\n\n \n\n S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.\n\n \n\n S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running  water.  Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n\n \n\n \n\n S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then  methylated spirit if available.  Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n\n \n\n S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.\n\n \n\n S5 If skin contact occurs, immediately remove contaminated clothing.  Flush skin under running water for 15 minutes.  Then apply calcium gluconate gel.  Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).\n\n \n\nSpecial Purpose\n\n \n\n SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once.  Remove any contaminated clothing and wash skin thoroughly.  If swallowed, activated charcoal may be advised.  Give atropine if instructed.\n\nAPPENDIX E\n\n \n\n \n\nFIRST AID INSTRUCTIONS\n\n \n\nStandard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).\n\n \n\n \n\nPOISON STANDARD STATEMENTS\n\n \n\nAcetic acid A,G3,E2,S1\n\n \n\nAcetic anhydride A,G3,E2,S1\n\n \n\nAcetone  A,G3\n\n \n\nAcrolein A,G1,G2,G3,E2,R2,S2\n\n \n\nAlkaline salts A,G3,E2,S1  \n\n \n\nAmines for use as curing agents A,G3,E1,S1\n\n \n\n4-Aminopyridine A,G1,G2,E1,S1\n\n \n\nAmmonia     \n\n \n\n• 5 per cent or less A\n\n \n\n• above 5 per cent A,G3,E1,R1,S1 \n\n \n\nAmmonium persulfate A,G3,E2\n\n \n\nAmmonium thiocyanate A\n\n \n\nAnhydrides, organic acid, for use as   curing agents for epoxy resins A,G3,E1,S1\n\n \n\nAniline A,E2,R1,S1\n\n \n\nAnise oil A,G3\n\n \n\nAntimony chloride A,E2,S2\n\n  \n\nAntimony compounds, except antimony chloride A \n\n \n\nAzadirachta indica (neem) including its extracts   and derivatives when included in Schedule 6.  A,E1\n\n \n\nBarium salts, except barium sulfate A\n\n  \n\nBasil oil A,G3\n\n   \n\nBay oil A,G3   \n\n \n\nBenzalkonium chloride \n\n \n\n• when included in Schedule 5 A,G3,E2\n\n  \n\n \n\nBenzene A,G3,E1,R1,S1\n\n \n\n1,2-Benzenediol (Catechol)   A,E1,S1\n\n \n\nBenzoyl peroxide   \n\n \n\n• above 20 per cent A,E2,S1\n\n  \n\n• above 10 per cent up to 20 per cent A,E1  \n\n \n\n• 10 per cent or less A  \n\n \n\nBergamot oil A,G3   \n\n \n\nBifluorides   (including ammonium, potassium and sodium salts)\n\n \n\n• when included in Schedule 5 A\n\n \n\n \n\nBorax A\n\n \n\nBoric acid A\n\n \n\nBoron trifluoride\n\n \n\n• when included in Schedule 5 A\n\n \n\nBromoform A,G3,E2,R1,S2\n\n \n\nBrucine A,G1,G2,G3,R2\n\n \n\n2-Butoxyethanol and its acetates A,E2,S1 \n\n \n\nCadmium compounds A  \n\n \n\nCajuput oil A,G3 \n\n \n\nCamphor  A,G1,G3,G5\n\n \n\nCarbamide peroxide\n\n \n\n• more than 9 per cent up to 60 per cent A,G3,E2,S1\n\n \n\n• more than 60 per cent A,G1,G3,G4,E2,S1\n\n \n\nCarbon disulfide A,G3,E2,R1,S2\n\n \n\nCarbon tetrachloride A,G3,E1,R1,S1\n\n \n\nCassia oil A,G3  \n\n \n\nChlorinating compounds, except when   separately specified, containing    \n\n \n\n• above 4 per cent and below 10 per cent    of available chlorine A,G3,E1,S1\n\n \n\n• 10 per cent or more of available chlorine A,G3,E2,S1 \n\n \n\nChlorine (gas) A,E1,R1 \n\n \n\nChlorocresol A,G3,E2,S2 \n\n \n\nChloroform A,G3,E1,R1,S1\n\n \n\nChromates A,G3,E2,S1\n\n \n\nChromium trioxide A,G3,E2,S1 \n\n \n\nCineole A,G1,G3  \n\n \n\nCinnamon bark oil A,G3  \n\n \n\nCinnamon leaf oil A,G3 \n\n \n\nClimbazole A\n\n \n\nClove oil A,G1,G3,E2 \n\n \n\nCopper sulfate A,G3,E2,S1\n\n  \n\nCreosote A,G3,E2,S1 \n\n \n\nCresols A,G3,E2,S3  \n\n \n\nCresols in pressurised spray packs A,G6,E1,S1  \n\n \n\nCyanides A,G1,E1,R2  \n\n \n\nCyanoacrylic acid esters A  \n\n \n\nCyanuric acid A  \n\n \n\nCyclohexanone peroxide A,G3,E2,S1 \n\n \n\nCysteamine  E1\n\n \n\northo-Dichlorobenzene A,G3,E1,S1\n\n \n\npara-Dichlorobenzene (PDB) A \n\n \n\nDichloroethyl ether A,G3,E1,R1,S1\n\n \n\nDichloroisocyanurates A,G3,E1,S1\n\n  \n\nDichloromethane (methylene chloride) A,G3,G5,E1,R1,S1\n\n  \n\n• in pressurised spray packs A,G6,S1 \n\n \n\nDichromates A,G1,G3,E2,S1\n\n \n\nDidecyldimethylammonium salts A,G3\n\n \n\nDiesel (distillate)  A,G3  \n\n \n\nDiethanolamine   \n\n \n\n• when included in Schedule 5  A,G3 \n\n  \n\n \n\n5,6-Dihydroxyindoline  E1\n\n \n\nDimethylformamide    \n\n \n\n• less than 75 per cent A \n\n  \n\n• 75 per cent or more A,E1,R1,S1  \n\n \n\nDimethyl sulfoxide A,G3,E1,S1 \n\n \n\nDinitrocresols A,G1,E1,S1  \n\n \n\nDinitrophenols A,G1,E1,S1  \n\n \n\nDioxane A,G3,E1,R1,S1 \n\n \n\nDistillate A,G3  \n\n \n\nN-(N-Dodecyl)-2-pyrrolidone\n\n    \n\n• when included in Schedule 5   A,G3,E1  \n\n \n\n \n\nEpoxy resins liquid A,G3,E2,S1  \n\n \n\nEssential oils containing camphor as natural   component unless otherwise specified. A,G3\n\n \n\nEthanolamine    \n\n \n\n  \n\n \n\nEther A,G3,E1,R1 \n\n \n\nEthyl bromide A,E2,S1,R1   \n\n \n\nEthylene glycol A \n\n \n\nEthylene glycol monoalkyl ethers and their   acetates, except when separately specified A,G3,E2,S1  \n\n \n\nEthylene oxide A,E2,R1  \n\n \n\nEucalyptus oil A,G1,G3  \n\n \n\nEugenol A,G1,G3,E2  \n\n \n\nFluorides except when separately specified    \n\n \n\n• when included in Schedule 5   A \n\n  \n\n• when included in Schedule 6  A,G1,G3,E2,S1  \n\n \n\nFormaldehyde (see also paraformaldehyde) A,G3,E2,R1,S1\n\n   \n\nFormic acid A,G3,E2,S1   \n\n \n\nFurfural        A,E1,S1\n\n \n\nGlutaraldehyde    \n\n \n\n• below 5 per cent A,G3,E1 \n\n  \n\n• 5 per cent or more A,G3,E2,S1  \n\n \n\nGlycolic acid A,G3,E2  \n\n \n\nGuanidine when included in Schedule 6 A,G3,E2,S1\n\n \n\nHexachlorophane when included in Schedule 6  A  \n\n \n\nHexyloxyethanol    A,G3,E2,S1\n\n \n\nHydrazine A,G1,G3,E2,R1,S1 \n\n \n\nHydrocarbons, liquid A,G3 \n\n \n\nHydrochloric acid A,G3,E2,S1  \n\n \n\n• when included in Schedule 5  A,G3   \n\n \n\nHydrofluoric acid and admixtures that   generate hydrofluoric acid   \n\n \n\n  \n\n \n\nHydrogen peroxide     \n\n \n\n• more than 3 per cent up to 20 per cent A,G3,E2,S1 \n\n  \n\n• more than 20 per cent  A,G1,G3,G4,E2,S1  \n\n \n\nHydroquinone\n\n \n\n• when included in Schedule 2  A\n\n \n\n• when included in Schedule 4 or 6 A,G2,G3,E2,R2,S1\n\n \n\nHydrosilicofluoric acid    \n\n \n\n  \n\n \n\nIodine (excluding salts, derivatives and iodophors)   \n\n \n\n• 2.5 per cent or more for human external use A,E2  \n\n \n\n• 2.5 per cent or more for other uses A,E2,S1  \n\n \n\n• below 2.5 per cent A   \n\n \n\nIodophors  A  \n\n \n\nIsocyanates, free organic A,E2,S1\n\n \n\nIsophorone A,G3,E2,S1  \n\n \n\nKerosene A,G3   \n\n \n\nLaureth carboxylic acids\n\n \n\n• leave-on or wash-off preparations above 5 per cent  E1\n\n \n\n• other preparations above 5 per cent E1,S1\n\n \n\nLauryl isoquinolinium bromide A,E1   \n\n \n\nLead compounds     \n\n \n\n• in hair cosmetics  A \n\n  \n\n• in other preparations A,S1  \n\n \n\nLemon oil A,G3   \n\n \n\nLeptospermum scoparium oil (manuka oil) A,G1,G3\n\n \n\nLime oil A,G3  \n\n \n\nMagnesium chlorate A  \n\n \n\nMalathion at 20 per cent or less A  \n\n \n\nMarjoram oil A,G3  \n\n \n\nMelaleuca oil A,G1,G3  \n\n \n\nMercuric chloride     \n\n \n\n• for external therapeutic use  A  \n\n• for other uses A,G1,G3,E2,R2,S1  \n\n \n\nMercuric iodide A,G1,G3,E2,R2,S1 \n\n \n\nMercuric nitrate A,G1,G3,E2,R2,S1  \n\n \n\nMercuric oxide A,G1,G3  \n\n \n\nMercuric potassium iodide A,G1,G3,E2,R2,S1  \n\n \n\nMercuric thiocyanate A,G1,G3,E2,R2,S1  \n\n \n\nMercurochrome A  \n\n \n\nMercurous chloride A  \n\n \n\nMercury metallic A  \n\n \n\nMercury, organic compounds A,S1 \n\n  \n\n• in preparations for human external use A  \n\n \n\nMetaldehyde A,E1,S1 \n\n \n\nMethanol     \n\n \n\n• above 10 per cent A,G3  \n\n \n\n• 10 per cent or less A   \n\n \n\nMethylated spirit A,G3  \n\n \n\nMethyl ethyl ketone A,G3   \n\n \n\nMethyl ethyl ketone oxime     A,E1,S1\n\n \n\nMethyl ethyl ketone peroxide A,G3,E2,S1 \n\n \n\nMethyleugenol  A\n\n \n\nMethyl isoamyl ketone  A,G3  \n\n \n\nMethyl isobutyl ketone  A,G3   \n\n \n\nN-Methyl-2-pyrrolidone    \n\n \n\n  \n\n• when included in Schedule 6 A,G3,E2  \n\n \n\nMethyl salicylate liquid when included   in Schedule 5 or 6  A,G3,E1  \n\n \n\nNaphthalene A,G1,G3 \n\n \n\nNitric acid A,G3,E2,S1  \n\n \n\nNitrobenzene A,G3,E1,S1  \n\n \n\nNitrophenol A,G3,E2,S1 \n\n \n\nNitroprussides\n\n \n\n• in aerosols A,G6,R1\n\n \n\n• in other preparations A,G3\n\n \n\nNonoxinol 9 A,E2 \n\n \n\nNutmeg oil A,G3 \n\n \n\n2-Octyl-4-isothiazolin-3-one (Ocithilinone)  A,G3,E2,S1\n\n \n\nN-(N-Octyl)-2-pyrrolidone\n\n \n\n• when included in Schedule 5 A,G3,E1  \n\n \n\n• when included in Schedule 6 A,G3,E2  \n\n \n\nOrange oil (bitter) A,G3   \n\n \n\nOxalic acid A,G3,E2,S1 \n\n \n\nParaformaldehyde A,G3,E2,R1,S1\n\n \n\nPennyroyal oil A,G3  \n\n \n\nPeracetic acid   \n\n \n\n• when included in Schedule 5  A,G3,E1,S1 \n\n  \n\n \n\nPetrol A,G3,R1   \n\n \n\n2-Phenoxyethanol       A, E1\n\n \n\nPhenols   \n\n \n\n• 25 per cent and less A,G3,E2,S3 \n\n \n\n• above 25 per cent A,G3,E2,S4 \n\n \n\nPhenols in pressurised spray packs A,E1  \n\n \n\nPhenylenediamines and   alkylated phenylenediamines    \n\n \n\n• in hair dyes   A,E1   \n\n \n\n• in other preparations  A,G1,G3,E1,S1  \n\n \n\nPhenyl methyl ketone   \n\n \n\n• as such, or in preparations of similar viscosity A,G3,E1  \n\n \n\nN,N-bis(phenylmethylene)-bicyclo  -(2.2.1)heptane-2,5-dimethanamine A,E2,S1  \n\n \n\nN,N-bis(phenylmethylene)-bicyclo-  (2.2.1)heptane-2,6-dimethanamine A,E2,S1   \n\n \n\northo-Phenylphenol A,G3,E2,S1 \n\n \n\n• in pressurised spray packs  A,G6,E2,S1   \n\n \n\nPhosphonic acid A,G3,E2,S1   \n\n \n\n• neutralised to pH 6 (approx) A   \n\n \n\n• in spray packs  A,E2,S1  \n\n \n\nPhosphoric acid A,G3,E2,S1 \n\n \n\nPhosphorus, yellow A,G1,G3,E2,R2,S2 \n\n \n\northo-Phthalaldehyde   \n\n \n\n• when included in Schedule 5  A,E1 \n\n  \n\n \n\nPicric acid A,G1,G3,E2,R1,S1 \n\n \n\nPolyethanoxy (15) tallow amine A,E2,S1 \n\n \n\nPoly(oxy-1,2-ethanediyl), α -  [2-[(2-hydroxyethyl)amino]-2-  oxoethyl]- α -hydroxy-,mono-C13-15  -alkyl ethers A,E1   \n\n \n\nPotassium bromate A   \n\n \n\nPotassium chlorate A  \n\n \n\nPotassium cyanate A,E1,S1  \n\n \n\nPotassium hydroxide A,G3,E2,S1   \n\n \n\nPotassium metabisulphite A  \n\n \n\nPotassium nitrite\n\n \n\n• when included in Schedule 7 A,G1,G3\n\n \n\n• when included in Schedule 5 or 6 A,G3\n\n \n\nPotassium peroxomonosulfate triple salt    \n\n  \n\n \n\nPotassium persulfate A,G3,E2   \n\n \n\nPotassium sulfide A,G3,E2,S1  \n\n \n\nPropionic acid A,G3,E1,S1 \n\n \n\nd-Pulegone A,G3   \n\n \n\nPyrithione zinc A,E1 \n\n \n\nQuaternary ammonium compounds  except\n\n when separately specified    \n\n \n\n• above 20 per cent A,G3,E2 \n\n  \n\n• 20 per cent and below A,E2 \n\n  \n\n• in pressurised spray packs A,E2,G6   \n\n \n\nSafrole A,G1,G3  \n\n \n\nSage oil (Dalmatian) A,G3  \n\n \n\nSassafras oil A,G1,G3   \n\n \n\nSelenium compounds  A,G1,E1,S1   \n\n \n\nSilicofluorides     \n\n \n\n  \n\n• when included in Schedule 6  A,G1,G3,E2,S1  \n\n \n\nSilver salts A,E2  \n\n \n\nSodium aluminate A,G3,E2,S1 \n\n  \n\nSodium bromate A,G1\n\n \n\nSodium chlorate A   \n\n \n\nSodium diacetate A,G3,E2,S1  \n\n \n\nSodium dichloroisocyanurate A,G3,E1,S1 \n\n \n\nSodium dodecylbenzene sulfonate A,G3,E2,S1 \n\n \n\nSodium hydrogen sulfate A,G3,E1,S1   \n\n \n\nSodium hydrosulfite A,G3,E2,S1  \n\n \n\nSodium hydroxide A,G3,E2,S1  \n\n \n\nSodium laureth-6 carboxylate A \n\n \n\nSodium lauryl sulfate\n\n \n\n• leave-on or wash-off preparations above 5 per cent  E1\n\n \n\n• other preparations above 5 per cent  E1,S1\n\n \n\nSodium metabisulphite A, G3   \n\n \n\nSodium nitrite  \n\n \n\n• when included in Schedule 7  A,G1,G3 \n\n  \n\n• when included in Schedule 5 or 6  A,G3  \n\n \n\nSodium percarbonate    \n\n \n\n• when included in Schedule 5  A,G3,S1 \n\n  \n\n \n\nSodium persulfate A,G3,E2   \n\n \n\nSodium stannate A,E1  \n\n \n\nSodium sulfide A,G3,E2,S1  \n\n \n\nSodium trichloroacetate A \n\n \n\nStrychnine A,G1,G2,G3,R2 \n\n \n\nStyrene A,G3,S1,E1 \n\n \n\nSulcofuron A  \n\n \n\nSulfamic acid A,G3,E2,S1 \n\n \n\nSulfuric acid A,G3,E2,S1 \n\n \n\nTerpenes, chlorinated A,G3   \n\n \n\nTetrachloroethane A,G3,E1,R1,S1 \n\n \n\nTetrachloroethylene A,G3,E2,R1,S1 \n\n \n\nThiourea A \n\n \n\nThujone A,G3  \n\n \n\nThyme oil A,G3   \n\n \n\northo-Tolidine A \n\n \n\nToluene     \n\n \n\n• above 75 per cent A,G3,E1,R1,S1\n\n  \n\n• 75 per cent and below A,G3 \n\n  \n\n• in pressurised spray packs  A    \n\n \n\nToluenediamine    \n\n \n\n• in hair dyes  A,E1 \n\n \n\n• in other preparations  A,G1,G3,E1,S1   \n\n \n\nTrichloroacetic acid A,G3,E2,S1 \n\n \n\nTrichloroacetic acid alkali salts  A \n\n \n\n1,1,1-Trichloroethane A,G3,E1,R1,S1 \n\n \n\nTrichloroethylene A,G3,E1,R1,S1 \n\n \n\nTrichloroisocyanuric acid A,G3,E1,S1 \n\n \n\nTriethanolamine A,G3,E1,S1  \n\n \n\nTriethyl phosphate A,E1  \n\n \n\nTrifluoromethanesulfonic acid A,G3,E2   \n\n \n\nTriisopropanolamine lauryl ether sulfate A,E1,S1  \n\n \n\nTurpentine (mineral) A,G3 \n\n \n\nTurpentine oil (vegetable) A,G3,E2 \n\n \n\nWhite spirit A,G3 \n\n \n\nXylene\n\n \n\n• above 75 per cent A,G3,E1,R1,S1 \n\n \n\n• 75 per cent and below A,G3  \n\n \n\n• in pressurised spray packs A,G6,E1,S1  \n\n \n\nXylenols A,G3,E2,S3   \n\n \n\n• in pressurised spray packs  A,E1  \n\n \n\nZinc chloride A,G3,E2,S1  \n\n \n\nZinc sulfate A,G3,E2,S1\n\n## APPENDIX F\n\n## WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS\n\n \n\n(other than agricultural and veterinary chemicals (including pesticides) registered by the\n\nAustralian Pesticides and Veterinary Medicines Authority and medicines for human use\n\n when compliant with the requirements of the Required Advisory Statements for Medicine Labels)\n\n \n\n \n\nINTRODUCTION\n\n \n\nWarning Statements and Safety Directions\n\n \n\nIt is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.\n\n \n\nUnder poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions.  The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied.  The following code has been prepared as a guide for this purpose.\n\n \n\nThe wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed.  Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.\n\n \n\nPoisons Information Centre Telephone Numbers\n\n \n\nCompanies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for  the product.\n\n \n\nCompanies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:\n\n \n\n1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and\n\n \n\n2. calls must be logged and submitted for incorporation into the official collection of poisoning data.\n\n \n\n \n\n \n\nWARNING STATEMENTS\n\n \n\n1. Highly corrosive.\n\n \n\n2. Corrosive.\n\n \n\n3. Corrosive liquid.\n\n \n\n4. Strongly alkaline.\n\n \n\n5. Irritant.\n\n \n\n6. May cause cancer.\n\n \n\n7. WARNING   Causes birth defects.\n\n \n\n8. WARNING   May be fatal to children.\n\n \n\n9. Can be fatal to children if sucked or swallowed.\n\n \n\n10. May produce severe burns.\n\n \n\n11. WARNING  Vapour may be harmful.\n\n \n\n12. Vapour is harmful to health on prolonged exposure.\n\n \n\n13. May be fatal if inhaled, swallowed or absorbed through skin.\n\n \n\n14. Dust will irritate and burn eyes, nose and skin.\n\n \n\n15. Liquid will cause burns.\n\n \n\n16. Forms dangerous gas near radiators or naked flames.\n\n \n\n17. Contact with eyes even for short periods can cause blindness.\n\n \n\n18. Product will irritate the eyes, nose, throat and skin.\n\n \n\n19. WARNING   Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.\n\n \n\n20. May give off dangerous gas if mixed with other products.\n\n \n\n21. WARNING  This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.\n\n \n\n22. Highly reactive oxidising chlorine compound.\n\n \n\n23. May cause fire or explosion.\n\n \n\n24. For external washing only.  Rinse skin thoroughly after use.\n\n \n\n25. Do not use on broken skin. Wash hands thoroughly after use.\n\n \n\n26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.\n\n \n\n27. Not for therapeutic use.\n\n \n\n28. (Over) (Repeated) exposure may cause sensitisation.\n\n \n\n29. If congestion persists, consult your doctor or pharmacist.\n\n \n\n30. WARNING   Do not use on face or on anal or genital areas.\n\n \n\n31. WARNING   Do not use on face or on anal or genital areas except on doctor’s advice.\n\n \n\n32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.\n\n \n\n33. Do not take for periods longer than four weeks except on medical advice.\n\n \n\n34. WARNING   This medication may be dangerous when used in large amounts or for a long time (period).\n\n \n\n35. CAUTION   This preparation is for the relief of minor and temporary ailments and should be used strictly as directed.  Prolonged use without medical supervision could be harmful.\n\n \n\n    or\n\n \n\n CAUTION   This preparation is for the relief of minor and temporary ailments and should be used strictly as directed.  Prolonged or excessive use without medical supervision could be harmful.\n\n \n\n36. For use under medical supervision only.\n\n \n\n37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.\n\n \n\n38. CAUTION  Do not use for children under 2 years old unless a doctor has told you to.\n\n \n\n39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.\n\n \n\n40. This medication may cause drowsiness and may increase the effects of alcohol.  If affected do not drive a motor vehicle or operate machinery.\n\n \n\n41. Do not give to children under 12 years of age.  Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.\n\n \n\n42. WARNING   Overuse may stain the skin or mouth.\n\n \n\n43. Use of this product is not necessary in areas supplied with fluoridated water.\n\n \n\n44. WARNING   May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.\n\n \n\n45. WARNING   If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately.  Do not use on children.  Do not use near the eyes.  Mild irritation may occur; stop use if it becomes severe.  If fading is not evident in three months, seek doctor’s advice.\n\n \n\n46. WARNING   Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).\n\n \n\n47. WARNING   This product contains (name of substance) which causes birth defects in certain laboratory animals.  Women of child bearing age are advised not to mix, load or spray this product.  They should keep out of crops being sprayed.\n\n \n\n48. WARNING   This product forms cyhexatin which causes birth defects in certain laboratory animals.  Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.\n\n \n\n49. WARNING   Do not mix with other medication except on veterinarian’s advice.\n\n \n\n50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.\n\n \n\n51.  Irritant to skin, eyes, mucous membranes and upper respiratory tract.\n\n \n\n52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.\n\n \n\n53. CAUTION   (Name of substance) should not be used by pregnant women.\n\n \n\n54.  Seek medical advice before first course of treatment.\n\n \n\n55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.\n\n \n\n56. WARNING   Can cause elevated blood pressure and interact adversely with other medication.\n\n \n\n57. Not to be applied to infants under 12 months of age unless on doctor’s advice.\n\n \n\n58. Highly reactive oxidising bromine and chlorine compound.\n\n \n\n59. May cause allergy.\n\n \n\n60. Do not mix with detergents or other chemicals.\n\n \n\n61. WARNING  Can react with other medicines. Ask your doctor or pharmacist before taking.\n\n \n\n62. Do not use if pregnant.\n\n \n\n63. See a doctor if you are pregnant or diabetic.\n\n \n\n64. See a doctor (or) (dentist) if no better after (Insert number of days as per approved Product Information) days.\n\n \n\n65. If getting better, keep using for (Insert number of days as per approved Product Information ) days.\n\n \n\n66. See a doctor if problem returns.\n\n \n\n67. Do not use if pregnant or likely to become pregnant.\n\n \n\n68. If symptoms persist beyond 5 days consult a doctor (or) (dentist).\n\n \n\n69. If symptoms recur within two weeks of completing the course, consult a doctor.\n\n \n\n70. Use only under medical supervision if you are taking other medicines.\n\n \n\n71. Do not use during the last three months of pregnancy.\n\n \n\n72. Do not use in the eyes.\n\n \n\n73. Do not use for acne.\n\n \n\n74. Do not use under waterproof bandages unless a doctor has told you to.\n\n \n\n75. Do not use for more than 7 days unless a doctor has told you to.\n\n \n\n76. Do not become pregnant during use or within (Insert number of months as per approved Product Information) month(s) of stopping treatment.\n\n \n\n77. WARNING  May cause birth defects.\n\n \n\n78. Attacks skin and eyes.\n\n \n\n79. Will irritate eyes.\n\n \n\n80. (Intentionally blank)\n\n \n\n81. (Intentionally blank)\n\n \n\n82. (Intentionally blank)\n\n \n\n83. This paint is dangerous to health, even when dry.\n\n For industrial use only.\n\n Do not use on toys or furniture.\n\n Do not use on, in or around the home.\n\n \n\n84. Breathing the vapour is dangerous.\n\n Provide adequate ventilation during application.\n\n Do not use in the presence of a naked flame.\n\n Do not smoke.\n\n \n\n85. This paint contains lead and is dangerous to health, even when dry.\n\n For industrial use only.\n\n Do not use on toys or furniture.\n\n Do not use for painting any building or fixed structure.\n\n Do not use where contact with food or drinking water is possible.\n\n \n\n86. This tinter contains lead.\n\n Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.\n\n \n\n87.   (Insert brand name) remains in the body for many months after treatment has stopped.  Do not become pregnant or father a child before consulting your doctor.\n\n \n\n88. This product is not recommended for dyeing eyelashes or eyebrows.  To do so may be injurious to the eye.\n\n \n\n89. Application to skin may increase sensitivity to sunlight.\n\n \n\n90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery.  Avoid alcohol.\n\n \n\n91. CAUTION  Total iodine intake may exceed recommended level when taking this preparation.\n\n \n\n92. WARNING  Contains iodine - do not take when pregnant except on physician’s advice.\n\n \n\n93. Causes severe burns, which are not likely to be immediately painful or visible.\n\n \n\n94. WARNING  Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.\n\n \n\n95. CAUTION  Do not use for children under 12 years old unless a doctor has told you to.\n\n \n\n96. CAUTION  This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.\n\n \n\n97. Adults:  Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.\n\n \n\n98. Children and adolescents:  Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.\n\n \n\n99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New  Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.\n\n \n\n100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.\n\n \n\n101. Don’t use [this product/name of the product]:  If you have a stomach ulcer\n\n In the last 3 months of pregnancy [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]\n\n If you are allergic to (name of substance) or anti-inflammatory medicines.\n\n \n\n102. Unless a doctor has told you to, don’t use [this prouct/name of the product]:\n\n For more than a few days at a time\n\n With other medicines containing aspirin or other anti-inflammatory medicines\n\n If you have asthma\n\n In children under 12 years of age\n\n In children 12-16 years of age with or recovering from chicken pox, influenza or fever\n\n If you are pregnant.\n\n \n\n103. See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients.]\n\n \n\n104. Unless a doctor has told you to, don’t use [this product/name of the product]:\n\n For more than a few days at a time\n\n With other medicines containing (name of substance) or other anti-inflammatory medicines\n\n If you have asthma\n\n If you are pregnant [This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea].\n\n \n\n105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.\n\n \n\n106. Contains formaldehyde.\n\n \n\n \n\nSAFETY DIRECTIONS - GENERAL\n\n \n\nTo be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Labels and Containers, subparagraph 7(n) to this Standard).\n\n \n\n1. Avoid contact with eyes.\n\n \n\n2. Attacks eyes  protect eyes when using.\n\n \n\n3. Wear eye protection when mixing or using.\n\n \n\n4. Avoid contact with skin.\n\n \n\n5. Wear protective gloves when mixing or using.\n\n \n\n6. Wash hands after use.\n\n \n\n7. Wash hands thoroughly after use.\n\n \n\n8. Avoid breathing dust (or) vapour (or) spray mist.\n\n \n\n9. Use only in well ventilated area.\n\n \n\n10. Ensure adequate ventilation when using.\n\n \n\n11.  No smoking.\n\n \n\n12. Do not allow product to come into contact with other chemicals, especially acids.\n\n \n\n13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.\n\n \n\n14. Do not allow to get damp.\n\n \n\n15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.\n\n \n\n16. Store and transport in an upright container.\n\n \n\n17. Do not mix with other chemicals.\n\n \n\n18. Do not mix with different types of chlorinating chemicals.\n\n \n\n19. Use clean containers for dispensing.\n\n \n\n20. Mix with water only.\n\n \n\n21. Do not add water to product  add product to water, but in case of fire drench with water.\n\n \n\n22. In case of spillage flush with large quantities of water.\n\n \n\n23. Keep away from heat, sparks and naked flames.\n\n \n\n24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.\n\n \n\n25. Avoid contact with food.\n\n \n\n26. Avoid contact with clothing.\n\n \n\n27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed. \n\n \n\n28. Do not mix with hot water.\n\n \n\n29. Obtain a supply of calcium gluconate gel.\n\n \n\n30. (Intentionally blank.)\n\n \n\n31. Do not use on broken skin.\n\n \n\n32. Do not use under occlusive dressing.\n\n \n\n33. Mix strictly according to instructions.\n\n \n\n34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.\n\n \n\n35. Wash gloves thoroughly, immediately after use.\n\n \n\n36. Protect cuticles with grease or oil.\n\n \n\nPART 3\n\n \n\nPOISONS (other than agricultural and veterinary chemicals)   TO BE LABELLED WITH WARNING STATEMENTS\n\nOR SAFETY DIRECTIONS\n\n \n\n(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)\n\n \n\n    WARNING SAFETY\n\nPOISON  STATEMENTS DIRECTION\n\n \n\nAcetic acid in concentrations of 80 per cent  2 1,4,8\n\n or more except when in Schedule 2.\n\n \n\nAcetic anhydride 2 1,4,8\n\n \n\nAcetone in concentrations greater than 75 per cent.  1,4,8\n\n   \n\n \n\nAcitretin  7,62,76\n\n \n\nAdapalene for topical use. 62,77\n\n \n\nAlclometasone when included in Schedule 3. 38,72,73,74,75\n\n \n\nAlkaline salts 4 1,4\n\n \n\nAmbrisentan 7,62,76\n\n \n\nAmines used as curing agentsfor epoxy resins.   1,3,4,5,8\n\n \n\nAmmonia/ammonium hydroxide in concentrations  4 1,4,8\n\n greater than 20 per cent ammonia except\n\n in smelling salts.\n\n \n\nAmmonium persulfate  5,21,25 1,5,23,33,34\n\n \n\nAnhydrides, organic acid, for use as curing agents  1,3,4,5,8\n\n for epoxy resins.  \n\n \n\nAniline  13 1,4,8\n\n \n\nAntihistamines not separately specified  39 or 40\n\n in this Appendix except:\n\n \n\n (a) dermal, ocular, parenteral and   paediatric preparations;\n\n \n\n (b) oral preparations of astemizole,\n\n  desloratadine, fexofenadine,\n\n  loratadine or terfenadine;\n\n (c) nasal preparations of azelastine; or\n\n \n\n (d) preparations for the treatment of animals.\n\n \n\nAromatic extract oils  1,3,4,5,6\n\n \n\nAspirin\n\n \n\n (a) for inhibition of platelet aggregation. 36   \n\n \n\n (b) in sustained release  preparations 36  containing 650 mg or more of aspirin.\n\n \n\n (c) in other preparations. 101,102,103\n\n \n\nAstemizole  61\n\n \n\nAzadirachta indica (neem) including its  extracts  and derivatives when included in Schedule 6. 67\n\n \n\nAzocyclotin 48\n\n \n\nBenomyl 46\n\n \n\nBenzene  12 1,4,9\n\n \n\n1,2-Benzenediol (Catechol)  51,59 1,4,8\n\n \n\nBenzoyl peroxide when included in Schedule 2. 55\n\n \n\nBenzoyl peroxide when included in Schedule 5.  1,4,8\n\n \n\nBergamot oil 89\n\n \n\nBeryllium   1,4,8\n\n \n\nBexarotene\n\n \n\n (a) for human use. 7,62,76\n\n \n\n \n\nBifluorides (including ammonium, potassium and sodium salts)\n\n \n\n \n\n (b) when included in Schedule 6 or 7. 1,17,93  1,3,4,5,8,29,35\n\n \n\nBithionol for the treatment of animals.  1,4,8\n\n \n\nBoron trifluoride (including mixtures that\n\n generate boron trifluoride)\n\n (a) when included in Schedule 5.  2 1,4\n\n \n\n \n\nBosentan  7,62,76\n\n \n\nBromoform  1,4,8\n\n \n\n2-Butoxy-2’-thiocyanodiethyl ether  1,4,8\n\n \n\n2-Butoxyethanol and its acetates  1,4,8\n\n \n\nCamphor\n\n \n\n (a) in block, ball, disc, pellet or flake form, 9 \n\n   enclosed in a device which, in normal use,\n\n   prevents removal or ingestion of its contents.\n\n \n\n (b) in other forms. 9 1\n\n \n\nCarbamide peroxide\n\n \n\n (a) more than 9 per cent up to 30 per cent. 5 1\n\n \n\n (b) more than 30 per cent up to 60 per cent. 5 2\n\n \n\n (c) more than 60 per cent. 2 2,4\n\n \n\nCarbon disulphide 12 1,4,8,9,23\n\n \n\nCarbon tetrachloride 12 1,4,8,9\n\n \n\nCassia oil   4\n\n \n\nChlorinating compounds\n\n \n\n (a) in household cleaning or bleaching 20\n\n   preparations.\n\n \n\n (b) in preparations containing less than 11 1,4,10\n\n   10 per cent of available chlorine.\n\n \n\n (c) in liquid preparations containing 3,18 1,4,6,8,10, 15,16,\n\n   10 per cent or more of available chlorine.  17,18, 19,20,22,26\n\n \n\n (d) in dry preparations containing 10 per cent  10,18,22,23 1,4,8,12,13,\n\n   or more of available chlorine.  14,15,16,17, 18,\n\n     19,20,21, 22,26\n\n \n\n (e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,    or more of available chlorine certified by a  14,15,16,17,    relevant State or  Territory authority as not  18,19,20,21,    being a Dangerous Good of Class 5,  22,26    Division 5.1:Oxidising substances, as\n\n   specified in the Australian Code for the\n\n   Transport of Dangerous Goods by Road\n\n  and Rail.\n\n \n\n (f) in compressed block or tablets containing 10,22,23 12,13,14,15,    10 per cent or more of  available chlorine  17,18,19,21    except in preparations for use in toilet     cisterns only, containing 15 g or less of  \n\n   trichloroisocyanuric acid.\n\n \n\n (g) in other compressed blocks or tablets 10,22 12,13,14,15,\n\n   containing 10 per cent or more of available  17,18,19,21\n\n   chlorine certified by a relevant State or\n\n   Territory authority as not being a Dangerous\n\n   Good of Class 5, Division 5.1: Oxidising\n\n   substances, as specified in the Australian\n\n   Code for the Transport of Dangerous Goods\n\n   by Road and Rail except in preparations for\n\n   use in toilet cisterns only, containing 15 g or\n\n   less of trichloroisocyanuric acid.\n\n \n\nChloroform when included in Schedule 6  1,4,8\n\n \n\nalpha-Chlorohydrin 13,51 1,4,8,9\n\n \n\nChromates (including dichromates) of alkali metals or ammonia  1,4,8\n\n \n\nChromium trioxide 2,14,15,23 1,4,8,13\n\n \n\nCimetidine when included in Schedule 3 70,96\n\n \n\nCinnamon bark oil  4\n\n \n\nClobetasone when included in Schedule 3. 72,73,74,75,95\n\n \n\nClotrimazole in vaginal preparations when included 54,63,64,66\n\n  \n\nClove oil   1\n\n \n\nCyanides when included in Schedule 7. 13 4,8\n\n \n\nCyanuric acid  1,4,8\n\n \n\nCyclohexanone peroxide  1,4,8\n\n \n\nCysteamine   1\n\n \n\n4,4-Diaminodiphenylmethane (methylene dianiline)  1,4,8\n\n \n\northo-Dichlorobenzene  1,4,8\n\n \n\npara-Dichlorobenzene  1,4\n\nDichloroethylene  1,4,8\n\n \n\nDichloroethyl ether  1,4,8\n\n \n\nDichloroisocyanurates\n\n \n\n (a) in household cleaning or bleaching 20     preparations. \n\n \n\n (b) in preparations containing less than 11 1,4,10    10 per cent of  available chlorine. . \n\n \n\n (c) in liquid preparations containing 10 per cent 3,18 1,4,6,8,10,    or more of available chlorine.  15,16,17,18,    .  19,20,22,26\n\n \n\n (d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,14,    or more of available chlorine.  15,16,17,18,19,    .  20,21,22,26\n\n \n\n (e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,14,\n\n   or more of available chlorine certified by a  15,16,17,18,19,\n\n   relevant State or Territory authority as not  20,21,22,26\n\n   being a Dangerous Good of Class 5,\n\n","sortOrder":9},{"sectionNumber":"Div 5","sectionType":"division","heading":"1: Oxidising substances, as","content":"   Division 5.1: Oxidising substances, as\n\n   specified in the Australian Code for the\n\n   Transport of Dangerous Goods by Road\n\n   and Rail.\n\n \n\n (f) in anti-bacterial tablets containing 2.5 g or 60    less of sodium  dichloroisocyanurate..\n\n  \n\n (g) in other compressed blocks or tablets containing 10,22,23 12,13,14,15,    10 per cent or more of available chlorine except  17,18,19,21    in preparations containing 21 g or less of sodium\n\n    dichloroisocyanurate for use in toilet cisterns only. \n\n \n\n (h) in other compressed blocks or tablets containing 10,22 12,13,14,15,17,\n\n   10 per cent or more of available chlorine  18,19,21\n\n   certified by a relevant State or Territory authority\n\n   as not being a Dangerous Good of Class 5,\n\n   Division 5.1: Oxidising substances, as specified\n\n   in the Australian Code for the Transport of\n\n   Dangerous Goods by Road and Rail except in\n\n   preparations containing 21 g less of sodium\n\n   dichloroisocyanurate for use in toilet cisterns only.\n\n \n\n (i) in other compressed blocks or tablets containing\n\n   10 per cent or more of available chlorine  in\n\n   preparations containing 5 g or less of sodium\n\n   dichloroisocyanurate for use in toilet bowls only:\n\n \n\n  \n\n  (i) during storage 10,22,23 12,13,14,15,17,\n\n      18,21\n\n \n\n  (ii) during use 5 1,4,7,12\n\n \n\n (j) in other compressed blocks or tablets containing\n\n   10 per cent or more of available chlorine certified\n\n   by a relevant State or Territory authority as not\n\n   being a Dangerous Good of Class 5, Division 5.1:\n\n   Oxidising substances, as specified in the\n\n   Australian Code for the Transport of Dangerous\n\n   Goods by Road and Rail in preparations\n\n   containing 5 g or less of sodium dichloroisocyanurate\n\n   for use in toilet bowls only.\n\n  \n\n  (i) during storage 10,22 12,13,14,15,17,\n\n      18,21\n\n \n\n  (ii) during use 5 1,4,7,12\n\n \n\nDichloromethane (methylene chloride)\n\n \n\n (a) in paint or lacquer removers. 12,16 1,4,8,11\n\n \n\n (b) other than in paint or lacquer removers  1,4,8,25\n\n \n\nDiclofenac  101,104\n\n \n\nDienestrol 67\n\n \n\nDiethanolamine when included in Schedule 5. 5 1,4\n\n \n\nDiethanolamine when included in Schedule 6. 2,11,18 1,4,8\n\n \n\nDiethyltoluamide for human use. 44\n\n \n\n5,6-Dihydroxyindoline 21,28\n\n \n\nDimethylformamide  1,4,8\n\n \n\nDimethyl sulfate 2 1,4,8\n\n \n\nDimethyl sulfoxide\n\n \n\n (a) when not packed and labelled for therapeutic use. 27 1,4,5,8\n\n \n\n (b) when packed and labelled for treatment of animals. 49 1,4,5,8\n\n \n\nDinitrocresols (and their homologues) except when for  1,4,8\n\n  therapeutic use.\n\n \n\nDinitrophenols (and their homologues) except when  1,4,8\n\n  for therapeutic use.\n\nDinocap  47\n\n \n\nDioxane   1,4,8\n\n \n\nDiphenoxylate when included in Schedule 3. 39 or 40,41\n\n \n\nEconazole in vaginal preparations when included 54,63,64,66\n\n \n\nEphedrine in nasal preparations for topical use. 29\n\n \n\nEpichlorohydrin  2 1,4,8\n\n \n\nEpoxy resins, liquid.  1,3,4,5,8\n\n \n\nEthanolamine when included in Schedule 5. 5 1,4\n\n \n\nEthanolamine when included in Schedule 6. 2,11,18 1,4,8\n\n \n\nEther when included in Schedule 5 or 6.  1,4,8\n\n \n\nEthoxyethylmercuric chloride  1,4\n\n \n\nEthyl bromide  1,4,8\n\n \n\nEthylene chlorohydrin  1,4,8\n\n \n\nEthylene glycol monoalkyl ethers and their acetates  1,4,8\n\n except when separately specified.\n\n \n\nEthylene oxide  1,4,8\n\n \n\nEthylmercuric chloride  1,4\n\n \n\nEthyl methacrylate 28 4,9,23\n\n \n\nEtretinate  7,62,76\n\n \n\nEugenol   1\n\n \n\nFamotidine when included in Schedule 2. 96\n\n \n\nFenoterol in metered aerosols. 32\n\n \n\nFluconazole in oral preparations when included in 64   Schedule 3.\n\n \n\nFluorides (including silicofluorides) when included in  1,4\n\n Schedule 5 or 6 except when separately specified.\n\n \n\nFormaldehyde \n\n \n\n (a) in nail hardener cosmetics. 106 1,4,8,36\n\n \n\n (b) in other preparations. 106 1,4,8\n\n \n\nFormic acid   1,4,8\n\n \n\nFurfural  5 1,4\n\n \n\nGlazing preparations containing lead compounds.. 50\n\n \n\nGlutaraldehyde except when in Schedule 2\n\n \n\n (a) 25 per cent or less. 5,59 1,4,5\n\n \n\n (b) more than 25 per cent. 3,59 1,4,5,8\n\n \n\nGlycolic acid 79 1,5,6,31\n\n \n\nHexachlorophane in preparations for skin cleansing 24\n\n purposes containing 3 per cent or less of\n\n hexachlorophane.\n\n \n\nHexyloxyethanol    2 1,4,8\n\n \n\nHydrazine   1,4,8\n\n \n\nHydrochloric acid\n\n \n\n (a) 30 per cent or less of HCl.  1,4\n\n \n\n (b) more than 30 per cent of HCl.  1,4,8\n\n \n\nHydrocortisone\n\n \n\n (a) for dermal use when included in 38,72,73,74,75\n\n   Schedule 2 or 3.\n\n \n\n (b) for topical rectal use when includeed 38,75\n\n   in Schedule 2 or 3.\n\n \n\nHydrocyanic acid when included in Schedule 7. 13 4,8\n\n \n\nHydrofluoric acid (including mixtures that generate\n\n hydrofluoric acid)\n\n \n\n \n\n \n\nHydrogen peroxide\n\n \n\n (a) more than 3 per cent up to 10 per cent. 5 1\n\n \n\n (b) more than 10 per cent up to 20 per cent. 5 2\n\n \n\n (c) more than 20 per cent. 2 2,4\n\n \n\nHydroquinone\n\n \n\n (a) when in Schedule 2. 45\n\n \n\n (b) except when in Schedule 2 or 4.  1,4\n\n \n\nHydrosilicofluoric acid (including mixtures\n\n that generate hydrosilicofluoric acid)\n\n \n\n \n\n \n\n8-Hydroxyquinoline (including salts and 33\n\n derivatives) when prepared for\n\n internal use.\n\n \n\nIbuprofen   101,104\n\n \n\nIodine\n\n \n\n (a) more than 20 per cent.  1,4,8\n\n \n\n (b) in preparations for human internal therapeutic 91,92     use containing 300 micrograms or more of\n\n   iodine per recommended daily dose. \n\n \n\nIpratropium bromide in metered aerosols. 32\n\n \n\nIsocyanates (free organic)\n\n \n\n (a) when in paint. 28,52 1,5,8,10,27\n\n \n\n (b) other than in paint. 28,52 1,4,8\n\n \n\nIsoprenaline in metered aerosols 32\n\n \n\nIsotretinoin\n\n \n\n (a) for human oral use. 7,62,76 \n\n \n\n \n\nLead compounds\n\n (a) in hair cosmetics. 25\n\n (b) when in Schedule 6.  1,4,8\n\n \n\nLeflunomide 7,62,87\n\n \n\nLemon oil  89\n\n \n\nLenalidomide 7,62,76\n\n \n\nLevocabastine\n\n (a) in eye or nasal preparations containing  62\n\n  0.5 mg/mL or less of levocabastine.\n\n (b)  in other preparations.  62 and\n\n     either 39 or 40\n\n \n\nLime oil  89\n\n \n\nLoperamide when in Schedule 2. 41\n\n \n\nMagnesium chlorate  1,4\n\n \n\nMefenamic acid 101,104\n\nMercuric thiocyanate  1,4\n\n \n\nMetacresolsulphonic acid and formaldehyde  1,4\n\n condensation product for the treatment of animals.\n\n \n\nMethanol except in methylated spirit.  1,4,8\n\n \n\nMethoxamine in nasal preparations for topical use. 29\n\n \n\nMethyl chloride  1,4,8\n\n \n\nMethyl ethyl ketone 5 1,4,8\n\n \n\nMethyl ethyl ketone oxime 5,28 1,4\n\n \n\nMethyl ethyl ketone peroxide 2 2,3,4,6\n\n \n\nMethyl iso-amyl ketone  1,4,8\n\n \n\nMethyl iso-butyl ketone  1,4,8\n\n \n\nMethyl iso-thiocyanate 5,12 1,4,8\n\n \n\nMethyl methacrylate 28 4,9,23\n\n \n\nMethyldibromo glutaronitrile 28 1,4,7\n\n \n\nMethylene bisthiocyanate  1,4\n\n \n\nMethyleugenol  1,6\n\n \n\nMethylnorbornylpyridine 59\n\n \n\n1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-\n\n N,N-diethylaminobenzene  1,4,8\n\n \n\nMiconazole in vaginal preparations when included 54,63,64,66\n\n \n\nMisoprostol  53\n\n \n\nNaphazoline in nasal preparations for topical use. 29\n\n \n\nNaphthalene\n\n \n\n (a) in block, ball, disc, pellet or flake form, 9,105\n\n  enclosed in a device which, in normal\n\n  use, prevents removal or ingestion of its\n\n  contents.\n\n \n\n (b) in other forms. 9,105 1\n\n \n\nNaproxen  101,104\n\n \n\nNicotine except when in tobacco or when included  1,4  in Schedule 2.  \n\n \n\nNitric acid\n\n \n\n (a) 75 per cent or less HNO3. 2 1,4\n\n \n\n (b) more than 75 per cent HNO3. 2 1,4,8\n\n \n\nNitrobenzene  1,4,8\n\n \n\nNitrophenols  1,4\n\n \n\nNitroprussides in aerosols. 84 8\n\n \n\nNizatidine when included in Schedule 2. 96\n\n \n\nNoradrenaline in metered aerosols. 32\n\n \n\nNystatin in vaginal preparations when included 54,63,64,65,66\n\n \n\nOrange oil (bitter) 89\n\n \n\nOrciprenaline in metered aerosols. 32\n\n \n\nOxalates, metallic  4,8\n\n \n\nOxalic acid  2 4,8\n\n \n\nOxymetazoline in nasal preparations for topical use. 29\n\n \n\nPaint\n\n \n\n (a)  First Schedule paints. 83\n\n \n\n (b)  Second Schedule paints. 84\n\n \n\nParacetamol 97 and/or 98,99,100\n\n \n\nPentachlorophenol  1,4,8\n\n \n\nPeracetic acid 2 1,4,8\n\n \n\nPermanganates 2 24\n\n \n\n2-Phenoxyethanol        5 1\n\n \n\nPhenol and any other homologue of phenol.  1,4\n\n \n\nPhenols   5\n\n \n\nPhenylenediamines and alkylated   phenylenediamines\n\n \n\n (a) in hair dyes. 21\n\n \n\n (b) in preparations other than hair dyes.  1,4,8\n\n \n\nPhenylephrine in nasal preparations 29\n\n for topical use.\n\n \n\nN,N-bis(phenylmethylene)-bicyclo-\n\n(2.2.1)heptane-2,5-dimethanamine 5,28 1,4,5,10\n\n \n\nN,N-bis(phenylmethylene)-bicyclo-\n\n(2.2.1)heptane-2,6-dimethanamine 5,28 1,4,5,10\n\n \n\northo-Phenylphenol except when in  1,4\n\n antiseptics.\n\n \n\nPhenylpropanolamine 56\n\n \n\nPhenytoin in pastes for the treatment of horses. 9\n\n \n\nPhosphonic acid  1,4\n\n \n\nPhosphoric acid  1,4\n\n \n\nPhosphorus (yellow) 2 1,4\n\n \n\northo-Phthalaldehyde \n\n \n\n (a) when included in Schedule 5. 51,52,59 1,4,5,8,10\n\n \n\n (b) when included in Schedule 6. 51,52,59 2,4,5,8,10\n\n \n\nPicric acid (more than 20 per cent).  1,4\n\n \n\nPodophyllin\n\n \n\n (a) in preparations specifically for use on 36\n\n   anal or genital area. \n\n \n\n (b) in other liquid preparations when included 31\n\n   in Schedule 2 or Schedule 3. \n\n \n\n (c) in other solid or semi-solid preparations 30\n\n   when included in Schedule 2.  \n\n \n\nPodophyllotoxin\n\n \n\n (a) in preparations specifically for  36\n\n   use on anal or genital area. \n\n \n\n (b)  in other liquid preparations when included 31\n\n   in Schedule 2 or Schedule 3. \n\n \n\n (c)  in other solid or semi-solid preparations 30\n\n   when included in Schedule 2.  \n\n \n\nPolihexanide  1,4,8\n\n \n\nPolyethanoxy (15) tallow amine  1,4\n\n \n\nPoly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino] 5,88 1,5\n\n -2-oxoethyl]- α -hydroxy-,mono-C13-15 -alkyl ethers    \n\nPotassium hydroxide\n\n \n\n (a) in preparations containing  5 1,4,6    0.5 per cent or less of potassium\n\n   hydroxide.\n\n \n\n (b) in solid preparations containing  2,10,78 3,5,28\n\n   more than 0.5 per cent of potassium     hydroxide. \n\n \n\n (c) in liquid preparations containing  2,10,78 3,5    more than 0.5 per cent of potassium     hydroxide.\n\n \n\nPotassium metabisulphite 5,26 1,4\n\n \n\nPotassium nitrite in pickling or curing salts. 94\n\n \n\nPotassium persulfate 5,21,25 1,5,23,33,34\n\n \n\nPotassium sulfide 2 1,4\n\n \n\nPropionic acid when in Schedule 6. 2 1,4\n\n \n\nRanitidine when included in Schedule 2. 96\n\n \n\nSafrole\n\n \n\n (a) in preparations for therapeutic use.  1\n\n \n\n (b) other than for therapeutic use.  1,4\n\n \n\nSalbutamol in metered aerosols or in dry 32  powder formulations. \n\n \n\nSalicylamide 34 or 35\n\n \n\nSassafras oil\n\n \n\n (a) in preparations for therapeutic use.  1\n\n \n\n (b) other than for therapeutic use.  1,4\n\n \n\nSelenium compounds except when for  1,4,8\n\n therapeutic use (human or animal).\n\n \n\nSilver in smoking deterrents. 42\n\n \n\nSitaxentan     7, 62, 76\n\n \n\nSodium aluminate 2 1,4\n\n \n\nSodium chlorate  1,4\n\n \n\nSodium dodecylbenzene sulfonate 79 1\n\n \n\nSodium fluoride in preparations for 43\n\n human ingestion when in Schedule 2.\n\n \n\nSodium hydrogen sulfate  1,4,8\n\n \n\nSodium hydrosulfite 5,26 1,4,8\n\n (more than 50 per cent)\n\n \n\nSodium hydroxide\n\n \n\n (a) in preparations containing 0.5 per cent 5 1,4,6    or less of sodium hydroxide. \n\n \n\n (b) in solid preparations containing more than 2,10,78 3,5,28    0.5 per cent of sodium hydroxide.\n\n \n\n (c) in liquid preparations containing more than 2,10,78 3,5    0.5 per cent of sodium hydroxide. \n\n \n\nSodium laureth-6 carboxylate 79 1\n\n \n\nSodium metabisulphite 5,26 1,4\n\n  (more than 50 per cent)\n\n \n\nSodium nitrite in pickling or curing salts 94\n\n \n\nSodium persulfate 5,21,25 1,5,23,33,34\n\n \n\nSodium sulfide 2 1,4\n\n \n\nStyrene   1,4,8\n\n \n\nSulfamic acid 2 1,4\n\n \n\nSulfuric acid 2 1,4\n\n \n\nSymphytum spp. (Comfrey) when included in Schedule 5.  31,32\n\n \n\nTazarotene for topical use. 77,62\n\n \n\nTerbutaline in metered aerosols or in dry powder formulations. 32 \n\n \n\nTerfenadine  61\n\n \n\nTeriflunomide.    7,62,87\n\n \n\nTerpenes, chlorinated  1,4,8\n\n \n\nTetrachloroethane 12 8\n\n \n\nTetrachloroethylene when in Schedule 5 or 6. 12,16 1,4,8,11\n\n \n\nTetrahydrozoline in nasal preparations for topical use. 29\n\n \n\nThalidomide 7,62,76\n\n \n\nThiourea   1,4\n\n \n\nToluene   1,4,8\n\n \n\nToluenediamine\n\n \n\n (a)  in hair dyes. 21\n\n \n\n (b)  in preparations other than hair dyes.  1,4,8\n\n \n\nTramazoline in nasal preparations for topical use. 29\n\n \n\nTretinoin\n\n \n\n (a) for human oral use. 7,62,76 \n\n \n\n \n\nTriamcinolone when in topical preparations 64 or 68\n\n for the treatment of mouth ulcers.\n\n \n\nTrichloroacetic acid except when for 2 1,4\n\n therapeutic use.\n\n \n\n1,1,1-trichloroethane  8,9\n\n \n\nTrichloroethylene except when for  12 1,4,5,8,9  therapeutic use.\n\n \n\nTrichlorophenol  1,4,8\n\n \n\nTriethanolamine 5 1,4\n\n \n\nTriethyl phosphate  1,4,8\n\n \n\nTrifluoromethanesulfonic acid\n\n \n\n (a) more than 10 per cent. 1,17 1,4,8\n\n \n\n (b) 10 per cent or less.  1,4,8\n\n \n\nTriisopropanolamine lauryl ether sulfate   1,4,6\n\n \n\n3,6,9-Trioxaundecanedioic acid 5 1\n\n \n\nTymazoline in nasal preparations for topical use. 29\n\n \n\nVinclozolin  46\n\n \n\nXylene   1,4,8\n\n \n\nXylometazoline in nasal preparations for topical use. 29\n\n  \n\nZinc chloride  1,4\n\n \n\nZinc sulfate when in Schedule 6.  1,4\n\n \n\n## APPENDIX G\n\n## DILUTE PREPARATIONS\n\n \n\nThe requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.\n\n \n\nColumn 1 Column 2\n\nPoison Concentration\n\n (quantity per litre\n\n or kilogram)\n\nACETYLCHOLINE 1 mg\n\nALDOSTERONE  10 micrograms\n\nANTIMONY COMPOUNDS 1 mg\n\nAPOMORPHINE 1 mg\n\nARSENIC 1 mg\n\nATROPA BELLADONNA (belladonna) 300 micrograms\n\nATROPINE 300 micrograms\n\nCANTHARIDIN 10 micrograms\n\nCHLORINE 5 mg\n\nCROTON TIGLIUM (croton oil) 1 mg\n\nDIOXANE 100 mg\n\nERYSIMUM spp. 1 mg\n\nFOLLICLE-STIMULATING HORMONE 100 micrograms\n\nGELSEMIUM SEMPERVIRENS 1 mg\n\nGLUCAGON 100 micrograms\n\nGLYCERYL TRINITRATE 100 micrograms\n\nGROWTH HORMONE 10 micrograms\n\nHALOPERIDOL 1 mg\n\nHYDROCYANIC ACID 1 microgram\n\nHYOSCINE 300 micrograms\n\nHYOSCYAMINE 300 micrograms\n\nHYOSCYAMUS NIGER 300 micrograms\n\nHYPOTHALAMIC RELEASING FACTORS 10 micrograms\n\nINDOMETHACIN 1 mg\n\nMERCURY 1 mg\n\nMETHYLMERCURY 300 micrograms\n\nNAPHTHALENE 1 mg\n\nNERIUM OLEANDER 1 mg\n\nOESTRADIOL 10 micrograms\n\nOESTRONE 100 micrograms\n\nOXYTOCIN 1 microgram\n\nPHOSPHORUS 1 mg\n\nPODOPHYLLUM RESIN (podophyllin) 1 mg\n\nPROGESTERONE 1 mg\n\nPROPRANOLOL 1 mg\n\nSELENIUM 100 micrograms\n\nSTROPHANTHUS spp. 1 mg\n\nSTRYCHNINE 1 mg\n\nTESTOSTERONE 1 mg\n\nTHYROXINE 10 micrograms\n\n## APPENDIX H\n\n## SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED\n\n \n\nButoconazole.\n\nClotrimazole.\n\nDiclofenac.\n\nDimenhydrinate for the prevention and relief of motion sickness.\n\nDiphenoxylate.\n\nEconazole.\n\nFluconazole.\n\nHydrocortisone.\n\nMiconazole.\n\nNystatin.\n\n \n\n## APPENDIX I\n\n## UNIFORM PAINT STANDARD\n\n \n\nThis Appendix provides regulations for adoption by the States and Territories.\n\n \n\n1. A person must not manufacture, sell, supply or use a First Schedule Paint for application to:\n\n (1) a roof or any surface to be used for the collection or storage of potable water; or\n\n (2) furniture; or\n\n (3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or\n\n (4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.\n\n \n\n2. A person must not manufacture, sell, supply or use a Third Schedule paint.\n\n \n\n3. A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012 entitled Safety of toys Part 3: Migration of certain elements (ISO 8124-03:2010, MOD).\n\n \n\n4. A person must not manufacture, sell, supply, or use a paint containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.\n\n \n\nThe First Schedule\n\nThe proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.\n\nANTIMONY or antimony compounds other than  more than 5 per cent\n\nantimony titanate pigments\n\nBARIUM salts except barium sulfate or barium metaborate  more than 5 per cent\n\nCADMIUM or cadmium compounds more than 0.1 per cent\n\nCHROMIUM as chromates of ammonia, barium, potassium,  more than 5 per cent\n\nsodium, strontium or zinc\n\nSELENIUM or selenium compounds more than 0.1 per cent\n\n \n\nThe Second Schedule\n\nCHROMIUM as chromates of ammonia, more than 5 per cent\n\nbarium, calcium, iron, potassium, sodium,\n\nstrontium or zinc\n\nDICHLOROMETHANE (methylene chloride) more than 5 per cent by wt\n\nETHYLENE GLYCOL MONOALKYL ETHERS and their acetates  more than 10 per cent by vol\n\nHEXYLOXYETHANOL  more than 10 per cent by vol\n\nTOLUENE more than 50 per cent by vol\n\nXYLENE more than 50 per cent by vol\n\n \n\nThe Third Schedule\n\nThe proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.\n\nLEAD or lead compounds  more than 0.1 per cent\n\n## APPENDIX J\n\n## CONDITIONS FOR AVAILABILITY AND USE OF  SCHEDULE 7 POISONS\n\n \n\n \n\n \n\nCONDITIONS FOR AVAILABILITY AND USE\n\n \n\nThe following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.\n\n \n\n1. Not to be available except to authorised or licensed persons.\n\n \n\n2. Not to be used in printing inks.\n\n \n\n3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.\n\n \n\n4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.\n\n \n\nAPPENDIX J\n\n \n\n \n\nA poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.\n\n \n\n \n\nPOISONS CONDITIONS\n\n \n\nAbamectin 1\n\nAcibenzolar-s-methyl 1\n\nAcrolein 1\n\nAcrylonitrile 1\n\nAlachlor 1\n\nAllyl alcohol 1\n\n4-Aminopyridine 1\n\nArprinocid 1\n\nArsenic 1\n\nAzocyclotin 1\n\nBenzene 1\n\nBifluorides (including ammonium, potassium and sodium salts) 1\n\nBoron trifluoride 1\n\nBrodifacoum 1\n\nBromadiolone 1\n\nBromine 1\n\nBrucine    1\n\nCalciferol 1\n\nCaptafol 1\n\nCarbadox 1\n\nCarbon tetrachloride 1\n\nCarbonyl sulphide    1\n\nChlordecone 1\n\nChlordimeform 1\n\nChlorine 1\n\nChloromethiuron 1\n\nChloropicrin 1\n\n4-Chloro-o-toluidine 1\n\nColecalciferol 1\n\nCoumatetralyl 1\n\nCyanogen 1\n\nCyhexatin 1\n\n4,4-Diaminodiphenylmethane (methylene dianiline) 1\n\n1,2-Dibromo-3-chloropropane 1\n\n1,3-Dichloropropene  1\n\nDifenacoum 1\n\n4-Dimethylaminoazobenzene 1\n\nDinitrocresols 1\n\nDinitrophenols 1\n\nDinoseb 1\n\nEpichlorohydrin 1\n\nEpidermal growth factor 1\n\nEtaconazole 1\n\nEthylene dibromide 1\n\nEthylene oxide 1\n\nFluoracetamide 3\n\nFluoroacetic acid 3\n\nFolpet 1\n\nHalofuginone 1\n\nHalogenated dibenzodioxins and dibenzofurans  1\n\nHCB 1\n\nHydrocyanic acid and cyanides 1\n\nHydrofluoric acid 1\n\nHydrosilicofluoric acid 1\n\nIodomethane 1\n\nMaduramicin 1\n\nMercury 1\n\nMethacrifos 1\n\nMethoxyethylmercuric acetate 1\n\nMethoxyethylmercuric chloride 1\n\nMethyl bromide 1\n\n4,4’-Methylenebis[2-chloroaniline] 1\n\nMirex 1\n\nMolinate 1\n\nNicotine 1\n\nNitrofen 1\n\nPhenylmercuric acetate 1\n\nPhosphides, metallic 1\n\nPhosphine 1\n\nPropylene oxide 1\n\nPyrinuron 1\n\nStrychnine 1\n\nSulcofuron 1\n\nTetrachloroethane 1\n\n2,2’,6,6’-Tetraisopropyl-diphenyl-carbodiimide 1\n\nThallium 3\n\northo-Tolidine 1\n\nTrichloroisocyanuric acid 1\n\nVinyl chloride 1  \n\n \n\n## APPENDIX K\n\n## DRUGS REQUIRED TO BE LABELLED\n\n## WITH A SEDATION WARNING\n\n \n\n(see Part 2, Labels and Containers, subparagraph 14(2))\n\n \n\nAlprazolam\n\nAmisulpride\n\nAmitriptyline\n\nAmylobarbitone\n\nAripiprazole\n\nASENAPINE\n\nAzatadine\n\nBaclofen\n\nBenztropine\n\nBromazepam\n\nBrompheniramine\n\nBuclizine\n\nBuprenorphine\n\nButobarbitone\n\nCetirizine\n\nChloral hydrate\n\nChlordiazepoxide\n\nChlormethiazole\n\nChlorpheniramine\n\nChlorpromazine\n\nClemastine\n\nClomipramine\n\nClonazepam\n\nClonidine\n\nClorazepate\n\nClozapine\n\nCodeine except when included in Schedule 2 or 3.\n\nCyclizine\n\nCyclobarbitone\n\nCycloserine\n\nCyproheptadine\n\nCysteamine\n\nDantrolene\n\nDesipramine\n\nDexchlorpheniramine\n\nDextromoramide\n\nDextropropoxyphene\n\nDiazepam\n\nDifenoxin\n\nDihydrocodeine\n\nDimenhydrinate\n\nDimethindene\n\nDiphenhydramine\n\nDiphenoxylate\n\nDiphenylpyraline\n\nDothiepin\n\nDoxepin\n\nDoxylamine\n\nDronabinol (delta-9-tetrahydrocannabinol)\n\nDroperidol\n\nDuloxetine\n\nEthylmorphine\n\nFenfluramine\n\nFlunitrazepam\n\nFlupenthixol\n\nFluphenazine\n\nFlurazepam\n\nGabapentin\n\nGemcitabine\n\nGlutethimide\n\nHaloperidol\n\nHydrocodone\n\nHydromorphone\n\nHydroxyzine\n\nImipramine\n\nLamotrigine\n\nLevetiracetam\n\nLevocabastine\n\nLorazepam\n\nLURASIDONE.\n\nMazindol\n\nMebhydrolin\n\nMeclozine\n\nMedazepam\n\nMeprobamate\n\nMepyramine\n\nMethadone\n\nMethdilazine\n\nMethocarbamol\n\nMethylphenobarbitone\n\nMianserin\n\nMirtazapine\n\nMorphine\n\nNABIXIMOLS .\n\nNalbuphine\n\nNitrazepam\n\nNormethadone\n\nNortriptyline\n\nOlanzapine\n\nOpium in any form except the alkaloids noscapine and papaverine.\n\nOxazepam\n\nOxycodone\n\nPaliperidone\n\nPapaveretum\n\nPentazocine\n\nPentobarbitone\n\nPERAMPANEL\n\nPericyazine\n\nPerphenazine\n\nPethidine\n\nPhenelzine\n\nPheniramine\n\nPhenobarbitone\n\nPhenoperidine\n\nPhenyltoloxamine\n\nPholcodine\n\nPimozide\n\nPizotifen\n\nPrazepam\n\nPregabalin\n\nProchlorperazine\n\nPromazine\n\nPromethazine\n\nProtriptyline\n\nQuetiapine\n\nQuinalbarbitone\n\nRETIGABINE\n\nRisperidone\n\nRotigotine\n\nRUPATADINE\n\nSecbutobarbitone\n\nTAPENTADOL\n\nTemazepam\n\nThenyldiamine\n\nThiethylperazine\n\nThiopropazate\n\nThioridazine\n\nThiothixene\n\nTramadol\n\nTranylcypromine\n\nTrifluoperazine\n\nTrimeprazine\n\nTrimipramine\n\nTriprolidine\n\nZiprasidone\n\nZolpidem\n\nZonisamide\n\nZopiclone\n\n \n\n## APPENDIX L\n\n## REQUIREMENTS FOR DISPENSING LABELS FOR\n\n## HUMAN AND VETERINARY MEDICINES\n\n \n\n \n\n \n\nGENERAL REQUIREMENTS FOR DISPENSING LABELS\n\n \n\n(see Part 2, Labels and Containers, subparagraph 14(1))\n\n \n\n(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.\n\n \n\n(2) All symbols, numbers and words on a label must be in durable characters.\n\n \n\n(3) The label on a container of a substance for therapeutic use must contain the following details:\n\n \n\n (a) the name, address and telephone number of the dispenser supplying the substance;\n\n (b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);\n\n (c) adequate directions for use;\n\n (d) the strength and form of the substance;\n\n (e) the total quantity of the goods in the container;\n\n (f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;\n\n (g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;\n\n (h) if the substance is a medicine, the name of the person for whom it was dispensed; and\n\n (i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.\n\n \n\n(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:\n\n \n\n (a) the prescription reference number;\n\n (b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and\n\n (c) the directions for use set out in the prescription.\n\nAPPENDIX L\n\n \n\n \n\nADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN MEDICINES\n\n \n\n(see Part 2, Labels and Containers, subparagraph 14(2))\n\n \n\nMedicines required to be labelled with certain warning statements A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as specified opposite in Column 2.\n\n \n\n______________________________________________________________\n\n Column 1  Column 2\n\n Substance  Warning statement\n\n ______________________________________________________________\n\n \n\nAcitretin:\n\n1.          for oral use. 7,62 and 76\n\n \n\nAdapalene:\n\n \n\nAmbrisentan. 7, 62 and 76\n\n \n\nBexarotene:\n\n \n\nBosentan. 7, 62 and 76\n\n \n\nDienestrol. 67\n\n \n\nEtretinate:\n\n \n\nFingolimod. 76\n\n \n\nIsotretinoin:\n\n \n\nLeflunomide. 7, 62 and 76\n\n \n\nLenalidomide:\n\n \n\nLevocabastine. 62\n\n \n\nMisoprostol. 53\n\n \n\nSitaxentan. 7, 62 and 76\n\n \n\nTeriflunomide. 7, 62 and 87\n\n \n\nThalidomide:\n\n \n\nTretinoin:\n\n2.      for topical use. 62 and 77\n","sortOrder":10}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":3013},"content_quality":"ok","complexity_score":9,"scope_assessment":{"changed":false,"description":"The legislation maintains the established framework for uniform scheduling of medicines and poisons across Australian jurisdictions, consistent with its original purpose under the Therapeutic Goods Act 1989 to provide model provisions for classification, labelling, and packaging."},"complexity_factors":["Nine-tier hierarchical scheduling system (Schedules 1-9) with distinct regulatory controls for each tier","Complex interpretation rules where 'poison' automatically includes salts, derivatives, esters, ethers, alkaloids, stereoisomers, and recombinant forms unless explicitly excluded","Exception-heavy structure with nested conditional logic (e.g., 'except in preparations containing X% or when compounded with Y or when included in Schedule Z')","Detailed technical specifications for labelling including precise font heights (e.g., '1.5 millimetres', 'four-tenths the height of signal words'), bold-face sans serif requirements, and color contrasts","Extensive cross-referencing to external Australian Standards (AS 2216 for packaging, AS 1928 for child-resistant closures, AS 1580 for paint testing)","Five appendices containing general exemptions (Appendix A), non-scheduled substances (Appendix B), prohibited substances (Appendix C), additional possession controls (Appendix D), and specific first aid instructions (Appendix E)","Concentration-based threshold rules determining scheduling status (e.g., 10 mg/kg or 10 mg/L cutoffs) and 'reverse scheduling' where specific label statements create exemptions","Jurisdictional variation requirements with references to State and Territory authorities for implementation of supply and possession controls"],"plain_english_summary":"The Poisons Standard 2014 (SUSMP) is Australia’s national rulebook for classifying medicines, chemicals and other hazardous substances into regulatory Schedules that determine legal availability and controls. It sets uniform labelling, packaging, storage and supply requirements to protect public health.\n\nIt affects manufacturers/importers (labelling, safety directions, child‑resistant packaging), pharmacists and prescribers (access and supply controls), retailers and consumers, and ensures consistent restrictions and exemptions across states and territories."}},"importantCases":[],"_links":{"self":"/api/acts/poisons-standard-2014","history":"/api/acts/poisons-standard-2014/history","analysis":"/api/acts/poisons-standard-2014/analysis","conflicts":"/api/acts/poisons-standard-2014/conflicts","importantCases":"/api/acts/poisons-standard-2014/important-cases","documents":"/api/acts/poisons-standard-2014/documents"}}